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ABSTRACT 
 
Among the various peripheral nervous system injuries seen clinically, facial nerve 
lesions are prevalent and have significant functional and emotional impact on patients.  
As injuries can occur in different segments of the facial nerve and lead to different 
pathophysiological outcomes, animal models that mimic the common sites of injury need 
to be developed so that potential therapies can be appropriately investigated.  The 
extratemporal facial nerve axotomy model, in which the nerve is crushed at its exit from 
the skull, has been well established in the past and used to study the regeneration program 
of motoneurons.  The present study uses this rat injury model to evaluate the therapeutic 
potential of two treatments, testosterone and nerve electrical stimulation (ES), alone and 
in combination.   
Results demonstrate that ES reduced the delay before sprout formation begins and 
led to rapid upregulation of regeneration-associated genes, testosterone accelerated the 
overall regeneration rate and led to delayed but more sustained gene upregulation, and the 
combinatorial treatment strategy had the most enhanced effects on regeneration events.  
A more clinically relevant model of facial nerve injury, in which the nerve is crushed 
during its course in the temporal bone, was also developed and found to lead to 
substantially prolonged functional recovery times as compared to an extratemporal facial
 xv 
nerve crush.  Finally, the combinatorial treatment of ES plus testosterone accelerated 
functional recovery following the more proximal, intratemporal crush injury.  In 
conclusion, the present study characterizes two models of facial nerve injury and suggests 
that a combinatorial treatment strategy of ES plus testosterone holds significant clinical 
potential.     
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CHAPTER I 
INTRODUCTION 
 
Among the various peripheral nervous system (PNS) injuries seen clinically, 
facial nerve lesions occur commonly and have significant functional and emotional 
impact on patients.  Due to the nerve’s complex anatomical course, injuries can occur in 
different segments of the nerve, leading to different pathophysiological outcomes.  
Animal models that mimic the common types of facial nerve injuries seen clinically need 
to be investigated so that potential therapies can be appropriately developed.  The 
extratemporal facial nerve axotomy model, in which the nerve is crushed at its exit from 
the skull, has been well established in the past and used to study the regeneration program 
of motoneurons.  The present study uses this model in rats to investigate the therapeutic 
potential of two treatments, testosterone and electrical stimulation (ES), alone and in 
combination.  Gonadal steroids such as testosterone have been shown to have significant 
neuroprotective and neurotrophic effects, and ES has also recently emerged as a potential 
therapy for enhancing nerve regeneration.  Our preliminary data shows that following an 
extratemporal facial nerve crush injury in rats, the use of a combinatorial treatment 
strategy of ES plus testosterone has additive effects on accelerating functional recovery 
as compared to the administration of either treatment alone.  To delineate the mechanism 
underlying these effects, this dissertation investigated the effects of ES and testosterone 
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on the rate of facial nerve regeneration and regulation of regeneration-associated genes 
following an extratemporal facial nerve crush injury.  The second half of this dissertation 
focuses on development of a more clinically relevant model of facial nerve injury, in 
which the nerve was crushed during its course in the temporal bone.  This intratemporal 
facial nerve injury model was compared to the pre-existing extratemporal facial nerve 
injury model.  Finally, the neurotherapeutic potential of ES and testosterone was then 
investigated in the newly developed intratemporal model of facial nerve injury.  
Corticosteroids such as prednisone are commonly administered in cases of facial nerve 
injury, although their use remains controversial.  Therefore, the effects of prednisone 
treatment was also compared to ES and testosterone treatments in the intratemporal 
model of facial nerve injury.    
 
Aim 1:  Determine if daily ES and/or testosterone propionate (TP) affect facial 
nerve regenerative properties following an extratemporal facial nerve crush in rats.  
The working hypotheses were that ES and TP independently increase rate of facial nerve 
regeneration, that ES also shortens the time delay before initial sprout formation begins, 
and that the combination of ES and TP has an enhanced effect on regenerative 
properties.  Gonadectomized adult male underwent right facial nerve crush axotomies 
near the stylomastoid foramen (SMF) and were left untreated or received daily ES and/or 
TP capsules.  The rats were divided into four experimental groups: 1) no treatment 2) ES-
only, 3) TP-only, and 4) ES + TP.  For each group, radioisotopic labeling of fast axonally 
transported proteins was used to analyze the outgrowth distance of facial nerves at 4- and 
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7-days post-axotomy and to calculate the regeneration rates and estimated time delay 
before sprouting begins.     
Aim 2:  Determine if daily ES and TP differentially affect regulation of 
regeneration-associated genes following an extratemporal facial nerve crush in rats.  
The working hypothesis was that regeneration-associate genes are significantly 
upregulated in animals receiving ES or TP and that the upregulation occurs earlier with 
ES as compared to TP treatment. Gonadectomized adult male rats underwent right facial 
nerve crush axotomies near the stylomastoid foramen (SMF) and were divided into four 
experimental groups: 1) no treatment, 2) ES-only, 3) TP-only, and 4) ES + TP.  Punches 
of facial motor nucleus (FMN) were harvested at various time points following axotomy 
(6 h, 1 d, 2 d, 7 d, and 21 d), and real-time reverse transcription-polymerase chain 
reaction (RT-PCR) was performed to analyze fold change in mRNA levels.  The 
candidate genes analyzed included α1-tubulin, βII-tubulin, 43-kilodalton growth-
associated protein (GAP-43), brain-derived neurotrophic factor (BDNF), pituitary 
adenylate-cyclase activating peptide  (PACAP), and neuritin.    
Aim 3:  Compare functional recovery and cell survival following an extratemporal 
facial nerve crush as compared to an intratemporal facial nerve crush in rats.  The 
working hypothesis was that an intratemporal crush of the facial nerve leads to a 
significantly prolonged recovery time and a greater loss of facial motoneurons as 
compared to the extratemporal injury.  For the rat intratemporal facial nerve injury 
model, the facial nerve was crushed during its course though the facial canal in the 
temporal bone, whereas for the extratemporal injury, the nerve was crushed near its exit 
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form the SMF.  Daily facial functional recovery, weekly motor nerve conduction, and 
facial motoneuron survival at 4 weeks post-operative were compared between the two 
injury models.    
Aim 4:  Determine the effects of one-time ES, TP, and prednisone on functional 
recovery following an intratemporal facial nerve crush axotomy.  The working 
hypothesis was that the administration of ES and/or TP will shorten recovery time even 
after a more proximal, intratemporal injury.  Immediately after the intratemporal injury, 
rats were either left untreated or divided into various treatment groups: one-time ES 
treatment immediately after injury, TP, or prednisone, a treatment currently used in cases 
of facial nerve paralysis.   The effects of the combination of the various treatments was 
also be investigated.  Daily facial functional recovery and weekly motor nerve 
conduction were compared among the following experimental groups: 1) control, 2) 
prednisone-only, 3) ES-only, 4) TP-only, 5) ES + prednisone, 6) TP + prednisone, 7) ES 
+ TP, and 8) ES + TP + prednisone.   
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CHAPTER II 
LITERAURE REVIEW 
 
A.  INTRODUCTION 
 
Peripheral nerve lesions are common types of nervous system injuries, often 
leading to substandard functional recovery.  Although neurons within the peripheral 
nervous system (PNS) have the ability to regenerate their injured axons, recovery is 
dependent upon the degree of cell loss, rate of regeneration, and successful reinnervation.  
The facial nerve is a commonly injured nerve in humans and thus can be used to design 
treatment strategies that enhance regeneration.  Injury to the facial nerve can result from a 
variety of causes, the most prevalent being Bell’s palsy and compression or stretching of 
the nerve due to tumors or bone fractures.  The susceptibility of the nerve to injury arises 
from its complex anatomical course from the brainstem to its muscles of innervation.  As 
the severity of facial paresis and the recovery outcome is dependent upon the site of 
facial nerve injury, development of animal models representing these different injury 
sites will be beneficial not only in characterizing the degree of regeneration but also in 
testing the effects of potential treatments.  Gonadal steroids and electrical stimulation 
(ES) are two interventions that have the potential to be translated to the clinic.   
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B.  PERIPHERAL NERVOUS SYSTEM INJURY 
 Whereas the central nervous system (CNS) usually cannot regenerate after injury, 
the mature peripheral nervous system (PNS) has a robust ability to regenerate because of 
activation of its intrinsic growth capacity and a permissive environment (Vargas and 
Barres, 2007).  Despite this regenerative capacity, functional recovery following 
peripheral nerve injury is often suboptimal.  Recovery outcomes vary depending on the 
proximity of lesion to the cell body, regeneration distance to target, and age of patient (Fu 
and Gordon, 1995a; Fu and Gordon, 1995b; Birch and Raji, 1991; White and Vaughan, 
1991; Vaughan, 1992).  Peripheral nerves are anatomically arranged with fatty protection 
at locations that are vulnerable to mechanical perturbations, but nerves are nonetheless 
frequently damaged by physical insults, such as disruption of the myelin sheath causing 
conduction blocks or severe forces that crush, stretch, or sever the nerve. 
 
1.  ANATOMY OF A PERIPHERAL NERVE 
 The outer sheath of an entire peripheral nerve consists of condensed layers of 
connective tissue called the epineurium (Sunderland, 1991; Lee and Wolfe, 2000).  Each 
peripheral nerve trunk is composed of multiple bundles or fascicles of nerve fibers.  As 
the epineurium encircles and runs between fascicles, its main function is to nourish and 
protect the fascicles.  Each nerve fascicle is surrounded by a well-defined sheath known 
as the perineurium.  The perineurial sheath contributes to nerve tensile strength.  Within 
the fascicles, each individual nerve fiber and its investing Schwann cell is surrounded by 
the endoneurium.  The endoneurium functions to protect and nourish the axons.   
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A complex network of blood vessels serves as the blood supply of a peripheral 
nerve.  There are two major arterial systems, one lying superficially on the nerve and the 
other lying within the interfascicular epineurium (Sunderland, 1991).  The two systems 
are linked to a minor longitudinal system by anastomoses.  The endoneurial capillaries 
are structurally and functionally similar to the capillaries of the central nervous system in 
that they act as an extension of the blood-brain barrier.  The tight junctions connecting 
the endothelial cells of these capillaries create a system impermeable to a wide range of 
macromolecules.  Injury, ischemia, or toxins can disrupt this barrier.       
 
2.  INJURY CLASSIFICATIONS 
 In 1972, Seddon first classified nerve injuries into three major groups:  
neurapraxia, axonotmesis, and neurotmesis.  Neurapraxia is characterized by local myelin 
damage that usually occurs as a result of nerve compression.  Axonotmesis is defined as a 
loss of continuity of axons, with variable damage of the endoneurial and perineurial 
sheaths but an intact epineurium.  Lastly, neurotmesis is the loss of the epineurial sheath 
and the complete physiologic disruption of the entire nerve trunk (Seddon, 1972).  After 
injury, function fails in the following sequence: motor, propioception, touch, temperature, 
pain, and sympathetic (Lee and Wolfe, 2000).  Recovery usually occurs in the reverse 
order.  Incomplete injuries are more frequent than complete severance.  Furthermore, 
mixed nerve injuries, in which all fibers are affected but to varying degrees, are fairly 
common.     
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3.  CLINICAL PICURE: FACIAL NERVE INJURIES 
Facial nerve injuries are common PNS injuries seen in the clinic that often lead to 
unsatisfactory or delayed recovery and thus serve as a target for new therapeutic 
interventions.  As the facial nerve controls the muscles of facial expression, victims of 
facial paralysis can have various functional problems of the eyelid and facial skin and 
muscles, in addition to severe emotional disturbances from the resulting facial deformity 
(Rosson and Redett, 2008; Kiese-Himmel et al., 1993).  Because the forehead on the 
paralyzed side of the face has no wrinkles and is unable to raise that eyebrow, the 
eyebrow droops and pushes the eyelid tissue down over the eye.  Although the eyelid 
itself can open, it has difficulty closing, leading to increased exposure of the eye, dry eye, 
infections, and in severe cases, corneal ulcers and loss of the eye from perforation 
(Kerrebijn and Freeman, 1998).  In addition, patients present with a flattened nasolabial 
fold and the corner of the mouth turned down.  Other complications can include drooling, 
speech difficulties, and inability to retain airway patency (Rosson and Redett, 2008).  
Another common complication in patients with facial nerve injury is synkinesis, or the 
involuntary movement of part of the face during the voluntary movement of another part 
of the face.   
a.  Anatomy & Etiology 
The three main segments of the facial nerve are intracranial, intratemporal, and 
extratemporal.  The intracranial segment of the nerve arises near the pons, travels in the 
cerebellopontine angle and enters the temporal bone through the internal auditory meatus 
(Figure 1).  In the temporal bone, the nerve travels a complex course confined within a 
prolonged bony canal that is in some cases not much greater in diameter than the nerve 
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itself (intratemporal segment).  The nerve exits the skull at the stylomastoid foramen 
(SMF), becoming extratemporal, and is then embedded in the parotid gland in its course.  
It exits the parotid gland, after branching into five main divisions and many smaller 
divisions, to finally reach the facial muscles.  The course of the facial nerve through the 
posterior fossa, temporal bone, and parotid gland renders it vulnerable to many 
neoplastic, traumatic, and infectious events.  
Lesions of the facial nerve within the cerebellopontine angle and the internal 
auditory meatus are usually due to compression by acoustic neuromas, meningiomas, 
epidermoids (sebaceous cysts), or tumors of the jugular vein (Mavrikakis, 2008; Rosson 
and Redett, 2008).  The nerve may further be damaged during surgical removal of 
neoplasms.  Lesions of the facial nerve within the temporal bone are due to Bell’s palsy, 
skull fractures, spread of inner ear infections, and petrous-temporal cancer.  Bell’s palsy 
is the most common, sudden cause of facial nerve paralysis and is believed to be caused 
by inflammation of the facial nerve during its course in the temporal bone, leading to 
compression and possible ischemia and demyelination (Tiemstra and Khatkhate, 2007).  
Although the inflammatory process is not completely understood, reactivation of the 
herpes simplex virus is thought to be the underlying cause. Extratemporal injuries of the 
facial nerve may result from traumatic injuries (lacerations and gun shot wounds) and 
complications arising from parotid gland tumors.    
 
b. Evaluation & Management 
The gold standard for grading facial nerve function is the House-Brackmann 
grading scale (House and Brackmann, 1985).  The grading system relies on evaluation of 
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IAM 
SMF 
Facial 
Nerve 
Facial Canal 
Extratemporal Injuries: 
Parotid gland tumors, 
iatrogenic, lacerations 
1 
IAM 
Inflamed 
Facial 
Nerve 
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Bell’s Palsy, tumor 
compression, 
infections bone 
factures 
2 
Facial Canal 
Facial 
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IAM 
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Pons 
 
Intracranial Injuries: 
Tumor compression 
3 
Figure 1:  Anatomy of the facial nerve.  Upon exit from the facial nucleus, the 
facial nerve runs intracranially, then enters the internal auditory meatus (IAM), 
turns in the facial canal, and exits the mastoid bone at the stylomastoid foramen 
(SMF).  Different types of injuries can occur at different segments of the nerve: 1) 
extratemporal 2) intratemporal and 3) intracranial.  CPA: cerebellopontine angle. 
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resting symmetry of the face, degree of voluntary movement on the affected side, and 
degree of synkinesis, with scores assigned from 1-6 in increasing severity of dysfunction.  
The degree of nerve damage is often also assessed by nerve conduction studies.  A 
reduction in the compound muscle action potential is suggestive of axonal degeneration, 
and an increase in latency is indicative of demyelination of the nerve (Kimura, 2006).   
Several medical and surgical interventions are currently used for facial nerve 
injuries.  Incomplete paralysis has an excellent prognosis and is managed purely by 
observation (Danner, 2008).  Following complete facial nerve paralysis, the use of 
corticosteroids is suggested to minimize nerve edema and degradation in nerve function.  
Whether corticosteroids should be administered, however, is still controversial, as their 
efficacy has not been clearly demonstrated (Turk-Boru, 2005).  Diagnosis of Bell’s palsy 
is usually also followed up with a course of anti-virals (i.e. acyclovir) due to the proposed 
viral etiology, but studies establishing their beneficial effects in animals and humans are 
still lacking (Tiemstra and Khatkhate, 2007).  Current surgical interventions include 
decompression, anastomoses, and nerve grafting.  If nerve function is significantly 
compromised at 2 weeks post-injury, decompression of the facial nerve is recommended 
(Danner, 2008).  In this procedure, the intratemporal portion of the facial nerve is 
decompressed to relieve pressure on the nerve from the surrounding bone. When the 
facial nerve is transected or sufficiently injured, requiring that the injured portion be 
removed, an end-to-end anastomoses is performed (Danner, 2008).  When additional 
nerve length is needed, an intervening nerve graft is used.  Even though these surgeries 
re-establish connection between the ends of the facial nerve, regeneration of axons across 
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the suture site may be hindered.  Therefore, the need to develop better treatments 
prevails as suboptimal functional recovery is often seen.   
 
C.  NEURONAL RESPONSE TO INJURY 
 Understanding the pattern of events that take place after a peripheral nerve injury 
can help develop potential treatments that enhance regeneration and recovery following 
facial nerve injury.  Complete repair of damaged axons depends upon a sequence of 
events: degeneration of nerve fibers distal to the injury site, development of growth cones 
proximal to the injury site, and regeneration of nerve fibers to reconnect with the original 
target (Ide, 1996).  The rate at which these events occur determines the recovery 
outcome.  A remarkable feature of the mature PNS is its ability to mount a robust 
regenerative response following injury.  Signals of cellular injury and stress are followed 
by activation of transcription factors, adhesion molecules, growth-associated proteins and 
structural proteins required for axon elongation (Makwana and Raivich, 2005; Bisby and 
Tetzlaff, 1992). 
 
1.  WALLERIAN DEGENGERATION 
 In 1850, Augustus Waller discovered that following lesion of a nerve, the distal 
segment undergoes progressive degeneration (Waller, 1850).  Calcium influx, after 
disruption of the axonal integrity, signals resealing of the severed end by a vesicle-
mediated process (Krause et al., 1994).  Distal to the site of injury, there is beading and 
swelling of the axonal membrane (George et al., 1995).  Following formation of these 
axolemmal blebs, the axonal cytoskeleton breaks via a process termed granular 
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disintegration, involving disassembly of microtubules, neurofilaments, and other 
cytoskeletal components (Vargas and Barres, 2007).  Recent studies using transgenic 
mice expressing the yellow fluorescent protein have shed insight into the spatial 
progression of granular disintegration.  Following nerve transection, disintegration 
progresses anterogradely, while a crush injury leads to retrograde degradation (Beirowski 
et al., 2005).  After axonal degeneration, blood-tissue permeability increases, the myelin 
sheath breaks down, and macrophages infiltrate the site of injury (Chen et al., 2007).  
Macrophages, along with Schwann cells, contribute to the clearance of myelin debris 
distal to the site of axonal injury.  In mammals the process of Wallerian degeneration 
takes approximately 7-14 days (Choi and Dunn, 2001). 
 At the cell soma, a critical component of the axon reaction is loss of afferent 
synaptic boutons from the surface of injured neurons (Graeber et al., 1993; Svensson and 
Aldskogius, 1993).  This phenomenon is known as “synaptic stripping” and is reversible 
following target reinnervation.  Microglia contribute to active stripping of detached 
presynaptic boutons (Blinzinger and Kreutzberg, 1968).  The amount of synaptic 
stripping correlates with the degree of stress produced by injury, depending on the type 
and proximity of injury.  In neurons disconnected from their target, removal of afferent 
inputs leads to significant alterations in the electrical properties of neurons and in turn 
may be related to an initial period of shock (Pinter and Vanden Noven, 1989).  
Treatments that target synaptic stripping may reduce neural stress and initiate 
regeneration earlier.      
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2.  AXONAL REGENERATION 
Whereas the distal axonal stump undergoes degeneration, the proximal stump 
begins regeneration.  Although the signals initiating the regeneration program have not 
been definitely identified, the disruption of retrograde flow of signals, calcium influx, and 
exposure of the injured axon end to the degenerating and inflammatory environment play 
a role in activating regeneration (Chen et al., 2007).  Peripheral axon lesions are thought 
to activate the intrinsic growth capacity by increasing levels of intracellular cyclic 
adenosine monophosphate (cAMP; Qiu et al., 2002a).  Not only are cAMP levels found 
to be elevated after injury, but injection of dibutyryl-cAMP into the dorsal root ganglia 
has been found to promote regeneration (Neumann et al., 2002; Qiu et al., 2002b).  The 
mechanism of action for cAMP involves protein kinase A (PKA; Neumann et al., 2002; 
Qiu et al., 2002).  The effects of cAMP and PKA on regeneration are dependent upon 
transcription, requiring activation of the cAMP response element binding (CREB) protein 
(Cai et l., 2002; Gao et al., 2004).  Activation of a coordinated pattern of gene expression 
is a crucial factor behind the intrinsic growth capacity of the PNS. 
 Functionally successful regeneration also depends upon a permissive environment 
and axon guidance cues that aid axons to regrow toward correct targets.  The tip of the 
regrowing axons, or the growth cone, responds to contact guidance cues, searching for an 
appropriate matrix and environment to support axonal growth (Chen et al., 2007; Lee and 
Wolfe, 2000).  Schwann cells play an important role in directing regeneration.  
Additionally, extracellular matrix proteins, such as laminin, mediate interaction between 
the growth cone and the Schwann cell membrane to promote neurite outgrowth and 
axonal guidance.          
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3.  MOLECULAR GROWTH PROGRAM 
Following axonal injury, several changes take place within the neuronal cell body 
that aid in the mounting of a regenerative response.  The cell body swells and undergoes 
chromatolysis, a process in which the Nissl granules become widely dispersed and the 
nucleus is displaced peripherally (Choi and Dunn, 2001).  These changes together reflect 
an increase in cellular metabolism, with a shift in priority from synthesis of 
neurotransmitters to production of structural materials and growth-associated proteins 
needed for axonal repair and regrowth.  Thus, axonal injury shuts down the differentiated 
functions of an adult neuron and activates a growth program instead (Snider et al., 2002). 
Over the years, the pattern of gene expression during regeneration has become 
increasingly well characterized.  Strategies designed to boost or accelerate the molecular 
growth program activated following injury can potentially be used as treatments. 
Signals of cellular injury and stress are followed by induction of transcription 
factors, adhesion molecules, cytoskeletal components, cytokines, and neurotrophic 
factors (Makwana and Raivich, 2005).  One of the earliest changes is the upregulation of 
polyamine-producing enzymes, linked to an increase in mRNA metabolism and protein 
synthesis (Tetzlaff et al., 1988a; Gilad et al., 1985; Gilad et al., 1996).  Blockade of 
polyamine synthesis thwarts the normal regenerative process.  Cell adhesion molecules 
are also upregulated following axonal injury.  Laminin as well as its receptor, alpha7 
beta1 integrin, have been shown to influence the speed of axonal regeneration and 
reinnervation of peripheral target (Werner et al., 2000).  A deletion in the laminin gene 
results in a significant decrease in the number of axons crossing the injury site to reach 
the distal portion of the crushed nerve.  Another cell adhesion molecule, galectin-1, 
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stimulates migration of Schwann cells to promote formation of cellular bridges that 
allow axonal growth into the distal part of the injured nerve (Fukaya et al., 2003; 
McGraw et al., 2004).   
 Successful axonal regeneration is accompanied by an increase in cytoskeletal-
associated proteins such as actin and microtubule subunits (Makwana and Raivich, 2005). 
At the growth cone, regulation of actin polymerization and microtubule assembly is 
crucial for axon elongation.  Therefore, axonal injury also leads to increased expression 
of various functionally diverse molecules that regulate cell surface and cytoskeletal 
interaction.  The 43-kilodalton growth-associated protein (GAP-43) and 23-kilodalton 
cytoskeletal-associated protein (CAP23) sequester the membrane phospholipid 
phosphoinositol 4,5-diphospate (PIP2) and regulate its availability at the raft regions of 
the cell membrane (Bomze et al., 2001; Laux et al., 2000).  Unbound PIP2 promotes actin 
polymerization.  Initially, upregulation of GAP43 and CAP23 may help to sequester PIP2 
at the axonal shaft and prevent early axonal branching.  Later, phosphorylation of GAP43 
and CAP23 may lead to release of PIP2, thus promoting actin polymerization at the edge 
of the growth cone.  Additionally, GAP43 and CAP23 modify recruitment of signaling 
molecules to rafts, thus altering cell surface interactions.  As these molecules also interact 
with calcium/calmodulin, they may translate calcium fluxes into signals that guide 
growth cone motility (Dunican and Doherty, 2000; Gerendasy, 1999).   
A crucial feature of the transcriptional program activated following injury is the 
increase in neurotrophic factors.  The concept of neurotrophic factors was first put forth 
by Ramon Y Cajal (Cajal, 1991).  Neurotrophic factors promote development and 
maturation during the embryonic period and maintain neuronal activity during adulthood 
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and regeneration (Terenghi, 1999).  The neurotrophin family includes nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), and a variety of neurotrophins 
(NT), NT3 to NT7 (Terenghi, 1999; Gordon, 2009).  Axonal injury in the PNS 
upregulates endogenous neurotrophins in neurons and in denervated Schwann cells.  
Motor and sensory systems show distinctive patterns of expression of neurotrophic 
factors.  NGF, BDNF, NT-4, and the common neurotrophin receptor, p75, are 
upregulated in primary sensory neurons following injury (Terenghi, 1999; Funakoshi et 
al., 1993; Meyer et al., 1992).  Upregulation of BDNF, glial-derived neurotrophic factor 
(GDNF), ciliary neurotrophic factor (CNTF), and NT-3 is associated with injury to 
motoneurons (Yan et al., 1992; Sendtner et al., 1990; Zhou and Rush, 1995).  Expression 
of tyrosine receptor kinase B (trkB), the neurotrophin receptor that binds specifically to 
BDNF and NT-4/5, also increases in motoneurons.  
BDNF increases survival of motoneurons following axotomy in neonates and 
ventral root avulsion in adults (Yan et al., 1992; Novikov et al., 1995; Novikova et al., 
1997a; Novikova et al., 1997b).  BDNF administration also reverses soma atrophy and 
prevents reduction of choline acetyl transferase (Kishino et al., 1997).  Administration of 
CNTF promotes muscle fiber reinnvervation, preservation of muscle mass, and 
myelination of regenerating axons (Ulenkate et al., 1994; Newman et al., 1996; Sahenk et 
al., 1994).  NT-3 has been shown to enhance neurite outgrowth in spinal cord explants 
and to increase the number of motor end-plates in vitro (Braun et al., 1996).  Like BDNF, 
GDNF also maintains motoneuron survival, reduces axotomy-induced soma atrophy, and 
prevents the decline in choline acetyl transferase (Henderson et al., 1994; Matheson et al., 
1997).  Exogenously administered BDNF and GDNF have been shown to promote axonal 
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sprouting shortly after axotomy (Boyd and Gordon, 2002).  In conditions of prolonged 
axotomy, BDNF and GDNF also increase the number of neurons regenerating their axons 
into the distal nerve stump (Boyd and Gordon, 2002; Boyd and Gordon, 2003).  In 
addition to neuronal and non-neuronal cells, neurotrophic factors can also be synthesized 
in the target muscle tissue.   
 
D.  NEUROTHERAPEUTIC ROLE OF GONADAL STEROIDS 
 A variety of hormones, including gonadal steroids, glucocorticoids, and thyroid 
hormones, have been explored as neurotherapeutic agents for the injured or diseased 
nervous system.  Extensive studies on gonadal steroids have distinguished them as 
potential therapeutic agents.  Estrogen is known not only to affect learning, memory, 
behavior and cognition, but has also been demonstrated to have neuroprotective and 
neuroregenerative effects (Green et al., 1997; McEwen and Alves, 1999; Matsumoto and 
Arai, 1981; Garcia-Segura et al., 2001).  Progesterone has been shown to promote 
recovery from spinal cord injuries and to rescue motoneurons from degeneration 
(Thomas et al. 1999; Labombarda et al., 2003; Gonzalez et al., 2002).  Androgens have 
been shown to play a neurotherapeutic role in various disease conditions and to enhance 
peripheral nerve regeneration, as described below.       
 
1.  ANDROGENS 
 Targeting numerous body tissues, androgens have a multitude of functions, 
including functions in reproduction, development of primary and secondary sexual 
characteristics, increasing muscle mass, and influencing neuronal functioning.  During 
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nervous system development, the presence or absence of androgens determines the 
sex-specific morphological and behavioral patterns of the adult (Kaiser and Morley, 
1994; Beyer and Hutchison, 1997).  Within the brain, testosterone not only exert long-
term organizational (permanent) effects during the developmental period, but they also 
have transient activation (reversible) effects during regenerative events (Arnold and 
Gorski, 1984).   
 Gonadal steroids are derived from cholesterol and synthesized primarily in the 
adrenal cortex and the gonads (Champe and Harvey, 1994).  The majority of testosterone 
production takes place in the Leydig cells of the testes.  After secretion from its sites of 
synthesis, testosterone is delivered via protein-bound transport in the blood stream to 
target organs.  Approximately 60-70% of testosterone is tightly bound to sex hormone 
binding globulins (SHBG), 30-40% is bound loosely to albumins, and 0.5-2% is free 
(Iqbal et al., 1983).  Sex differences in SHBG influence the circulating levels of 
testosterone in males and females (Bialek et al., 2004).  Also, SHBG levels are known to 
increase with age, thereby reducing the levels of free testosterone (Leifke et al., 2000).  
Testosterone, in its free form, can cross the blood brain barrier and have effects on the 
CNS and the PNS (Champe and Harvey, 1994).  As it is lipid soluble, the hormone can 
easily cross the cell membrane to bind to its intracellular receptor, the androgen receptor 
(AR).  Testosterone can act either directly through an androgen pathway or indirectly 
through its aromatization to estrogen.  
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2.  MECHANISM OF ACTION 
Steroid hormones act on the nervous system using two different mechanisms, 
genomic and non-genomic.  The genomic mechanism is slow-acting and involves binding 
of the hormone to its nuclear receptor.  Subsequent binding of the hormone-receptor 
complex to DNA sites called hormone response elements acts to alter gene expression 
(Beato, 1989).  The non-genomic mechanism is fast-driven and involves interaction of 
the hormone with membrane or neurotransmitter receptors (McEwen, 1991; Falkenstein 
et al., 2000).  Steroid utilization of one or both of these mechanisms leads to changes in 
cells of the nervous system and effects on neurotropism and regeneration.   
The presence of nuclear ARs in various regions of the brain and spinal cord 
allows testosterone to exert genomic effects.  The distribution of ARs has been identified 
autoradiographically, biochemically and with in situ hybridization and 
immunocytochemical methods (Morrell and Pfaff, 1978; McEwen et al., 1982; Simerly et 
al., 1990).  ARs are predominantly found in the medial hypothalamic area, ventromedial 
and dorsomedial nucleus, preoptic area, arcuate nucleus, amygdala, regions of the 
hippocampus, and lower motoneurons of the brainstem and spinal cord (Ozawa, 2005; 
Sar and Stumpf, 1977; Yu and McGinnis, 2001).  There are sex-related differences in AR 
distribution, with males having higher concentration of the AR protein than females (Lu 
et al., 1998).  Exposure to gonadal steroids induces rapid ultrastructural changes in 
neurons, including alterations in the nucleolus and rough endoplasmic reticulum, 
increases in cell size, increases in nuclear size and changes in nuclear shape from 
ellipsoid to spherical (Cohen and Pfaff, 1981; Jones et al., 1990).  The interval between 
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rRNA transcription and processing is also shortened in the presence of gonadal steroids 
(Kinderman and Jones, 1993). 
Recent evidence also points towards a non-genomic mechanism of action for 
gonadal steroids.  Extranuclear ARs have been identified in neuronal axons and dendrites 
as well as glial processes of the cerebral cortex, hippocampus, and amygdala (DonCarlos 
et al., 2003; Tabori et al., 2005; DonCarlos et al., 2006).  The function of extranuclear 
ARs remains unknown.  Wagner et al. (1998) has suggested that the estrogen-receptor 
complex retains its function as a transcription factor to act on mitochondrial DNA.  Also, 
mitchondrial DNA is known to contain several genes with androgen response elements in 
the promoter region (Solakidi et al., 2005).  Another non-genomic role of androgens may 
be to activate signal transduction pathways.   Androgens have been demonstrated to 
activate mitogen-activated protein kinase (MAPK) and phophatidlyinositol-3 (PI3) kinase 
pathways in various cell culture systems, including hippocampal neurons, epithelial cells, 
and skeletal muscle cells (Nguyen et al., 2005; Baron et al., 2004; Estrada et al., 2003).  
In male rat osteoblasts, testosterone also increases intracellular levels of Ca2+ within 5 s 
by increasing Ca2+ influx and Ca2+ mobilization from the endoplasmic reticulum 
(Lieberherr and Grosse, 1999).   
In the mouse facial motor nucleus (FMN), AR protein is localized to the 
cytoplasm but becomes concentrated to the nucleus upon treatment with testosterone 
(Tetzlaff et al., 2007a).  Therefore, androgens may have genomic as well as non-genomic 
effects within the FMN.  Unbound steroid receptors are known to complex with heat 
shock proteins (hsp; Pratt and Toft, 1997).  AR has been shown to associate with hsp70 in 
prostatic cell lines (Veldscholte et al., 1992).  Thus, the administration of androgens may 
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mediate the cell response following neuronal injury by binding to ARs and releasing 
hsp70.  Previous studies from our laboratory have shown that hsp70 mRNA levels 
increase by 364% following facial nerve transection in hamsters (Jones et al., 2000).  The 
administration of testosterone, however, prevents this increase, suggesting that it 
substitutes the need to synthesize hsp70 by making available pre-existing hsp70.  This 
mechanism would allow injured neurons to mount a regenerative response more 
immediately, without the need to mount a stress response first.   
 
3.  NEUROTROPHIC EFFECTS  
 It is now well understood that gonadal steroids have a variety of trophic effects on 
the nervous system.  Studies have demonstrated their effects on cell survival, 
neurotransmission, growth and development, elaboration of processes, and 
synaptogenesis (Nordeen et al., 1985; Luine, 1985; Jones et al., 1985; Matsumoto et al., 
1988a; Matsumoto et al., 1988b).  Androgen-mediated regulation of synaptic connectivity 
and neurite outgrowth has been well documented in the sexually dimorphic cluster of 
spinal motoneurons (SNB or spinal nucleus of the bulbocavernosus), which innervate the 
perineal muscles in the male rodent (Breedlove and Arnold, 1980, Kurz et al. 1986).  For 
example, following castration, the number of synaptic contacts in the SNB decreases, 
along with a reduction in dendritic length and soma atrophy (Breedlove and Arnold, 
1981).  These changes are reversed by androgen replacement, suggesting that androgens 
regulate neuronal function in adulthood (Matsumoto et al., 1988b). 
 In addition to the SNB, the dorsolateral nucleus (DLN) is another motor neuron 
population in the rodent spinal cord that is sexually dimorphic.   Autoradiographic studies 
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demonstrated that adult DLN motor neurons concentrate androgens and ARs 
(Breedlove and Arnold, 1980).  In both the SNB and DLN, perinatal exposure to 
androgens attenuates the cell loss that normally occurs during development in rodent 
females (Breedlove and Arnold, 1981; Sengelaub and Arnold, 1989).  Another well-
studied example of androgens effects on cell survival is the sexually dimorphic nucleus 
of the preoptic area (SDN-POA).  Male rodents have larger cells and a greater percentage 
of cells than females, while neonatal females treated with androgens demonstrate 
increased volume of SDN-POA (Gorski et al, 1978; Jacobson et al., 1981; Murakami and 
Arai, 1989).  The effects of androgens on survival of non-sexually dimorphic spinal 
motor neurons have also been demonstrated.  Lumbosacral spinal cords of developing 
embryos cultured in the presence of androgens exhibit an increased number of cells fated 
to become ventral motor neurons (Hauser and Toran-Allerand, 1989).       
  
4.  ROLE IN NEUROBIOLOGICAL DISEASES 
 Increasing evidence demonstrates that gonadal steroids play a neuroprotective 
role in diseases of the nervous system.  Testosterone levels gradually decrease as a 
normal consequence of aging in men, and this may make the brain more susceptible to 
neurodegeneration (Bialek et al., 2004).  Glial fibrillary acidic protein (GFAP) has been 
shown to increase with aging in several regions of the brain, including the hippocampus, 
striatum, cerebral cortex, and white fiber tract (Nichols et al., 1993).  Changes in GFAP 
expression reflect reactive astrocyte hypertrophy and are often used as a marker for 
neurodegeneration.  Testosterone replacement in 24-month old rats is reported to reverse 
the age-related increase in GFAP expression (Day et al., 1998).  Testosterone 
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replacement in aging mice also alleviates age-related learning and memory impairment 
(Flood et al., 1995).  Castration has also been shown to reduce cognitive function in male 
dogs (Hart , 2001).  
 Testosterone is also proposed to play a neuroprotective role in Alzheimer’s 
disease (AD).  Hyperphosphorylation of tau protein, a pathological hallmark of AD, can 
be reduced by testosterone administration in male rats (Papasozomenos, 1997).  Secretion 
of amyloid-β (Aβ) peptide, a component of plaques found in AD brain, is also decreased 
following treatment with testosterone (Gouras et al., 2000).  Testosterone has also been 
shown to protect hippocamapal cultures from Aβ-mediated apoptosis through an 
estrogen-dependent mechanism involving the aromatization of testosterone to estradiol 
(Pike, 2001).  These and other reports implicate that testosterone may be beneficial for 
prevention or alleviation of AD.  Randomized clinical trials have also examined the 
effects of testosterone on cognitive function in healthy men aged 50-80 years and shown 
that testosterone enanthate supplementation improves spatial and verbal memory 
(Cherrier et al., 2001).  An additional study reported that testosterone enanthate also 
improves working memory in healthy volunteers (Janowsky, 2000).  The potential of 
androgen treatment for mild cognitive impairment and AD is worth exploring.   
 A neuroprotective role of androgens is also associated with motor neuron 
diseases.  Amyotrophic lateral sclerosis (ALS) is a progressive and fatal motor neuron 
disease, characterized by progressive weakness and atrophy of skeletal muscles.  
Deficiencies in androgen receptor are linked to ALS as cranial motoneurons III, IV, and 
VI, which normally lack AR, are spared from degeneration (Williams and Windebank, 
1991).  Serum levels of free testosterone are also significantly decreased in ALS patients 
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(Militello et al., 2002).  Spinal bulbar muscular atrophy (SBMA) is another motor 
neuron disease associated with AR that results in progressive weakness and wasting of 
the muscles of the limbs and face.   An abnormal expansion of the polyglutamine tract in 
the AR gene leads to a toxic gain-of-function, with aggregates leading to obstacles in 
cellular processes such as trafficking and connectivity (Poletti, 2004; Brooks et al., 1998).  
A loss-of-function is also thought to result from the SBMA AR mutation, as the 
elongated polyglutamine tract leads to reduced transcription of AR (Abdullah et al., 1998; 
Mhatre et al., 1993).  A lack of androgenic control of neurite outgrowth in motoneurons 
may lead to an inability to maintain or recover normal shape and function of dendrites 
and axons.  In fact, immortalized motoneurons expressing mutant AR display short and 
dystrophic neurites with abnormal branching patterns (Poletti, 2005).  Therefore, a further 
understanding of androgen-mediated neurotherapeutic effects will be valuable to finding 
treatment strategies for neurodegenerative diseases. 
 Several studies have also demonstrated that androgen treatment protects against 
hypoxic-ischemic brain damage.  For example, in a study performed on neonatal rats, a 
hypoxic-ischemic injury causes obvious signs of injury in cortical and hippocampal 
neurons, including cell organ decreasing, nuclear swelling, chromatic agglutination, 
mitochondria decreasing and swelling, and an increase in apoptotic cells (Li et al., 2008; 
Li et al., 2006).  In comparison, treatment with testosterone maintains an integrated 
nuclear membrane, well-distributed chromatin, and abundant cell organelles, and it 
reduces apoptosis and enhances regeneration.   
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5.  ROLE IN PERIPHERAL NERVE REGENERATION 
 The therapeutic effects of androgens following peripheral nerve injury have been 
examined in several model systems.  Over a course of numerous studies, our lab 
investigated the role of gonadal steroids in the neuronal reparative process using a 
hamster facial nerve axotomy model, in which the facial nerve is crushed or transected at 
its exit from the SMF.  Initial studies were aimed at determining the effects of an ester of 
testosterone, testosterone propionate (TP), on functional recovery following a facial nerve 
crush in adult male Syrian hamsters (Kujawa et al., 1989).  Varying doses and 
administration methods of TP were tested: 1) subcutaneous injection of TP in sesame oil 
vehicle every other day, 2) subcutaneous injection of TP in sesame oil vehicle every day, 
and 3) subcutaneous Silastic implant of TP.  Results demonstrated accelerated functional 
recovery in each TP-treated group, along with a dose-response relationship.  Higher and 
more frequent doses of TP had better effects on functional recovery, with the continuous 
dose achieved by Silastic implants having the most enhanced effects.  Additionally, 
gonadectomized male hamsters were not different than gonadally intact animals, 
indicating that normal endogenous levels of testosterone had little or no effect.   
The next study examined the effects of TP on rate of facial nerve regeneration 
following a facial nerve crush at the nerve’s exit from SMF and found that testosterone 
administration increased the regeneration rate by 26-30% (Kujawa et al., 1991).  
Furthermore, our lab has found that treatment with testosterone metabolites, 
dihydrotestosterone (DHT) and estrogen, increases regeneration rates (Tanzer and Jones, 
1997).  The effects of testosterone on molecular events have also been investigated in the 
facial nerve axotomy model.  Results demonstrate that TP selectively upregulates 
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regeneration-associated genes such as βII-tubulin and GAP-43 and decreases 
expression of GFAP in the FMN (Jones and Oblinger, 1994; Jones et al., 1997a; Jones et 
al., 1997b).  TP administration also has a pronounced effect on synaptic stripping 
following facial nerve transection in hamsters (Jones et al., 1997c).  TP preserves 
approximately half of the axosomatic synapses that are otherwise removed in untreated 
animals, suggesting that TP treatment may reduce the initial shock to injured neurons. 
 Other peripheral nerve injury models also support a neurotherapeutic role for 
gonadal steroids in nerve regeneration.  Yu and Srinivasan (1981) have shown that TP 
administration enhances hypoglossal nerve regeneration in rats.  TP also increases 
regeneration in rat sciatic motoneurons and accelerates functional recovery following 
hind limb paralysis (Kujawa et al., 1993; Brown et al., 1999).  Vita et al. (1983) have also 
reported the accelerative effects of androgens on sciatic nerve regeneration in male 
rabbits.  Apart from enhancing axonal regeneration, gonadal steroids also mitigate cell 
loss following axotomy.  Administration of DHT and estrogen reduces loss of facial 
motoneurons following a facial nerve transection in neonatal hamsters (Huppenbauer et 
al., 2005).  A study by Perez and Kelley (1996) also found that androgen treatment 
enhanced survival of laryngeal motoneurons in Xenopus laevis.  Therefore, androgens 
serve as a potential treatment strategy for peripheral nerve injuries.  
 
E.  NEUROTHERAPEUTIC ROLE OF ELECTRICAL STIMULATION 
Electrical activity is a normal environmental component within the nervous 
system and plays an important role from development to adulthood.  Application of 
electrical fields affects morphological and functional properties of neurons such as nerve 
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branching, rate and orientation of neurite growth, rapid sprouting, and guidance during 
axon regeneration (McCaig, 1990; Borgens et al., 1981; Patel and Poo, 1982; 
Manivannan and Terakawa, 1994; Borgens, 1999).  Electrical stimulation has been 
explored as a therapeutic strategy for various neurobiological diseases, including 
movement disorders, seizures, psychiatric disorders, chronic pain syndromes, and spinal 
cord and peripheral nerve injuries (Wan and Lin, 2009).   
 
1.  HISTORY OF ELECTRICAL STIMULATION 
Early in vitro experiments investigated the effects of ES on morphological 
properties of neurons.  For example, Jaffe and Poo (1979) demonstrated that growing 
nerve fibers react within minutes of exposure to an applied direct current (DC) field and 
orient themselves parallel to the gradient.  McCaig (1990) reported that applying electric 
field in Xenopus laevis further shaped neurite morphology by increasing the number of 
filopidia at the growth cone and the number of cytoplasmic spines along a neurite shaft 
and by enhancing nerve branching.  Mannivanan and Terakawa (1994) found that brief 
pulse stimulation of nerve terminals of bovine chromaffin cells and PC12 cells induced 
exocytosis and rapid formation of filopidia.      
A series of studies also examined axonal regeneration with applied DC fields in 
giant reticulospinal neurons of the brain and spinal cord of a primitive vertebrate, the 
lamprey Petromyzon marinus.  Borgens et al. (1981) applied a weak, steady electric 
current across completely severed spinal cords of lamprey larvae and found the 
regeneration rate to be enhanced.  The regenerated axons were also able to make 
functional synaptic connections with the caudal end of the injured spinal cord in the 
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presence of the applied electric gradient.  In another study, Roederer et al. (1983) 
found that one mechanism by which ES may augment regeneration of the severed 
lamprey spinal cord is by decreasing the initial “die-back” response, or the retrograde 
degeneration of the proximal axonal stump.  Application of steady electric gradients 
across injured spinal cords of guinea pigs also induced both anatomical and functional 
recovery.  Wallace et al. (1987) extended these findings by studying the effects of DC 
fields on axonal regeneration following severe compressive injuries in rats and finding 
significant acceleration of functional recovery.   
ES also influences survival of neuronal populations following axotomy in the 
CNS.  ES of the transected optic nerve for 2 h promoted survival of retinal ganglion cells 
following transection of the optic nerve in rats (Morimoto et al., 2002).  Okazaki et al. 
(2008) have further examined different ES parameters of optic nerve stimulation.   While 
10 min of ES was found to be ineffective, 30 min of ES was as effective as 1 h and 2 h of 
ES in enhancing neuronal survival.  The frequency of ES also affected neuroprotection, 
and a frequency of 20 Hz was found to be optimal, with lower (10Hz) and higher (50Hz) 
frequencies having no beneficial effect.  In summary, numerous experiments over the 
past two decades have established that ES provides directional cues, influences 
orientation and regeneration in vitro and in vivo, promotes survival of CNS neurons, and 
accelerates functional recovery following spinal cord injury.         
  
2.  EMERGING ROLE IN PERIPHERAL NERVE REGENERATION 
 Several studies in the 1980s investigated the effects of ES of injured nerves on 
axonal regeneration.  Nix and Hopf (1983) stimulated the crushed motor nerve 
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innvervating the soleus muscle in rabbits for 24 h daily, over a period of 4 weeks.  
Contraction parameters and muscle action potential showed accelerated improvement in 
stimulated animals.  Pockett and Gavin (1985) examined varying periods (5-60 min) of 
ES of the crushed sciatic nerve in rat.  Results indicated that 15-30 min of daily ES 
accelerated the return of the toe-spread reflex, an index of reinnervation of the flexor 
muscles.  Although these studies were essential in establishing that ES accelerated 
functional recovery following peripheral nerve injury, they did not distinguish whether 
the results were due to enhanced regeneration of axons or reinnervation of muscle fibers. 
Towards this goal, Al-Majed et al. (2000a) used the rat femoral nerve model of 
transection and surgical repair to assess the efficacy of ES in accelerating axonal 
regeneration and promoting reinnervation specificity.  A frequency of 20 Hz was used, 
similar to the normal firing patterns of slow motoneurons.  Results demonstrated that 1 h 
to 2 weeks of ES increased the number of motoneurons that had regenerated not only 
farther from the site of injury but also into the appropriate branch.  Further studies using 
proximal labeling revealed that 1 h ES of the femoral nerve increased the number of 
axons that regenerated across the suture gap (Brushart et al., 2002).  ES has also been 
shown to promote regeneration of sensory axons and improve their selective 
reinnervation following peripheral nerve injury (Brushart et al., 2005).  
Recently, studies done in rats were translated to humans in whom the median 
nerve had been damaged from carpal tunnel syndrome (Gordon et al., 2007).  In a 
randomized clinical trial, the median nerve was stimulated for 1h during carpal tunnel 
release surgery.  ES increased the motor unit number estimates and accelerated functional 
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recovery in patients.  Given these findings, ES can be used as a strategy to improve the 
outcome of peripheral nerve injury.    
       
3.  MECHANISM OF ACTION 
 Investigating the mechanism by which ES helps regeneration can add additional 
insight on how recovery may be promoted.  Al-Majed et al. (2000a) determined that the 
regeneration-associated effects of ES were mediated by the cell body.  In this experiment, 
transected and repaired femoral nerve in rats was stimulated with or without the 
application of tetrodotoxin (TTX; blocker of voltage-gated sodium channels), at a dose 
that is effective in completely blocking action potential transmission to the cell bodies of 
nerves.  TTX completely abolished the ability of ES to enhance axonal regeneration, 
suggesting that ES acts to enhance the growth program initiated by the cell body.  
 In a subsequent study, Al-Majed et al. (2000b) demonstrated that ES accelerated 
the upregulation of BDNF and its trkB receptor in axotomized femoral motoneurons of 
rats.  This was followed by an upregulation of GAP-43 and cytoskeletal proteins (actin 
and α1-tubulin) and a downregulation of neurofilaments (Al-Majed et al., 2004).  A 
decrease in neurofilament to tubulin ratio is associated with enhanced regeneration, as 
neurofilaments interfere with axonal transport of actin and tubulin (Bisby and Tetzlaff, 
1992).  English et al. (2006) have further demonstrated that the lack of NT-4/5 in 
transgenic mice abolishes the enhanced regeneration induced by ES.  Therefore, an 
increase in neurotrophic factor production appears to be an essential downstream effect of 
ES.    
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 ES is believed to mediate changes in expression of regeneration-associated 
genes by increasing intracellular levels of cAMP (Gordon, 2009).  This early increase in 
cAMP with ES is most likely preceded by increased calcium entry into the cell body.  
Interestingly, administration of rolipram, a specific inhibitor of the neuronal enzyme that 
hydrolyses cAMP (phosphodiesterase IV), mimics the enhanced regenerative effects of 
ES (Gordon, 2009).  Besides stimulating neural cells to synthesize regeneration-
associated gene products, ES may work through additional mechanisms.  Wan and Lin 
(2009) recently presented the hypothesis that electrical stimulation of injured nerves may 
work to accelerate the transport of mRNAs to axons.  As axonal injury has been shown to 
activate local protein synthesis, an enhanced capacity to transport mRNAs and locally 
translate them may improve the reparative response.  Therefore, the authors propose that 
electrical stimulation may modulate the interaction between RNAs/proteins and carriers 
or regulate microtubule dynamics.   
 
F.  COMBINATORIAL TREATMENT STRATEGY 
Based on the numerous studies reporting that gonadal steroids positively affect 
nerve regeneration and the emerging studies demonstrating that ES significantly affects 
neuronal properties, this dissertation aims to examine the therapeutic effects of 
combining both treatments in facial nerve injury models.  The extratemporal model of 
facial nerve injury is a well-established model that has been used to study the response of 
neurons and their microenvironment to injury (Moran and Graeber, 2004).  In this 
axotomy paradigm, the facial nerve is crushed or transected at its exit from the SMF.  
Clinically, this model is relevant only to facial nerve injuries that occur after the nerve’s 
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exit from the skull.  As more proximal injuries are exceedingly prevalent in cases of 
facial paresis, there is a need to develop animal models representing more proximal 
injury sites.  A rodent intracranial model of facial nerve injury has been described, with 
the facial nerve being transected ~0.5 mm from its exit from the brainstem (Mattson et 
al., 1999).  However, lesions of the facial nerve during its course in the temporal bone 
comprise a majority of cases that present in the clinic.  Thus development of an animal 
intratemporal model of facial nerve injury would be beneficial to studying degenerative 
and regenerative responses and their treatment.    
 
A.  PRELIMINARY FINDINGS 
Our laboratory has recently tested the effectiveness of ES and TP, administered 
alone and in combination, in accelerating functional recovery in a rat extratemporal facial 
nerve injury model (Lal et al., 2008; Hetzler et al., 2008).  Successful crushing of the 
nerve resulted in complete loss of the eyeblink reflex, vibrissae orientation, and vibrissae 
movement.  Functional recovery was assessed over time by comparing the return of these 
parameters on the axotomized side to the unaxotomized side.   
We found that the recovery time for the onset of the eyeblink reflex, an indicator 
of initiation of recovery, was shortened selectively by ES (Figure 2A).  In the ES-only 
group and the ES plus TP group, the average time until the onset of eyeblink was 3.71 ± 
0.97 days post-operative (dpo) and 4.14 ± 0.55 dpo, respectively.  In comparison, the 
untreated group and the TP-only group showed significantly delayed recovery at 9.57 ± 
1.86 dpo and 8.38 ± 0.91 dpo, respectively.  The presence of TP, therefore, did not affect 
onset of the eyeblink reflex.  When analyzing the effects of treatments on complete 
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functional recovery, we found that the percent change in recovery time was similar 
with both treatments administered alone.  Either with ES-only or TP-only, recovery 
occurred ~8% faster than in untreated animals (Figure 2B).  In the presence of both 
treatments (ES plus TP), however, animals recovered occurred ~22% faster than 
untreated animals.  This significant improvement with the combined treatment may be a 
result of each treatment affecting different aspects of cellular events associated with 
regeneration, therefore leading to an overall additive effect.   
 
B.  GAPS IN KNOWLEDGE 
Further studies need to assess the effects of our combinatorial treatment strategy 
at the molecular and cellular level to determine if ES and TP work through different 
mechanisms.  A previous study in the hamster extratemporal facial nerve axotomy model 
has shown that systemic administration of TP accelerates the rate of nerve regeneration 
but has no effect on the delay before sprouting begins (Kujawa et al., 1991).  Whether ES 
is able to shorten this delay in sprouting remains to be determined.  Furthermore, 
although both ES and testosterone independently have been shown to upregulate 
regeneration associated genes, it would now be beneficial to compare the differences in 
specificity and timing of gene expression between the two treatments.  If the 
combinatorial treatment has enhanced effects on axonal regenerative properties and gene 
expression, then the strategy would demonstrate translational potential for improving 
recovery following injury of peripheral nerves, such as the facial nerve. 
A clinically relevant model of intratemporal facial nerve injury is lacking.  
Comparing animal models representing two facial nerve injury sites, such as 
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extratemporal and intratemporal, will allow assessment of how the pathological results 
and functional outcomes differ between the two.  Furthermore, this would provide insight 
into predicting the course of recovery in patients presenting with the varying facial nerve 
lesions.  Therefore, the overall goal of this dissertation is to investigate the 
therapeutic effects of ES and testosterone, alone and in combination, in two 
translational facial nerve injury models, the well-established extratemporal and the 
proposed intratemporal.  
 
 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  Effects of ES and TP on facial functional recovery following an 
extratemporal facial nerve crush injury in rats.  (A) The effects of ES and TP 
on the onset of the eyeblink reflex, the earliest functional parameter to return. All 
data are reported as mean days post-axotomy ± the standard error of the mean.   
(* = p<0.05 as compared to no treatment; ** = p<0.05 as compared to TP-only).  
(B) Effects of ES and TP on percent change in complete recovery as compared 
to the no treatment group. (Adapted from Lal et al. 2008 and Hetzler et al., 2008).  
A.  Onset of Eyeblink Reflex 
B.  Complete Functional Recovery 
A.  Onset of Eyeblink Reflex 
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CHAPTER III 
MATERIALS AND METHODS 
 
 
A.  ANIMALS 
All animals used in the present study were adult, male Sprague-Dawley rats (2 
months old or ~250 g), purchased from Harlan (Indianapolis, IN).  Animals were allowed 
to acclimate to their environment for at least 3 days upon arrival, prior to any 
manipulation.  Rats were housed under a 12 h light/dark cycle in microisolater cages and 
received a standard rodent diet and water ad libitum.  All surgical procedures were 
completed in accordance with the National Institutes of Health guidelines on the care and 
use of laboratory animals for research purposes and approved by the institutional animal 
care and use committee.   
Sterile, aseptic techniques were used throughout the study.  Any animals 
displaying ≥15% weight loss were removed from the experiment.  Sutures were removed 
10-14 days post-operative (dpo).  Carbon dioxide asphyxiation was used to sacrifice all 
animals at the appropriate post-operative survival time.  
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B.  SURGICAL PROCEDURES 
 
1.  GONADECTOMY 
Gonadectomies were performed 3-5 days prior to facial nerve axotomy.  Animals 
were anesthetized with 3.5% isofluorane, and the surgical area was prepped with ethanol 
and providone-idodine.  A small horizontal incision between the penile and the anal 
openings was made, and both testicles were pulled through one at a time.  The testicular 
and epididymal arteries were ligated bilaterally with 4-0 silk suture, and testicles were 
severed distal to the sutures.  Wound site was sutured with 4-0 prolene, and animals were 
allowed to recover under observation. 
 
2.  EXTRATEMPORAL FACIAL NERVE AXOTOMY 
  Animals were anesthetized by intraperitoneal injections of Ketamine (100 mg/ml; 
0.1 ml/100g body weight) and Xylazine (20 mg/ml; 0.025 ml/100g body weight).  The 
right post-auricular area was shaved and prepped with ethanol and providone-iodine 
solution.  All crush-axotomies were performed on the right facial nerve, with the left 
facial nerve remaining intact and serving as an internal control in each animal.  A small 5 
mm incision was made posterior to the right ear cartilage.  The underlying muscle layer 
was carefully dissected away to expose the facial nerve at its exit from the SMF.  Under a 
dissecting microscope, the nerve was gently cleaned to free it from surrounding 
connective tissue.  A fine jeweler’s forceps was used to crush the nerve ~1 mm from the 
SMF.  Two 30 sec crushes, from alternating sides, were done to ensure a full crush.  
(Note:  For Aim #3, a single 1 min crush was performed to allow direct comparison to the 
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intratemporal crush axotomy described below).  The injury paradigm severed the axons 
but left the neural sheath intact to provide a route for regenerating axons.  The wound site 
was sutured with 4-0 prolene and coated with Triple Antibiotic Ointment (Henry Schein).  
Successful crush was verified by complete loss of the eyeblink reflex and loss of 
vibrissae orientation and movement in animals upon recovery from anesthesia. 
 
3.  INTRATEMPORAL FACIAL NERVE AXOTOMY 
 Animals were anesthetized by intraperitoneal injections of Ketamine-Xylazine, as 
described above.  During surgery, animals were kept on a heating pad to avoid 
hypothermia.  The right post-auricular area was shaved and prepped, and a curvilinear 
incision was made ~5 mm behind the ear.  Under a dissecting microscope, the 
extratemporal potion of the nerve was exposed at its exit from the SMF, anterior to the 
sternocleidomastoid muscle.  The sternocleidomastoid tendon was divided to provide 
better exposure of the nerve.  The dorsal and caudal aspects of the ear canal were incised 
so that the incision was immediately lateral to the tympanic membrane.  Next, the ridge 
of bone superior to the temporal bone and the tympanic membrane was identified.  The 
temporalis muscle inserting on this ridge anteriorly and the rhomboid capitis muscle 
inserting posteriorly were sharply incised with a #15 scalpel blade.  The muscles were 
gently dissected off the ridge, down to the level of the temporal bone, to expose ~1.5 cm 
of the bone superior to the tympanic membrane.          
 Next, during drilling of the temporal bone, the facial nerve was constantly kept in 
view to avoid inadvertent injury.  A #3 French suction-irrigator was used to bathe the 
operative field in room temperature 0.9% saline to prevent thermal injury to the temporal 
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bone and the facial nerve from the drilling procedure.  Using a dental drill and a 3 mm 
cutting burr, the superior tympanic bulla was drilled in a saucerized manner.  The lateral 
bony aspect of the epitympanic region was also removed to expose the ossicles.  The 
malleus, incus, and stapes were removed with jeweler’s forceps to allow access to the 
region of the temporal bone medial to the ossicles, where the intratemporal portion of the 
facial nerve lies.    
 A 2 mm diamond burr was then used to further remove bone from the superior 
tympanic rim and to thin the antero-superior aspect of the SMF.  A 1 mm diamond burr 
was used as the drill came closer to the underlying facial nerve.  Starting at the posterior 
aspect of the SMF and continuing antero-medially, the bone covering the facial nerve was 
progressively removed.  Vibrissae twitching on the ipislateral side was observed as the 
drill came nearer to the nerve.  After the bone covering the facial nerve had been 
sufficiently thinned, a Rosen needle was used to remove any remaining bone from the 
surface of the nerve.  Jeweler’s forceps were used to crush the nerve firmly for 1 min.  
Due to limited access to the nerve, the nerve could only be crushed in one orientation 
(from top).   
Any bleeding during the surgical procedure was controlled with epinephrine-
soaked pellets.  Gelfoam was lightly packed into the middle ear cavity prior to closure.  
The external ear canal incision was closed internally using 4-0 silk suture to prevent 
contamination of the middle ear from the external ear.  The muscle and skin were closed 
in separate layers.  Upon recovery from anesthesia, successful crush in all animals was 
verified by examining loss of the eyeblink reflex and vibrissae orientation and movement.       
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4.  STEREOTAXIC PROCEDURE 
 Stereotaxic injection of isotopes was performed for the facial nerve regenerative 
properties study.  A 1:1 mixture of tritiated leucine and lysine was prepared as follows.  
Each labeled amino acid, purchased from GE Healthcare, arrived at a concentration of 10 
mCi, in 5ml of ethanol.  Next, 500 µl of each isotope was combined together in 10 
Eppendorf tubes for a final volume of 1000 µl in all tubes.  A Speedvac was then used to 
dehydrate the samples.  The pelleted isotope in the first Eppendorf tube was redissolved 
in 100 µl of physiological saline.  The entire solution was then transferred to the next 
Eppendorf tube containing a pelleted isotope.  This step was repeated for each tube until 
the final tube contained 1000 µl of the leucine-lysine mixture, concentrated to 100 
µCi/µl.  This tube of isotope mixture was covered with parafilm and store at -20 ºC until 
needed for stereotaxic injection. 
 Eighteen hours prior to the time of sacrifice, rats were anesthetized with 
Ketamine-Xylazine, as described in the previous section.  The dorsal surface of the 
cranium was shaved and prepped, and animals were placed in a stereotaxic apparatus.  
The mouthpiece was adjusted to ensure that the head was flat.  A midline incision was 
made over the scalp, and the soft tissue overlying the skull was gently scraped off to 
expose bregma.  A 26-gauge stainless steel guide cannula was lowered to the surface of 
the skull, and the tip was placed exactly over bregma.  The coordinates 
(anterior/posterior, medial/lateral, and dorsal/ventral) of the cannula at this position were 
noted.  From here, the stereotaxic apparatus was adjusted to the coordinates of the right 
facial nucleus in rats (AP: -11.2; ML: -2.2; Paxinos and Watson, 2007).  A mark was 
made on the surface of the skull to denote the position of the guide cannula.  The cannula 
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was then raised, and a 1 mm hole was made in the skull using a dental drill.  The guide 
cannula was lowered into the brainstem, slightly above the location of the FMN (DV = -
7.2).  A 33-gauge injection cannula, having a 3 mm overhang as compared to the guide 
cannula, was then placed into the guide cannula and lowered into the brain stem to reach 
the appropriate FMN coordinate (DV = -10.2).  A small digital pump that depressed the 
plunger of a 10 µl Hamilton syringe, connected to cannula tubing (PE 20 intramedic 
polyethylene tubing), was used to deliver tritiated lecuine/lysine.  A total of 1µl (100 
µCi) of the isotope was injected into the right facial nucleus, at a rate of 0.16 µl/min.  
After injection, pressure within the brainstem was allowed to equilibrate for 5 min before 
removing the cannula.  The hole in the skull was covered with Gelfoam, and the wound 
was closed with 4-0 prolene suture.  Animals were sacrificed 18 h after stereotaxic 
injection of radioisotope, and axonal regeneration was measured as described in section 
F.    
 
C.  ELECTRICAL STIMULATION 
 
1.  DESIGN OF ELECTRODE APPARATUS 
A custom electrode apparatus was constructed in our laboratory for implantation 
in rats. Two Teflon-coated wires (Cooner Wire, Chatsworth, CA) were bared of 
insulation for 2-3 mm and soldered to two “male” connector pins (Wire Pro) in a 
connector strip (Allied Electronics).  The connector pins soldered to the wires were 
covered with insulation tubing (Allied Electronics) and epoxy and allowed to dry 
overnight.  One of the wires and its respective connector pin was marked with red 
insulation tape to designate it as the positive end of the electrode while the other wire and 
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its connector pin were left unmarked to designate that as the negative end. The 
connector assembly was then cemented into a syringe base using dental acrylic.  Two 
holes had been drilled on both sides of the syringe base to allow suturing of the electrode 
apparatus in animals.  All electrode apparatuses were tested with a voltmeter to ensure 
that they were functional prior to use in animals. 
 
2.  ELECTRICAL STIMULATION IN ANIMALS 
Electrodes were implanted in animals at the time of axotomy.  A midline incision 
was made over shaved and prepped skin on the back of animals.  The syringe base of the 
electrode apparatus was sutured using 4-0 silk onto the paraspinal back muscles of rats.  
The wires were run through subcutaneously, and the positive wire was sutured proximal 
to the crush site adjacent to the facial nerve, while the negative wire was sutured ~3-5 
mm away onto surrounding connective tissue.  The connector pins of the electrode were 
connected to the leads of an isolated pulse stimulator (W-P Instruments, Inc.), and current 
was directed from the negative to the positive lead.  Voltage was increased slowly and set 
at a threshold at which animals displayed a right ear flutter.  The supramaximal, 
monophasic pulses were delivered at a frequency of 20 Hz.  During the stimulation 
period, animals were allowed to roam freely in a chamber.  Unstimulated animals were 
connected to the stimulator, placed in the chamber, but the voltage was kept at 0 V.      
For the regenerative properties study in aim 1, ES was begun 1 dpo and 
administered daily for a 30 min period until the time of sacrifice.   For the gene 
expression study in aim 2, ES was begun immediately after axotomy and administered 
daily for a 30 min period until the time of sacrifice.  For the intratemporal facial nerve 
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axotomy model in aim 4, ES was administered at only one time, for a 30 min period, 
beginning immediately after axotomy.  In this paradigm, the electrode apparatus was not 
implanted in animals, but rather the wires were sutured temporarily in place for the one-
time treatment.  
  
D.  STEROID ADMINISTRATION 
 
1.  TESTOSTERONE PROPIONATE 
 TP was administered using subcutaneous capsule implants.  Capsules were made 
of Silastic tubing (0.062 in. ID x 0.095 in. OD) and were 18 mm in total length.  Of this 
length, 10 mm contained 100% crystalline TP (Sigma) while 4 mm wooden plugs sealed 
both ends of the capsule.  Prior to use in animals, capsules were equilibrated overnight in 
physiological saline.  In each animal receiving TP treatment, 2 capsules were implanted 
at the time of axotomy.   A subcutaneous pocket for the capsules was created by making 
an incision on the mid-dorsal surface of animals or using the same incision site used for 
electrode implantation. Capsules were left in animals until the time of sacrifice.  This 
dose of TP has previously been shown to establish supraphysiological levels of systemic 
testosterone (Hetzler et al., 2008; Tanzer and Jones, 2004; Kujawa et al., 1989). 
 
2.  PREDNISONE 
            A tapering dose of prednisone (Sigma) was administered using oral gavage. Either 
prednisone dissolved in physiological saline or saline alone was delivered into the 
esophagus of animals using a syringe connected to 2” curved, 18-gauge gavage needle 
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(Braintree Scientific).  The tip of the gavage needle was lubricated with Puralube prior 
to insertion into animals.  Beginning immediately post-axotomy, a 2.5 mg/kg dose of 
prednisone was administered as follows: twice daily on 0-2 dpo, once daily on 3-5 dpo, 
and once every other day on 6-10 dpo.  In animals not receiving prednisone, similar 
volume of saline was injected at the same dosing intervals.   
 
E.  ANIMAL TESTING 
 
1.  FUNCTIONAL RECOVERY TESTING 
 In rodents, a complete crush or transection of the facial nerve results in ipsilateral 
loss of the eyeblink reflex, backwards vibrissae orientation, loss of vibrissae movement, 
and drooping of the mouth, and return of facial nerve function can be easily observed.  
Animals were allowed to roam freely in an empty cage, placed on a black background, to 
observe return of vibrissae orientation and movement.  To elicit the eyeblink reflex, a 
puff of air was blown into the animal’s eye and the extent of eyelid closure was observed.  
Since symmetry of the mouth in rats was not obvious from observation alone and could 
not be easily scored, improvement in mouth droop was not used as an analysis parameter 
for facial nerve function.   
For all functional recovery studies described herein, function on the crushed, right 
side was always compared to the intact function on the left side using a 3-point recovery 
scale.  A score of ‘1’ was used to indicate complete lack of function, ‘2’ to indicate the 
onset of any return in function, and ‘3’ to indicate complete, symmetrical function as 
compared to the left side.  Recovery time for each functional parameter (eyeblink reflex, 
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vibrissae orientation, vibrissae movement) was defined as the number of dpo until the 
animals received a score of ‘3’.  For eyeblink function, the number of dpo until the onset 
of the reflex (score of ‘2’) was also analyzed.  Behavioral observations were conducted 
daily in all animals until a score of ‘3’ was attained for all functional parameters.  
Complete functional recovery was defined as the number of dpo when all of the 
parameters had returned to normal.           
 
2.  NERVE CONDUCTION TESTING 
 Motor nerve conduction studies were performed weekly, beginning on the day of 
axotomy and continuing until the day of sacrifice.  Animals were anesthetized with 
intraperitoneal injections of Ketamine-Xylazine, as described in the previous section.  A 
total of 5 electrodes (Grass Technologies, Astro-Med, Inc.) were used for testing.  Two 
stimulating electrodes were placed below the infraorbital ridge to stimulate the facial 
nerve, while two recording electrodes were placed on the vibrissae pad to record the 
response.  As the vibrissae pad in rats contains organized rows of indentations, the 
placement of electrodes could be easily replicated for each recording.  A ground electrode 
was placed inferior to the external ear.  Electrodes were connected to an 
electomyographic machine (Advanced Medical) that stimulated and displayed the 
response.  The size of the response (amplitude) in mV and the time in ms (latency) for the 
electrical impulse to travel from the stimulation to the recording site were the two 
parameters used to analyze facial nerve conduction. 
 The optimal current for stimulation of the facial nerve was first determined in test 
animals.  Current was increased to obtain maximal response of the uninjured facial nerve, 
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thereby ensuring that the current would be high enough to capture any response upon 
stimulation of the injured facial nerve.  By this method, the optimal current intensity was 
determined to be 15 mA.  The facial nerve was stimulated at a frequency of 0.5 Hz, and 
an average of 25 responses was recorded for each trial.  Trials were repeated at least once 
to verify consistency of the recorded response. Recordings were conducted both on the 
right and the left sides, and percent change in amplitude and latency for the right facial 
nerve, relative to the left, was analyzed.   
 
F.  MEASUREMENT OF AXONAL REGENERATION 
 
1.  FACIAL NERVE DISSECTION & QUANTIFICANTION OF RADIOACITIVITY 
 Eighteen hours following stereotaxic injection of radioisotope, animals were 
sacrificed at 4- or 7-dpo to analyze axonal regenerative properties.  The right facial nerve 
was carefully dissected out from the SMF to the snout using iridectormy scissors.  Nerves 
were placed on an index card, rapidly frozen with powdered dry ice, and then cut into 1 
mm segments using a gel slicer (Mickel Engineering Co., Ltd.).  Each nerve segment was 
then placed into an individual scintillation vial and solubilized overnight in 100 µl of 
Solvabe (Sigma).  Next day, 100 µl of 10% acetic acid and 5 ml of scintillation cocktail 
was added to each vial.  Radioactivity was assessed on a scintillation counter that was set 
to count for 3 min on a tritium channel.   
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2.  ANALYSIS OF AXONAL REGENERAITON 
 To determine axonal regeneration rate, the radioactivity of each nerve segment 
was first plotted as a function of distance.  The leading edge of the regenerating facial 
motor axons was defined as the farthest point two standard deviations (SD) above the 
mean tissue background levels of radioactivity (Oblinger and Lasek, 1984; Forman and 
Berenberg, 1978).  Tissue background was calculated from the most distal nerve 
segments that were too far from the crush injury site to contain any regenerating axons at 
the post-axotomy times examined.  Outgrowth distance calculated in this manner was 
then plotted as a function of post-operative time.  Two post-operative times, 4 and 7 d, 
were used.  Regeneration rates were calculated from the slope of the line, and 
extrapolation of the line to the x-interecept provided an estimate for the initial delay in 
axonal sprouting (Oblinger and Lasek, 1984).       
 
G.  REAL TIME REVERSE TRANSCRITION-POLYMERASE CHAIN REACTION 
 Real time RT-PCR was used to assess fold changes in gene expression.  Animals 
were sacrificed at post-operative survival times 0 h, 6 h, 1 d, 2 d, 7 d, and 21 d.  Brains 
were removed and immediately placed, ventral side up, on a rat brain matrix (Redding) 
on ice to provide support during sectioning.  One razor blade was placed at the level of 
the pontine band, while another was placed 1 mm caudal to it.  This coronal section was 
placed on a Petri-dish on ice, and 1 mm concentric punches of the right and left FMN 
were taken.  Rostral to the site of section, the internal genu of the facial nerve was 
identified to verify the precise location of the FMN and symmetry between the control 
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and axotomized sides.  Tissue was then homogenized with Lysing Matrix D (MP 
Biochemicals) and 80 µl of Solution D (Sigma).   
RNA was extracted using the phenol/chloroform extraction method, precipitated 
with 100% ethanol, and quantified on a Nano-Drop Spectrophotometer.   Samples 
containing 275 ng of total RNA were treated with DNase I amplification grade 
(Invitrogen) to remove any genomic DNA.  Next, 100 ng of DNA-free RNA was used for 
the reverse transcription reaction (Superscript II, Invitrogen) to yield 100 µl of cDNA 
samples.  Amplification reactions were performed in triplicates using 96-well optical 
plates and iCycler (Bio-Rad).  The total volume of PCR mix per well was 25µl [12.5 µl 
SYBR Green PCR Mix (Applied Biosystems), 10.5 µl H2O, 1 µl gene-specific primer 
pair (10µM each primer), and 1µl cDNA].   
The following rat-specific primers were purchased from SuperArray Biosciences, 
Inc. and used to amplify cDNA of candidate genes:  α1 tubulin (Tuba1), βII Tubulin 
(Tubb2), GAP43, BDNF, PACAP (Adcyap1), and neuritin (Nrn1).  Cycling parameters 
were as follows: initial denaturation at 95ºC for 10 min, followed by 40 cycles 
comprising 15 sec at 95ºC and 60 sec at 60ºC.  After PCR amplification, the samples 
were heated from 60ºC to 95ºC to perform melt curve analysis and verify the specificity 
of the amplified products.  Fold changes in mRNA levels on the axotomized side as 
compared to the control side were calculated using the 2(-ΔΔCt)-1 method, and fold 
changes were normalized to the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase.  The cycle threshold (Ct) represents the PCR cycle number at which the 
increase in fluorescence (and therefore cDNA) is exponential.  In the equation 2(-ΔΔCt), 
∆∆Ct = ∆Ct(axotomy) -  ∆Ct(control).  Here, ∆Ct(axotomy) is the Ct value for axotomized sample 
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normalized to the endogenous housekeeping gene and ∆Ct(control) is the Ct value for the 
control sample normalized to the endogenous housekeeping gene. 
 
H.  TISSUE SECTIONING AND CELL COUNTS 
 Animals were sacrificed at the appropriate post-operative survival time, and 
brains were removed, flash frozen in n-butyl bromide/2-methylbutane, and stored at -
80ºC.  Brains were allowed to equilibrate at -20ºC at least 24 h prior to cryosectioning.  
At -20ºC, serial 40 µm cryostat sections were collected through the entire caudal to 
rostral end of the FMN onto Superfrost Plus slides (Fisher Scientific), and slides were 
stored at -20ºC.  Prior to histological processing, slides were allowed to equilibrate to 
room temperature for 20 min.  Sections were first fixed in 4% paraformaldehyde, in 0.01 
M phosphate buffered saline, for 15 min.  Sections were then stained with thionin for 5-8 
min and dehydrated in graded ethanol concentrations (50, 75, 95, and 100%) for 30 sec 
each.  Slides were allowed to clear in Hemo-De (Fisher-Scientific) overnight and 
coverslipped using Permount (Fisher-Scientific).  Coverslipped slides were left lying flat 
for several days and allowed to dry at room temperature.  Slides were organized in 
correct order for each animal and given to a second investigator for counting under blind 
conditions. 
 Neuronal survival in the FMN was counted using the Neurolucida software.  The 
abducens nuclei and the internal genu of the facial nerve were used to match the location 
of the left (control) and right (axotomized) FMN.  Only surviving facial motoneurons, 
with a clearly visible nucleus, were counted.  Cell profile counts were taken for every 40 
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µm section of each rat.  The number of facial motoneurons on control and axotomized 
side were totaled and compared to obtain percent survival.       
  
         
I.  STATISTICAL ANALYSES  
 All statistical analyses were performed using the GraphPad Prism software. To 
determine significant differences between two groups, a two-tailed Student’s t-test with 
unequal variances and p<0.05 was performed.  To determine significant differences 
between three or more groups, a one-way analysis of variance (ANOVA), with a 
Newman-Keuls’ multiple comparison post-hoc test at p<0.05, was conducted.  A two-
way ANOVA was done when two independent variables, such as time and treatment, 
were present.  This statistical test was again followed by a Newman-Keul’s multiple 
comparisons post-hoc test to determine specific differences among groups.         
 
 
 52 
CHAPTER IV 
EFFECTS OF ELECTRICAL STIMULATION AND TESTOSTERONE ON 
REGENERATIVE PROPERTIES FOLLOWING  
EXTRATEMPORAL FACIAL NERVE INJURY 
 
A.  ABSTRACT 
As functional recovery following peripheral nerve injury is dependent upon 
successful repair and regeneration, treatments that enhance different regeneration events 
may be advantageous.  The neurotherapeutic effects of nerve electrical stimulation and 
gonadal steroids have independently been demonstrated.  The purpose of the first aim of 
this dissertation was to investigate the therapeutic potential of combining ES with 
gonadal steroids on peripheral nerve regeneration.  Following a facial nerve crush 
axotomy near the nerve’s exit from the SMF in gonadectomized adult male rats, TP was 
systemically administered with/without daily ES of the proximal nerve stump.  Facial 
nerve outgrowth was assessed at 4 and 7 dpo using radiolabeling of fast axonally 
transported proteins.  Administration of ES alone reduced the estimated delay in sprout 
formation but failed to accelerate the overall regeneration rate.  Conversely, TP treatment 
alone accelerated the regeneration rate by ~10% but had no effect on the sprouting delay.  
Combining TP with ES, however, maintained the enhanced rate and reduced the 
sprouting delay. The findings suggest that as ES and TP differentially enhance
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properties, the combination of both may boost regenerative properties more than the 
use of either treatment alone. 
 
B.  INTRODUCTION 
Peripheral nerve lesions are common types of nervous system injuries, often 
leading to substandard functional recovery.  Although the peripheral nervous system has 
a robust ability to regenerate, recovery from injured nerves is dependent upon cell 
survival, repair, and mounting of a successful regenerative response.  Despite available 
techniques to surgically repair transected peripheral nerves, complete functional recovery 
is often hindered by slow rates of regeneration over long distances and/or inadequate 
target reinnervation (Valero-Cabre et al., 2004).  Strategies to increase the rate of axonal 
regeneration and recovery are thus valuable therapeutic approaches. 
It has been well established that gonadal steroids have significant trophic effects 
on the nervous system, including changes in cell survival, neurotransmitter metabolism, 
and neuronal regeneration (Schumacher et al., 1996; De Nicola, 1993; Jones, 1994; 
Jones, 1993a; Tetzlaff et al., 2006; Bialek, et al., 2004).  Accordingly, gonadal steroids 
have been explored as a therapeutic strategy for improving the outcome of peripheral 
nerve injury.  Over a course of several studies, our lab has used the well-established 
facial nerve axotomy model, in which the nerve is crushed extratemporally at its exit 
from the SMF, to demonstrate that exogenously applied testosterone accelerates 
functional recovery and regeneration rates in hamsters (Kujawa et al.,1989; Kujawa et al., 
1991; Jones, 1993b; Tanzer and Jones, 1997).  Following an extratemporal facial nerve 
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transection in neonatal hamsters, we have also found that gonadal steroids (androgens 
and estrogen) can rescue facial motoneurons from degeneration (Huppenbauer et al., 
2005).  Studies in other injury models further support the neurotherapeutic role of 
gonadal steroids.  Estrogen and selective estrogen receptor modulators have been 
reported to stimulate sciatic nerve regeneration in mouse models (Islamov, et al., 2002; 
McMurray et al., 2003).  Testosterone has been shown to accelerate functional recovery 
from hind limb paralysis following a sciatic nerve crush in rats and also to increase 
axonal regeneration rates following axotomy of the rat hypoglossal nerve (Brown et al., 
1999; Yu, 1982; Yu and Yu, 1983).   
Gonadal steroids primarily exert their effects on target tissue using a receptor-
mediated mechanism.  Although binding of androgens to AR can have some non-
genomic effects, the primary mechanism of action for androgens involves binding of the 
hormone-receptor complex to DNA sites to alter gene expression.  Gonadal steroid 
receptors are found in many populations of neurons within the brain and spinal cord, 
including most cranial and spinal motor neurons (Yu and McGinnis, 2001; Tetzlaff et al., 
2007a).  Administration of testosterone at the time of nerve injury has been shown to 
upregulate expression of regeneration-associated genes such as βII tubulin and GAP-43 
(Jones et al., 1997a; Jones et al., 1999).  Since receptor-mediated mechanisms require 
multiple steps for signal transduction, the therapeutic effects of gonadal steroids may be 
delayed in comparison to therapies that can exert more immediate effects. 
ES is one potential intervention that is increasingly being studied in different 
nerve injury paradigms.  Application of electrical fields has long been known to affect 
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morphological and functional properties of neurons, such as nerve branching, rate and 
orientation of neurite growth, rapid sprouting, and guidance during axon regeneration 
(Borgens et al., 1981; Patel and Poo, 1982; Manivannan and Terakawa, 1994; Borgens, 
1999).  More recently, brief ES of the rat femoral nerve proximal to the injury site was 
shown to enhance axonal regeneration and specificity of motor re-innervation pathways 
(Al-Majed et al., 2000).  ES also improves reinnervation and modulates spinal plastic 
changes following sciatic nerve injury in rats (Vivo et al., 2008).  Direct ES of the 
transected rat optic nerve improves survival of retinal ganglion cells, demonstrating that 
such an intervention can also rescue neurons from degeneration (Morimoto et al., 2002).  
ES appears to exert these effects by influencing the neuronal soma response, in part by 
increasing expression of neurotrophic factors and their receptors and elevating levels of 
intracellular messengers such as cAMP soon after injury (Al-Majed et al., 2000; Al-
Majed et al., 2004; Udina et al., 2008). 
In the first aim of this dissertation, the effects of a combinatorial treatment 
strategy, administering both gonadal steroids and ES, on nerve regenerative properties 
were investigated in the extratemporal facial nerve axotomy model.  The rationale for this 
strategy was that, if the two treatments work through different mechanisms or during 
different phases of regeneration, then using them in combination may enhance recovery 
to a greater extent than using either treatment alone.  Our previous studies have tested the 
effects of ES and gonadal steroids, alone and in combination, on functional recovery 
following a facial nerve crush injury in rats.  Results show that while either treatment 
alone accelerates recovery by ~8%, the combination treatment of electrical stimulation 
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plus TP shortens recovery time by ~22% compared to untreated animals (Lal et al., 
2008; Hetzler et al., 2008).  In the present study, to further assess the therapeutic potential 
of ES and TP, we used radiolabeling of fast axonally transported proteins to analyze how 
the two treatments affect axonal regeneration rates and initial delay in sprout formation 
following an extratemporal facial nerve crush injury in gonadectomized adult male rats.   
 
C.  MATERIALS AND METHODS 
 
1.  ANIMALS & NERVE INJURY PARADIGM  
Adult male Sprague-Dawley rats, weighing 250g, were purchased from Harlan 
(Indianapolis, IN) and used for all experiments, as described in Chapter III.  Three to five 
days prior to nerve injury, rats were anesthetized with isofluorane and castrated.  For 
facial nerve axotomy, rats were anesthetized by intra-peritoneal injections of Ketamine 
(100mg/ml; 0.1ml/100g body weight) and Xylazine (20mg/ml; 0.025ml/100g body 
weight).  The right facial nerve was crushed near its exit from the SMF (refer to Chapter 
III for details).  Two successive 30-second crushes, on alternating sides, were done with 
fine jeweler’s forceps to ensure a full crush.  
The experimental design for this study is presented in Figure 3.  Animals were 
divided into 4 experimental groups: [1] no treatment, animals receiving axotomy but no 
treatment, [2] ES only, animals receiving axotomy and ES treatment, [3] TP only, 
animals receiving axotomy and TP treatment, and [4] ES + TP, animals receiving 
axotomy and the combination of ES and TP treatments.  For each treatment group, rats  
Figure 3:  Experimental Design for Aim 1. This timeline will be followed for all four experimental groups: 
no treatment, ES only, TP only, and ES plus TP.    
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were further divided into two sets of postoperative survival times, 4 and 7 days.  
Ultimately, each treatment group had an n of 6 animals per time point, for a total of 48 
animals in the study.   
 
3.  ELECTRICAL STIMULATION 
A custom electrode apparatus constructed in our laboratory was implanted in all 
rats (refer to Chapter III).  Two Teflon-coated wires, bared of insulation for 2-3mm, were 
soldered to two “male” connector pins in a connector strip.  The connector assembly was 
cemented into a syringe base using dental acrylic.  At the time of axotomy, the base of 
the syringe was sutured onto the paraspinal back muscles of rats.  Wires were run through 
subcutaneously and sutured ~2 mm proximal to the injury site (cathode) and ~3-5mm 
away from it (anode). The connector pins of rats were attached to leads of an isolated 
pulse stimulator, and rats were stimulated at a voltage at which they displayed a right ear 
flutter.  Starting at 1-day post-axotomy, rats were either stimulated with supramaximal 
pulses delivered at a frequency of 20 Hz or sham stimulated for 30 min daily until 
sacrifice.   
 
4.  HORMONE ADMINISTRATION 
Immediately after injury, rats receiving testosterone treatment were 
subcutaneously implanted with two Silastic capsules (0.062 in. id x 0.095 in. od; 10-mm 
length), equilibrated in physiological saline and containing 100% crystalline TP (refer to 
Chapter III for details).  The dosage given has previously been shown to establish 
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supraphysiological levels of systemic TP (Kujawa et al., 1989; Tanzer and Jones, 
2004; Hetzler et al., 2008). 
 
5.  STEREOTAXIC SURGICAL PROCEDURE 
Eighteen hours prior to sacrifice at 4 and 7 days post-axotomy, anesthetized 
animals were injected with 1µl of a 1:1 mixture of 3H-leucine and lysine (concentrated to 
100µCi/µl) into the right facial nucleus, as previously described in Chapter III.  Animals 
were placed in a stereotaxic apparatus, a 1mm hole was drilled in the skull, and a 
stainless steel cannula was placed into the brainstem at the appropriate stereotaxic 
coordinates for the right facial nucleus (ML = -2.2, AP = -11.2, and DV = -10.2), based 
on the atlas of Paxinos and Watson (2007).  The tritiated leucine/lysine mixture was 
delivered through the cannula at a rate of 0.16 µl/min.  After delivery, pressure within the 
brainstem was allowed to equilibrate for 5 min before the cannula was removed.  The 
skull hole was filled with Gelfoam and the incision site was sutured. 
Eighteen hours following injection of isotope, animals were sacrificed by CO2 
asphyxiation. The right facial nerve was dissected from the SMF to the snout and rapidly 
frozen.  Nerves were cut into 1mm segments using a gel slicer.  Each nerve segment was 
placed into an individual vial and solubilized overnight in 100 µl of Solvable.  Next day, 
100 µl of 10% acetic acid and 5ml of scintillation fluid was added to each vial, and 
radioactivity was assessed on a scintillation counter (refer to Chapter III for details).  
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6.  MEASUREMENTS OF AXONAL REGNERATION & STATISTICAL 
ANALYSIS 
Axonal regeneration was measured as previously described in Chapter III.  To 
determine axonal regeneration rate, the radioactivity of each nerve segment was first 
plotted as a function of distance.  The leading edge of the regenerating facial motor axons 
was defined as the farthest point ≥2 SD above the mean tissue background levels of 
radioactivity (Oblinger and Lasek, 1984; Forman and Berenberg, 1978).  Regeneration 
rates (slopes) were then calculated by plotting outgrowth distance as a function of days 
post-axotomy.  Extrapolation of the line to the x-intercept provided an estimate of the 
initial delay in axonal sprouting (Oblinger and Lasek, 1984).  A two-way ANOVA 
(factors = treatment and post-operative time) and a F test at p<0.05 was used to assess 
significant differences between lines (Forman et al., 1980).  Significance among 
outgrowth distances was determined using Newman-Keuls’ multiple comparison post-
hoc test.  For ease of visual display, each treatment group (ES only, TP only, or ES + TP) 
is graphed separately to compare it to the no treatment group.  
 
D.  RESULTS 
The radioisotopic labeling method is a well-established and sensitive assay for 
measuring axonal regeneration.  Radiolabeled amino acids are incorporated into proteins 
that are fast axonally transported to the growing tips of the regenerating facial motor 
axons, and the extent of radioactivity along the nerve correlates to the outgrowth 
distance.  Figure 4 shows an example of distribution of transported radioactivity at 4 days 
Figure 4.  Distribution of fast axonally transported radioactivity in regenerating 
facial motor axons at 4 days post-axotomy.  Location of crush site is 0 mm.  In this 
sample graph, the leading edge of the regenerating axon has reached an outgrowth 
distance of 13 mm. Outgrowth distance is defined as the point that is 2 SD or more 
above mean tissue background levels calculated from the most distal segments of the 
facial nerve. 
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post-axotomy.  High levels of radioactivity are present in proximal portions of the 
regenerating facial nerve, and they fall to a constant low level of background activity 
distally along the nerve.  The leading edge of the regenerating axons is defined as that 
distance at which the radioactivity is ≥2 SD above mean tissue background levels 
(Oblinger and Lasek, 1984), calculated from the most distal segments of the dissected 
facial nerve that does not contain regenerating fibers.  Previous studies using this 
radioisotopic labeling method to measure regeneration have demonstrated that the rate of 
axonal elongation is linear (Oblinger and Lasek, 1984; Forman and Berenberg, 1978; 
Bisby, 1979; Bisby, 1978).  Studies in our lab have previously established that 
regeneration of facial motor axons in rodents is linear as well (Kujawa et al., 1991).  
Therefore, to conserve the use of animals, outgrowth distances at only two post-operative 
times were collected to calculate the regeneration rates in the present study.   
    
1.  EFFECTS OF ES ON FACIAL NERVE REGENERATIVE PROPERTIES  
The effects of daily ES of the proximal nerve stump on facial nerve outgrowth of 
gonadectomized male rats are presented in Figure 5 and summarized in Table 1.  
Following an extratemporal facial nerve crush injury, the outgrowth distance of the 
regenerating facial motor axons in untreated animals was 7.3±1.0 mm at 4 dpo and 
19.0±1.6 mm at 7 dpo.  In comparison, ES significantly increased the outgrowth distance 
to 11.2±1.0 mm and 22.5±1.4 mm, at both the early and the late time points, respectively 
(p<0.05; Fig. 5).  Based on the outgrowth distances, the untreated animals displayed a 
regeneration rate of 3.9 mm/d, and extrapolation to the x-intercept indicated an estimated  
Figure 5.  Effects of ES on axonal regeneration following an extratemporal facial 
nerve crush injury in rats.  The mean outgrowth distances at 4 and 7 dpo are plotted 
as a function of days post-axotomy.  The slopes of the lines represent the rate of 
regeneration while extrapolation of the data points to the x-intercept gives an estimate 
for the initial delay in sprout formation.  Untreated animals and animals receiving 
only daily ES are shown.  Asterisks represent significant differences between the 
outgrowth distances of groups.  Vertical lines represent standard error of the mean. 
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No treatment ES only TP only ES plus TP
Rate of Regeneration 
(mm/d)
3.9                            
n = 12   
3.8                        
n = 12
4.3                      
n = 12 
4.4                                                                          
n = 11
Delay of Sprout Formation 
(d) 2.1 1.0 1.9 1.3
Table 1.  Summary of effects of ES and TP on facial nerve regenerative properties 
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initial delay in sprouting of 2.1 d (Table 1).  Daily ES of the facial nerve did not alter 
the regeneration rate (3.8 mm/d) but did reduce the delay of sprout formation to 1.0 d.  
Since electrical stimulation did not affect the regeneration rate, the significant increase in 
outgrowth distances at 4 and 7 dpo was attributed to the reduced delay in sprout 
formation. 
 
2.  EFFECTS OF TP ON FACIAL NERVE REGENERATIVE PROPERTIES 
 Figure 6 compares the effects of TP administration alone to no treatment.  The 
outgrowth distance of the regenerating facial nerve fibers was significantly higher in the 
presence of TP was 9.0±0.9 mm at 4 dpo and 21.8 ±1.8 mm at 7 dpo.  While the 
outgrowth distance in TP-treated animals was significantly greater than that of untreated 
animals at 7 dpo (19.0±1.6 mm; p<0.05), it was not significantly greater than untreated 
animals at 4 dpo (9.0±0.9 mm).  Additionally, the outgrowth distance at 4-dpo was also 
significantly lower in the TP-treated group compared to the group receiving ES only 
(p<0.05).  In contrast to ES, systemic exposure to TP accelerated the regeneration of 
facial motor axons to 4.3 mm/d (Table 1).  This represents a 10% increase in the 
regeneration rate as compared to untreated animals.  TP did not, however, affect the 
initial delay in sprout formation, which was 1.9 d in TP-treated animals and 2.1 d in 
untreated animals (Table 1).  As the delay in sprout formation was not affected, the 
increase in outgrowth distance with TP administration may be attributed to a significant 
acceleration of regeneration rate.  
 
Figure 6.  Effects of TP on axonal regeneration following an extratemporal facial 
nerve crush injury in rats.  The mean outgrowth distances at 4 and 7 dpo are plotted 
as a function of days post-axotomy.  The slopes of the lines represent the rate of 
regeneration while extrapolation of the data points to the x-intercept gives an estimate 
for the initial delay in sprout formation.  Untreated animals and animals receiving only 
systemic testosterone are shown.  Asterisks represent significant differences between 
the outgrowth distances of groups.  Vertical lines represent standard error of the mean. 
66 
  
67 
3.  EFFECTS OF ES PLUS TP ON FACIAL NERVE REGENERATIVE 
PROPERTIES 
Since electrical stimulation affected the delay in sprout formation and TP affected 
the regeneration rate, the combination of both treatments would be expected to have 
additive effects on axonal regenerative properties.  Figure 7 demonstrates that the facial 
nerve outgrowth distance for the animals receiving the combined treatment was 
significantly increased to 11.8±0.7 mm at 4-dpo, relative to the outgrowth of 7.3±1.0 mm 
in untreated animals (p<0.05).  At 7-dpo, the facial motor axons of animals receiving the 
combined treatment had regenerated to 25.0±0.7 mm, farther than not only untreated 
animals (19.0±1.6 mm) but also animals receiving only TP (21.8±1.8 mm) or only ES 
(22.5±1.4; p<0.05).  The animals receiving the combined treatment ES plus TP also 
demonstrated an increased regeneration rate of 4.4 mm/d and a reduced delay in sprout 
formation of 1.3 d, relative to a rate of 3.9 mm/d and a delay of 2.1 d in untreated animals 
(Table 1).  Therefore, both the regeneration rate and initial delay before sprout formation 
begins were beneficially affected with the combined treatment, whereas individual 
treatment with ES or TP affected only one of the properties.   
 
E.  DISCUSSION 
Our previous study demonstrated that administration of TP or daily ES alone 
improved functional recovery by ~8%, whereas the combination of both accelerated 
recovery by ~22%   (Lal et al., 2008; Hetzler et al., 2008).  This study further delineates 
the mechanism underlying the additive effects of gonadal steroids and ES.  While ES of
Figure 7.  Effects of ES plus TP on axonal regeneration following an 
extratemporal facial nerve crush injury in rats.  The mean outgrowth distances at 4 
and 7 dpo are plotted as a function of days post-axotomy.  The slopes of the lines 
represent the rate of regeneration while extrapolation of the data points to the x-
intercept gives an estimate for the initial delay in sprout formation.  Untreated animals 
and animals receiving only daily ES and systemic testosterone are shown.  Asterisks 
represent significant differences between the outgrowth distances of groups.  Vertical 
lines represent standard error of the mean. 
68 
  
69 
the proximal nerve stump reduced the delay in sprout formation, systemic TP treatment 
augmented the regeneration rate.  Thus, each single treatment had differential effects, but 
with the combined treatment, both of the regenerative properties were enhanced. 
Therefore, the therapeutic strategy of using both ES and TP is worthy of clinical 
consideration in cases of peripheral nerve injury.  
Assessment of functional recovery following an extratemporal facial nerve crush 
injury demonstrated that the onset of the eyeblink reflex occurred significantly earlier in 
animals receiving ES, suggesting that ES may help initiate early events in axonal 
regeneration (Lal et al., 2008).  Our present results further support this, as ES reduced the 
initial delay before sprout formation began, thus increasing facial nerve outgrowth 
distances.  However, as ES did not alter the regeneration rate, it may work to enhance 
functional recovery by promoting early sprout formation rather than changing the rate at 
which the axon elongates.  Application of electric field to nerve terminals has been 
shown to induce rapid filopodial sprouting in primary neuron cell cultures in the presence 
of extracellular Ca2+ (Manivannan and Terakawa, 1994).  It has also been reported that, 
following sciatic nerve crush injury in rats, administration of ES accelerates the 
appearance of the toe-spreading reflex, a sensitive indicator of the onset of motor 
recovery (Pockett and Gavin, 1985).  Therefore, ES may enhance early regeneration 
events to initiate sprout formation.  
In the literature, there is considerable variability in the initial delay before sprout 
formation occurs, ranging from 0.4 to 5.2 d, during which a growth program has to be 
initiated for axonal outgrowth to begin (Oblinger and Lasek, 1984; Forman and 
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Berenberg, 1978).  In the present study, ES of the proximal nerve stump was begun at 
1 dpo, and the initial delay in sprouting was reduced from 2.1 d to 1 d post-injury in 
animals treated with ES.  Therefore, ES may have immediate effects on regenerative 
properties, and if the treatment is initiated on the day of injury, the effects may be even 
more pronounced.  ES is thought to mediate its positive effects on regeneration by 
enhancing the cell body response to injury.  Expression of the neurotrophin BDNF, its 
high affinity receptor trkB, GAP-43, and Tα 1-tubulin significantly increase soon after 
femoral nerve injury in the presence of low-frequency ES (Al-Majed et al., 2000b; Al-
Majed et al., 2004).  Rather than altering the rate of axonal transport or regeneration rate, 
as little as 1 h of ES has been shown to accelerate axonal growth across the injury site, 
thereby reducing the time needed for motor neurons to reinnervate muscles following rat 
femoral nerve transection and surgical repair (Brushart et al., 2002).  Unstimulated motor 
nerves, on the other hand, show a prolonged delay for axons to cross the injury site.  
Similar effects of ES in the CNS have also been demonstrated.  ES of the sciatic nerve 
peripherally promotes onset of regeneration of centrally injured dorsal root ganglion 
axons (Udina et al., 2008).  Investigators report that while ES increased axonal outgrowth 
into the lesion site, it failed to increase axonal elongation rate.  Therefore, the results 
from our present study further support the idea that ES accelerates the onset of 
regeneration but does not affect the overall rate of axonal regeneration.  
To study the effects of gonadal steroids on facial nerve regeneration, we used a 
standard neuroendocrine paradigm, consisting of removal of the endogenous source of 
testosterone by gonadectomy and replacement with supraphysiological levels of TP.  Our 
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previous studies using the hamster extratemporal facial nerve axotomy model have 
shown that axonal outgrowth rates and functional recovery are similar in intact and 
gonadectomzied animals (Kujawa et al., 1989; Kujawa et al., 1991).  Rather, it is the 
administration of exogenous supraphysiological levels of androgens and estrogen that is 
capable of accelerating axonal regeneration rate.  We used gonadectomized instead of 
intact animals in this study to minimize variability and establish similar baseline levels.  
Systemic administration of TP increased the regeneration rate by ~10%.  Interestingly, 
TP accelerated functional recovery by a similar magnitude (~8%) as compared to 
untreated animals (Hetzler et al., 2008).  The present results concur with those of 
previous studies in different models showing that systemic exposure of TP accelerates 
axonal regeneration rate but fails to reduce the initial delay before sprout formation 
begins (Kujawa et al., 1991).  
The effects of testosterone on axonal outgrowth rates parallel those of 
conditioning lesion studies, where a first (priming) lesion of a peripheral nerve precedes a 
second (testing) lesion.  Both the conditioning paradigm and gonadal steroids may act by 
priming the cell body metabolically to enhance the neuronal response to injury and 
increasing the synthetic capabilities of the regenerating neuron (Tetzlaff et al., 2006; 
McQuarrie and Grafstein, 1981).  It has been shown that the administration of flutamide, 
an AR blocker, abolishes the effects of testosterone on hamster facial nerve regeneration, 
indicating that TP works in an AR-dependent manner (Kujawa et al., 1995).  
Administration of testosterone at the time of facial nerve axotomy in hamsters 
upregulates the expression of regeneration-associated genes βII tubulin, GAP-43, and 
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neuritin, associated with neurite outgrowth (Jones et al., 1997; Jones et al., 1999; Fargo 
et al., 2008a).  In addition to using a genomic mechanism to enhance regeneration, 
androgen treatment may mediate the motoneuron stress response following injury.  Heat 
shock proteins, principal players of the stress response, normally complex with unbound 
AR in the cytoplasm (Tetzlaff et al., 2007b; Jones et al., 2000).  Our lab has previously 
shown that TP exposure allows HSPs to liberate from ARs, thus reducing the need for the 
cell to produce more HSPs after injury and instead to direct its metabolic energy towards 
synthesis of growth-associated proteins. 
It must be noted that the regeneration rates presented in this study are for the 
fastest growing facial motor axons and thus do not represent slower regenerating fibers.  
Also, the delay times reported are estimations only, as values were obtained by 
extrapolation of the line to the x-intercept.  Quantitative analysis of the regenerating 
nerve at the ultrastructural level is required to verify the effects of ES and gonadal 
steroids on the initial delay before sprout formation begins. Our future studies will 
examine if a short-term ES treatment is just as beneficial as daily stimulation and thus 
better able to translate clinically.  Also, since TP can be converted to estradiol via 
aromatization and to dihydrotestosterone (DHT) via 5α-reduction, its effects on 
accelerating the regeneration rate may be attributed to androgenic and/or estrogenic-
mediated mechanisms.  DHT, in contrast to TP, is a nonaromatizable form of androgen 
that cannot be converted to estrogen.  Therefore, in a subsequent study, our lab 
investigated the effects of DHT and estradiol, alone and in combination ES, on functional 
recovery and regenerative properties following an extratemporal facial nerve crush in rats 
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(Foecking et al., 2009; Sharma et al., 2009).  Our findings indicated that neither DHT 
nor estradiol in combination with ES is as effective as TP in enhancing functional 
recovery or accelerating regeneration.  Therefore, a synergism between androgenic and 
estrogenic actions may be required to obtain maximal effects in augmenting regeneration.  
Future studies will examine the effects of the combination therapy of ES and the various 
gonadal steroids in female rodent models.   
Combining ES and gonadal steroid administration had an enhanced effect on 
regeneration as compared to the use of either treatment alone.  The finding that the 
regeneration rate was similar in TP-treated and combination-treated animals suggests that 
perhaps ES does not further enhance the molecular mechanism by which TP mediates 
this effect.  Alternatively, the regeneration rate for the rat facial nerve system may 
already be at its preset maximal level with the administration of TP alone and therefore 
the use of the combined treatment cannot further increase the rate.  Independently, each 
treatment differentially affected regeneration as ES enhanced immediate events such as 
sprouting and outgrowth distance at the early time point of 4-dpo whereas TP enhanced 
the overall regeneration rate.  Therefore, the combinatorial treatment strategy of gonadal 
steroids and ES promises to be a beneficial therapeutic intervention following peripheral 
nerve injury.   
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CHAPTER V 
EFFECTS OF ELECTRICAL STIMULATION AND TESTOSTERONE ON 
EXPRESSION OF REGENERATION-ASSOCIATED GENES FOLLOWING 
EXTRATEMPORAL FACIAL NERVE INJURY 
 
A.  ABSTRACT 
As functional recovery following peripheral nerve injury is often suboptimal, treatments 
that enhance the intrinsic ability to neurons to regenerate may be advantageous.  Using 
the injury paradigm of extratemporal facial nerve crush, our previous study investigated 
the effects of a combinatorial treatment strategy, consisting of ES of the proximal nerve 
stump and systemic TP administration in Aim 1.  Results indicated that the two 
treatments differentially enhance facial nerve regenerative properties, whereby ES 
reduced the delay before sprout formation, TP accelerated the overall regeneration rate, 
and the combinatorial treatment had additive effects.  To delineate the molecular 
mechanisms underlying such treatments, the second aim of this dissertation investigated 
the effects of ES and TP on expression of specific regeneration-associated genes.  
Following a right facial nerve crush at the SMF, gonadectomized adult male rats were 
administered only ES, only TP, a combination of both, or left untreated.  Real time RT-
PCR analysis was used to assess fold changes in mRNA levels FMN at 0 h, 6 h, 1 d, 2 d, 
7 d, and 21 d post-axotomy.  The candidate genes analyzed included two tubulin isoforms 
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(α1-tubulin and βII-tubulin), GAP-43, BDNF, pituitary adenylate cyclase-activating 
peptide (PACAP), and neuritin (candidate plasticity-related gene 15).  The two treatments 
were found to have differential effects on gene expression, with ES leading to early but 
transient upregulation and TP producing late but steady increases in mRNA levels.  In 
comparison to individual treatments, the combinatorial treatment strategy had the most 
enhanced effects on the transcriptional program activated following injury.    
 
B.  INTRODUCTION 
Despite the robust ability of the peripheral nervous system to regenerate, 
functional and clinically relevant recovery following injury is often suboptimal.  Delays 
in nerve regeneration may occur due to hindered axonal outgrowth across the site of 
injury, slow regeneration rate over long distances, inadequate reinnervation, or target 
atrophy (Valero-Cabre et al., 2004; Lee and Wolfe, 2000; Lundborg, 2000).  A crush or 
transection injury switches a fully differentiated adult neuron into a growth mode, 
inducing a coordinated pattern of gene expression that underlies the intrinsic regenerative 
capacity of peripheral nerves.  This growth program includes an increase in expression of 
transcription factors, cell-adhesion molecules, growth factors, cytokines, and structural 
components needed for axonal elongation (Makwana and Raivich, 2005).  Therapeutic 
strategies that accelerate the onset or enhance the degree of this regenerative response 
may improve functional recovery outcome following injury. 
Gonadal steroid hormones have significant trophic effects on the nervous system 
and play a neuroprotective role in conditions of injury or disease (Schumacher et al., 
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1996; De Nicola, 1993; Jones, 1993a; Bialek et al., 2004; Tetzlaff et al., 2006; Fargo et 
al., 2008b).  Over a course of several studies in the rodent facial nerve axotomy model, in 
which the nerve is crushed or transected at its exit from the SMF, our lab has shown that 
testosterone administration at the time of injury accelerates functional recovery and 
increases the rate of nerve regeneration (Tetzlaff et al., 2006; Kujawa and Jones, 1990; 
Kujawa et al., 1989; Kujawa et al., 1991).  These neurotherapeutic effects of testosterone 
are mediated by its binding to the AR, abundantly found in the motor nuclei of brainstem 
and spinal cord neurons (Yu and McGinnis, 2001; Tetzlaff et al., 2007a; Kujawa et al., 
1995).  Molecular studies further demonstrate that testosterone administration following 
injury attenuates GFAP expression and increases levels of ribosomal RNA and mRNA 
levels of regeneration-associated genes such as βII-tubulin and GAP-43 (Kinderman and 
Jones, 1994; Jones and Oblinger, 1994; Jones et al., 1997a; Jones et al., 1997b).  
However, since receptor-mediated mechanisms require multiple steps for signal 
transduction, the therapeutic effects of testosterone may be delayed in comparison to 
therapies that can exert more immediate effects. 
Multiple studies have shown that low frequency ES of the proximal nerve stump 
following injury promotes axonal regeneration.  ES in the rat femoral and sciatic nerve 
injury models results in enhanced regeneration and improved reinnervation specificity 
(Al-Majed et al., 2000a; Vivo et al., 2008).  Studies also report that ES accelerates the 
onset of functional recovery, increases axonal growth across the injury site, and improves 
neuronal survival following axotomy (Pockett and Gavin, 1985; Brushart et al., 2002; 
Morimoto et al., 2002).  Although the mechanisms by which ES mediates its effects are 
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not fully known, it has been demonstrated that it influences the neuronal soma 
response, rapidly increasing expression of neurotrophin-4/5 and BDNF, as well as their 
receptor trkB (English et al., 2006; Al-Majed et al., 2000b).  ES is also associated with 
increased expression of α1-tubulin and GAP-43 in motor and sensory nerve regeneration 
systems (Al-Majed et al., 2004; Geremia et al., 2007).       
We have previously investigated the therapeutic potential of ES and TP in the 
extratemporal facial nerve injury model and found that the combinatorial treatment has 
additive effects on acceleration of functional recovery (Lal et al., 2008; Hetzler et al., 
2008).  To investigate the mechanism underlying the additive effects of gonadal steroids 
and ES, we used a radioisotopic labeling method to measure facial nerve outgrowth in 
Aim 1 and found that ES of the proximal nerve stump reduced the delay before sprout 
formation begins but failed to accelerate the regeneration rate.  TP treatment, on the other 
hand, augmented the regeneration rate but had no effect on the sprouting delay.  While 
each single treatment had differential effects, their combined treatment enhanced both of 
the regenerative properties, resulting in an accelerated rate and a reduced delay in 
sprouting.  Therefore, the combinatorial treatment strategy may have a better therapeutic 
potential since ES may be used to initiate regeneration and testosterone to increase the 
rate of elongation over time.   
Since a successful regenerative response is dependent upon expression of 
regeneration-associated genes, the objective of the current study (Aim 2) was to examine 
the effects of ES and TP on gene regulation.  We hypothesized that treatment with ES or 
TP alone may upregulate different populations of genes and/or display temporal 
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differences in gene regulation, while their combined treatment may have additive 
effects.  The number of genes that compose the regeneration program is immense and yet 
incomplete.  Therefore, the present study characterized changes in expression of six 
genes in response to ES and TP.  These genes were chosen as they have previously been 
shown to be upregulated in the FMN following injury.  These include two members of 
the tubulin family (α1-tubulin and βII-tubulin) that provide cytoskeletal support for the 
elongating axon, as well as GAP-43, a well-known regeneration-associated gene that 
regulates the growth cone during regeneration.  The study also includes BDNF and 
PACAP, known for their multiple neurotrophic effects.  Lastly, we analyzed expression 
of neuritin, originally identified as candidate plasticity-related gene 15, which enhances 
neurite extension in vitro and induces dendritic growth and axonal elaboration in vitro 
(Nedivi et al., 1998, Cantallops et al., 2000, Javaherian and Cline, 2005).  Characteristics 
of the six candidate genes are outlined in Table 2.  Following a facial nerve crush injury 
in adult rats, the effects of ES and/or TP on gene expression were assessed using real 
time RT-PCR analysis.  The results demonstrate that the two treatments not only target 
different genes, but also that ES rapidly but transiently upregulated gene expression 
whereas TP had delayed but sustained effects in facial motoneurons.     
      
C.  MATERIALS AND METHODS 
 
1.  ANIMALS & NERVE INJURY PARADIGM  
Adult male Sprague-Dawley rats (~2 months old) were purchased from Harlan  
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(Indianapolis, IN) and used for all experiments, as described in Chapter III.  Three to 
five days prior to nerve injury, rats were anesthetized with isofluorane and castrated.  For 
facial nerve axotomy, rats were anesthetized by intra-peritoneal injections of Ketamine  
 (100mg/ml; 0.1ml/100g body weight) and Xylazine (20mg/ml; 0.025ml/100g body 
weight).  The right facial nerve was crushed near its exit from the SMF, as described 
previously in Chapter III.  Two successive 30-second crushes, on alternating sides, were 
done with fine jeweler’s forceps to ensure a full crush.   
The experimental design for this study is illustrated in Figure 8.  Animals were 
divided into 4 experimental groups: [1] no treatment, animals receiving axotomy but no 
treatment, [2] ES only, animals receiving axotomy and ES treatment, [3] TP only, 
animals receiving axotomy and TP treatment, and [4] ES + TP, animals receiving 
axotomy and the combination of ES and TP treatments.   
 
2.  ELECTRICAL STIMULATION  
A custom electrode apparatus constructed in our laboratory was implanted in all 
rats (refer to Chapter III for details).  Two Teflon-coated wires, bared of insulation for 2-
3mm, were soldered to two “male” connector pins in a connector strip.  The connector 
assembly was cemented into a syringe base using dental acrylic.  At the time of axotomy, 
the base of the syringe was sutured onto the paraspinal back muscles of rats.  Wires were 
run through subcutaneously and sutured ~2mm proximal to the injury site (cathode) and 
~3-5mm away from it (anode).  The connector pins of rats were attached to leads of an 
isolated pulse stimulator, and rats were stimulated at a voltage at which they displayed a  
Figure 8:  Experimental Design for Aim 2. This timeline will be followed for all four experimental groups:
no treatment, ES-only, TP-only, and ES plus TP.
Gonadectomy
1. Facial Nerve Crush Injury
2. Electrode Implant
3. TP capsule Implant
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right ear flutter.  Starting immediately post-axotomy, rats were either stimulated with 
supramaximal pulses delivered at a frequency of 20Hz or sham stimulated for 30 min 
daily until sacrifice.   
 
3.  HORMONE ADMINISTRATION  
Immediately following injury, two Silastic capsules (0.062 in. id x 0.095 in. od; 
10-mm length), equilibrated in physiological saline and containing 100% crystalline TP 
(Sigma), were subcutaneously implanted in rats receiving hormone treatment.  The 
dosage given has previously been shown to establish supraphysiological levels of 
systemic TP (Kujawa et al., 1989; Hetzler et al., 2008; Tanzer and Jones, 2004).   
 
4.  REAL-TIME RT-PCR  
Rats were sacrificed by CO2 asphyxiation at 0 h, 6 h, 1 d, 2 d, 7 d, or 21 d 
following facial nerve axotomy.  Brains were removed and placed in a rat brain matrix on 
ice to provide support during sectioning.  Using 2 razor blades spaced 1mm apart, 
sections were taken at the border of the pontine band and moving caudally.  The precise 
rostral-caudal location of the facial motor nucleus and symmetry between the control and 
axotomized side was verified by identifying the internal genu of the facial nerve rostral to 
the site of section.  On the coronal sections taken, 1mm concentric punches of the control 
and axotomized facial motor nuclei were collected for harvest.  Tissue was homogenized 
with Lysing Matrix D and Solution D, and RNA was extracted, precipitated, and 
quantified on a Nano-Drop Spectrophotometer.  DNAse treatment and reverse 
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transcription on 100 ng of total RNA were done to obtain cDNA samples (refer to 
Chapter III for details). 
The following rat-specific primers purchased from SuperArray Biosciences were 
used to amplify cDNA of candidate genes:  α1 tubulin, βII Tubulin, GAP43, BDNF, 
PACAP, and neuritin.  PCR amplification was carried out in triplication using SYBR 
Green PCR Mix.  Cycling parameters were as follows: initial denaturation at 95ºC for 10 
min, followed by 40 cycles comprising 15 sec at 95ºC and 60 sec at 60ºC.  After PCR 
amplification, the samples were heated from 60ºC to 95ºC to perform melt curve analysis 
and verify the specificity of the amplified products.  Fold changes in mRNA levels on the 
axotomized side as compared to the control side were calculated using the 2(-ΔΔCt)-1 
method, and fold changes were normalized to the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase.   
 
5.  STATISTICAL ANALYSIS  
Significant changes in mRNA levels among all four experimental groups were 
determined using a two-way ANOVA (factors = days post-axotomy and treatment), 
followed by a Newman-Keuls’ multiple comparison post-hoc test at p<0.05.  However, 
for the ease of visually displaying the differences, three graphs were plotted for each gene 
analyzed, to compare the fold change in mRNA levels between the no treatment and each 
of the treatment groups (ES only, TP only, or ES plus TP).  
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D.  RESULTS  
 
1.  EFFECTS OF ES AND TP ON EXPRESSION OF TUBULIN ISOFORMS 
The gene expression pattern in the axotomized, untreated animals confirmed that 
injury alone significantly increased the fold change in α1-tubulin mRNA levels by 7 dpo 
(0.63 ± 0.07), as compared to baseline levels (-0.06 ± 0.15; p<0.05; Fig. 9).  Figure 9A 
demonstrates that compared to no treatment, ES of the facial nerve significantly enhance 
α1-tubulin expression as early as 2 dpo (0.23 ± 0.05 vs. 3.30 ± 0.22 fold change, 
respectively; p<0.05).  By 7 dpo, the fold change in α1-tubulin mRNA levels in ES-
treated animals decreased to values of untreated animals (0.52 ± 0.06 vs. 0.63 ± 0.07, 
respectively).          
Systemic administration of TP did not alter α1-tubulin expression patterns relative 
to no treatment.  Fold change in α1-tubulin mRNA levels in TP-treated animals was also 
highest 7 dpo (0.69 ± 0.10), as compared to 0.63 ± 0.07 with no treatment (Fig. 9B).  
However, combining ES with TP more rapidly upregulated α1-tubulin expression, with 
the fold change in mRNA levels peaking to 2.80 ± 1.12 at 2 dp0 (p<0.05 as compared to 
control; Fig. 9C).  By 7 dpo, α1-tubulin expression in the combined treatment group 
returned to values of untreated animals (0.40 ± 0.10 vs. 0.63 ± 0.07 fold change, 
respectively).  This expression pattern of α1-tubulin in the combined treatment group was 
upregulated in a manner similar to the ES only group.  Therefore, the data suggest that ES 
of the facial nerve leads to an earlier and significant increase in α1-tubulin expression, 
while TP has no supplementary effect.      
Figure 9.  Effects of ES and TP on expression of α1-tubulin following an
extratemporal facial nerve crush injury in rats.  Shown is a time-course of fold
changes in mRNA levels of α1-tubulin in the axotomized FMN relative to the control
FMN, with post-operative survival times being 0h, 6h, 1d, 2d, 7d, and 21d  Following
axotomy, untreated animals are compared to animals receiving only ES (A), only TP
(B), or the combination of both (C).  Within the untreated group, α1-tubulin is
significantly higher 7d following injury, relative to the baseline levels at 0h (p<0.05).
Asterisks are used to represent significant differences between different groups
(p<0.05).  Vertical lines represent standard error of the mean.  For each experimental
group, n = 3-6 animals/time point.
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 βII-tubulin expression was also upregulated in axotomized, untreated animals 
by a 2.30 ± 0.39 fold change at 7 dpo, relative to baseline levels (0.08 ± 0.08; p<0.05; 
Fig. 10).  However, the treatments produced an effect contrary to that seen with α1-
tubulin.  ES did not alter the timing or degree of upregulation in βII-tubulin expression, 
since the highest fold change (2.47 ± 0.34) at 7 dpo was comparable to the no treatment 
group (Fig. 10A).  Administration of TP, however, augmented the fold change in βII-
tubulin mRNA levels to 6.28 ± 2.06 at 7 dpo, relative to no treatment (2.30 ± 0.39; 
p<0.05; Fig 10B).  Although this increase in expression did not occur earlier, the 
magnitude of the change was nearly tripled.  When the combination treatment of ES plus 
TP was given, the fold change in βII-tubulin expression again increased to 6.04 ± 1.19 at 
7 dpo (p<0.05 relative to no treatment; Fig 10C).  Therefore, systemic administration of 
TP augmented βII-tubulin expression while ES had no additional effect. 
 
2.  EFFECTS OF ES AND TP ON EXPRESSION OF GAP-43 
 In axotomized untreated animals, the fold change in GAP-43 expression 
significantly increased at 2 dpo and peaked at 7 dpo (3.98 ± 0.55 and 8.05 ± 0.24, 
respectively; p<0.05 relative to baseline; Fig 11).  Treatment with ES enhanced this 
change in GAP-43 expression by an additional ~10-fold, raising the peak to 19.6 ± 2.86 
at 7 dpo (p<0.05 as compared to control; Fig 11A).  Administration of TP alone had no 
additional effect on GAP-43 expression, with the degree of fold change in mRNA levels 
being 7.85 ± 1.19 at 7 dpo, similar to the 8.05 ± 0.24 fold change observed in untreated 
animals (Fig 11B).   
Figure 10.  Effects of ES and TP on expression of βII-tubulin following an
extratemporal facial nerve crush injury in rats.  Shown is a time-course of fold
changes in mRNA levels of βII-tubulin in the axotomized FMN relative to the control
FMN, with post-operative survival times being 0h, 6h, 1d, 2d, 7d, and 21d  Following
axotomy, untreated animals are compared to animals receiving only ES (A), only TP
(B), or the combination of both (C).  Within the untreated group, βII-tubulin is
significantly higher 7d following injury, relative to the baseline levels at 0h (p<0.05).
Asterisks are used to represent significant differences between different groups
(p<0.05).  Vertical lines represent standard error of the mean.  For each experimental
group, n = 3-6 animals/time point.
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Figure 11.  Effects of ES and TP on expression of GAP-43 following an
extratemporal facial nerve crush injury in rats.  Shown is a time-course of fold
changes in mRNA levels of GAP-43 in the axotomized FMN relative to the control
FMN, with post-operative survival times being 0h, 6h, 1d, 2d, 7d, and 21d
Following axotomy, untreated animals are compared to animals receiving only ES
(A), only TP (B), or the combination of both (C).  Within the untreated group, GAP-
43 is significantly higher 2-7d following injury, relative to the baseline levels at 0h
(p<0.05).  Asterisks are used to represent significant differences between different
groups (p<0.05).  Vertical lines represent standard error of the mean.  For each
experimental group, n = 3-6 animals/time point.
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Treatment with the combination of ES plus TP upregulated GAP-43 expression 
by a 17.6 ± 2.7 fold change at 7 dpo (Fig 11C).  This increase in the combined treatment 
group was significantly higher than that seen in untreated animals (8.05 ± 0.24 fold 
change; p<0.05) but similar to that seen in the ES only group (19.6 ± 2.86 fold change; 
Fig 11A).  Administration of ES did not accelerate the time at which GAP-43 expression 
peaked (Fig 11A and C).  Nonetheless, ES of the proximal nerve stump did significantly 
increase the fold change in GAP-43 mRNA levels while TP treatment had no added 
effect on GAP-43 expression.     
 
3.  EFFECTS OF ES AND TP ON EXPRESSION OF BDNF 
In axotomized, untreated animals, BDNF expression was significantly 
upregulated to a 5.15 ± 1.33 fold change at 1 dpo, relative to baseline (p<0.05; Fig 12).  
At 1 dpo, treatment with ES led to an additional 5-fold upregulation in BDNF expression, 
with levels increasing to 11.14 ± 1.14-fold (p<0.05 as compared to control; Fig 12A).  
However, in both untreated and ES-treated animals, BDNF mRNA levels began to 
decline by 2 dpo.     
At 1 dpo, untreated and TP-treated animals displayed a similar fold change in 
BDNF mRNA levels (5.15 ± 1.33 and 3.82 ± 0.22, respectively; Fig 12B).  At 2 and 7 
dpo, however, TP treatment maintained BDNF expression (6.28 ± 2.11 and 5.79 ± 1.28 
fold change, respectively), while levels declined to 2.78 ± 0.67 and 2.12 ± 0.61 fold 
change, respectively, in untreated animals (p<0.05; Fig 12B).  The combinatorial 
treatment displayed both the early effects of ES and late effects of TP (Fig 12C).  At 1  
Figure 12.  Effects of ES and TP on expression of BDNF following an
extratemporal facial nerve crush injury in rats.  Shown is a time-course of fold
changes in mRNA levels of BDNF in the axotomized FMN relative to the control
FMN, with post-operative survival times being 0h, 6h, 1d, 2d, 7d, and 21d
Following axotomy, untreated animals are compared to animals receiving only ES
(A), only TP (B), or the combination of both (C).  Within the untreated group,
BDNF is significantly higher 1d following injury, relative to the baseline levels at 0h
(p<0.05).  Asterisks are used to represent significant differences between different
groups (p<0.05).  Vertical lines represent standard error of the mean.  For each
experimental group, n = 3-6 animals/time point.
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dpo, an additional 6-fold increase in BDNF levels occurred with the ES plus TP 
treatment (11.08 ± 1.80), relative to no treatment (5.15 ± 1.33; p<0.05).  This increase 
was sustained until 7d post-axotomy, when the fold change in mRNA levels was at 5.72 
± 0.79 in animals receiving the combined treatment and 2.12 ± 0.61 in untreated animals 
(p<0.05).  Together, these data suggest that ES rapidly increases BDNF expression for a 
transient period, whereas TP induces a late but long-term increase.  In the combined 
treatment group, a temporally additive effect of both treatments was seen, with an 
immediate yet sustained upregulation of BDNF.   
 
4.  EFFECTS OF ES AND TP ON EXPRESSION OF NEURITIN  
Neuritin mRNA levels were not upregulated in axotomized, untreated animals at 
any time point post-axotomy (Fig 13).  However, administration of ES significantly 
increased neuritin expression by a 4.73 ± 1.48 fold change just 6 hours post-operative 
(hpo), relative to no treatment (-0.16 ± 0.09 fold change; p<0.05; Fig 13A).  Following 
the rapid increase with ES, neuritin mRNA levels quickly returned to baseline by 1 dpo (-
0.03 ± 0.75 fold change).  Systemic TP treatment also upregulated neuritin expression.  
However, the effects were seen later at 2 dpo, when fold change in neuritin mRNA levels 
was 1.89 ± 0.47 in TP-treated animals and -0.07 ± 0.24 in untreated (p<0.05; Fig 13B).  
In TP-treated animals, neuritin mRNA levels remained elevated at a fold change of 1.94 
± 0.69 up till 7 dpo.  
 Early and late effects on neuritin upregulation were observed in animals 
receiving both ES and TP.  With the combined treatment, neuritin mRNA levels rapidly  
Figure 13.  Effects of ES and TP on expression of neuritin following an
extratemporal facial nerve crush injury in rats.  Shown is a time-course of fold
changes in mRNA levels of neuritin in the axotomized FMN relative to the control
FMN, with post-operative survival times being 0h, 6h, 1d, 2d, 7d, and 21d
Following axotomy, untreated animals are compared to animals receiving only ES
(A), only TP (B), or the combination of both (C).  Within the untreated group,
neuritin expression did not significantly increase at any time point, relative to the
baseline levels at 0h (p<0.05).  Asterisks are used to represent significant differences
between different groups (p<0.05).  Vertical lines represent standard error of the
mean.  For each experimental group, n = 3-6 animals/time point.
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increased to a 4.48 ± 0.64 fold change at 6 hpo, relative to no treatment (-0.16 ± 0.09; 
p<0.05; Fig 13C).  Furthermore, neuritin levels remained elevated at a 2.33 ± 0.41 fold 
change at 2 dpo (p<0.05 relative to no treatment).  Like treatment with TP alone, the fold 
change in neuritin expression in the combined treatment group was also sustained until 7 
dpo (1.94 ± 0.82).  Therefore, administration of ES and TP together led to an immediate 
and prolonged upregulation of neuritin expression.     
 
5.  EFFECTS OF ES AND TP ON EXPRESSION OF PACAP  
In axotomized, untreated animals, PACAP expression significantly increased to a 10.56 ± 
1.25 fold change at 1 dpo (p<0.05 relative to baseline; Fig 14).  Furthermore,PACAP 
mRNA levels remained elevated until 7 dpo (13.76 ± 4.63 fold change).  In animals 
receiving ES, the fold change in PACAP expression tripled to 30.98 ± 7.13 at 1 dpo and 
29.50 ± 6.98 at 2 dpo, while the fold change in untreated animals was 10.56 ± 1.25 at 1 
dpo and 6.52 ± 2.51 at 2d post-axotomy (p<0.05; Fig 14A).  By 7 dpo, PACAP 
expression in animals receiving ES returned to levels of untreated animals (25.23 ± 4.24 
and 13.76 ± 4.63, respectively).   
Unlike ES, TP treatment had no additional effect on PACAP expression relative 
to no treatment.  Fold change in PACAP mRNA levels remained elevated in TP-treated 
animals from 1 dpo (5.66 ± 2.35) to 7 dpo (24.56 ± 11.78), but there was no significant 
increase relative to untreated animals (Fig 14B).  Combining TP with ES, however, had a 
dramatic effect on PACAP expression.  The combined treatment led to a significant 
upregulation in PACAP expression, as the fold change in mRNA levels was 27.45 ± 
Figure 14.  Effects of ES and TP on expression of PACAP following an
extratemporal facial nerve crush injury in rats.  Shown is a time-course of fold
changes in mRNA levels of neuritin PACAP in the axotomized FMN relative to the
control FMN, with post-operative survival times being 0h, 6h, 1d, 2d, 7d, and 21d
Following axotomy, untreated animals are compared to animals receiving only ES
(A), only TP (B), or the combination of both (C).  Within the untreated group,
PACAP expression is significantly higher 2-7d post injury, relative to the baseline
levels at 0h (p<0.05).  Asterisks are used to represent significant differences between
different groups (p<0.05).  Vertical lines represent standard error of the mean.  For
each experimental group, n = 3-6 animals/time point.
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10.05 at 1 dpo and 35.27 ± 10.57 at 2 dpo (p<0.05 relative to no treatment; Fig 14C).  
However, at 7 dpo, there was a further increase in PACAP expression by 56.72 ± 8.37-
fold, a change double than that seen with ES alone (25.23 ± 4.24) or TP alone (24.56 ± 
11.78).  Therefore, treatment with both ES and TP led to an additive effect on PACAP 
expression.   
 
E.  DISCUSSION  
Our previous studies have shown that administration of daily, low frequency ES 
accelerates the onset of functional recovery and reduces the initial delay in sprout 
formation but fails to increase the rate of axonal regeneration (Lal et al., 2008; Chapter 
IV).  TP treatment, in contrast, accelerates the overall regeneration rate without affecting 
the sprouting delay.  The combinatorial treatment of daily ES plus systemic TP was 
found to enhance functional recovery and facial nerve regenerative properties more than 
the use of either treatment alone (Hetzler et al., 2008; Chapter IV).  In this study, we 
characterized the molecular effects of ES and TP, and determined that the two treatments 
enhance gene expression in distinct patterns when administered alone and have combined 
upregulatory effects when administered together.      
 Axonal elongation requires reconstruction of the microtubule cytoskeleton, 
composed of heterodimers of α and β tubulin.  Of the five different α-tubulin isotypes 
and the five different β-tubulin isotypes expressed in the mammalian brain, axotomy 
upregulates expression of α1, βII, and βIII forms of tubulin (Hoffman and Cleveland, 
1988; Miller et al., 1989; Moskowitz and Oblinger, 1995; Wong and Oblinger, 1990).  
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The present study confirmed that the mRNA levels of α1- and βII-tubulin are 
upregulated following a facial nerve crush axotomy in rats.  Our previous studies in the 
hamster facial motoneuron and the rat sciatic motoneuron systems have demonstrated 
that systemic administration of TP selectively upregulates expression of βII-tubulin but 
not α1- or βIII-tubulin (Jones and Oblinger, 1994; Brown et al., 1999).  Similarly, in the 
current study, we found that TP differentially upregulated mRNA levels of βII-tubulin, 
but not α1-tubulin, in a time course similar to previous work.  It is also important to note 
that although TP tripled the magnitude of βII-tubulin fold change in the FMN, it did not 
induce an earlier increase in βII-tubulin expression relative to no treatment.  In contrast, 
ES had no additional effect on βII-tubulin expression.  Instead, it not only enhanced 
expression of α1-tubulin but also causes the upregulation to peak earlier as compared to 
axotomy without treatment.  Al-Majed et al. (2004) have reported a similar increase in 
expression of α1-tubulin with 1 h ES of the rat femoral nerve following nerve transection 
and repair.   
A potential mechanism by which ES mediates its effects is through the use of 
calcium and cAMP as second messengers (Brushart et al., 2002; Al-Majed et al., 2000a; 
Kocsis et al., 1994).  Electrical activity is known to increase Ca2+ influx, which in turn 
has been coupled to changes in gene expression (Finkbeiner and Greenberg, 1998).  Ca2+ 
influx also activates Ca2+-dependent adenylate cyclase to increase intracellular levels of 
cAMP (Hempel et al., 1996; Shen et al., 1999).  Previous studies have shown that cAMP 
itself can enhance axonal regeneration in vivo (Neumann et al., 2002; Gershenbaum and 
Roisen, 1980, Kilmer and Carlsen, 1984).  Moreover, injecting dibutyryl cAMP, a 
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membrane-permeable analogue of cAMP, in the dorsal root ganglia increases levels of 
α1- and βIII-tubulin (Han et al., 2004).  Activation of cAMP-dependent signaling 
pathways in primary cultures of guinea pig enteric ganglia also increases mRNA levels of 
α1-tubulin (Simeone et al., 1994).  Although the effects of cAMP on βII-tubulin 
expression have not been reported, the specific upregulation of α1-tubulin expression 
following treatment with ES may be due to cAMP-mediated effects.   
Although it is unclear why ES and TP upregulate different isoforms of tubulin, 
there are several possible explanations.  While there is 40% sequence conservation 
between α and β forms of tubulin, the two can diversify further based upon their post-
translational modifications, such as acetylation, phosphorylation, detyrosylation, 
polyglutamylation, and polyglyclation (Luduena, 1998).  The two isoforms may also 
differ in their interactions with microtubule-associated proteins.  Such properties may 
affect the stability, dynamics, and motility of different αβ heterodimers, allowing them to 
impart unique properties to the cytoskeleton.  The enhanced effect of ES on α1-tubulin 
expression may have some relation to it also reducing the delay before sprout formation 
begins and increasing levels of intracellular messengers that specifically activate 
transcription of the α1-tubulin, but not the βII-tubulin, gene.  On the other hand, TP-
mediated increase in βII-tubulin may be due to there being steroid response elements on 
the βII-tubulin, but not the α1-tubulin, gene.  An increase in βII-tubulin may also be 
correlated to an increase in axonal elongation rate, a property enhanced by TP but not ES.  
ES and TP appear to be working through distinct mechanisms to specifically alter 
expression of either α1-tubulin or βII-tubulin.  The combinatorial treatment of ES plus TP 
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upregulates both α1- and βII-tubulin, and thus may provide regenerating axons with the 
functional benefits of both isoforms.   
Regulation of microtubule assembly and actin polymerization at nerve endings are 
crucial for axon elongation and synaptogenesis.  GAP-43 is a well-known regeneration-
associated gene implicated in this process during development and regeneration (Chong 
et al., 1992; Aigner et al., 1995).  Transgenic mice overexpressing GAP-43 demonstrate 
spontaneous formation of new synapses and enhanced sprouting after injury, whereas a 
loss in function of the GAP-43 gene disrupts axonal pathfinding (Aigner et al., 1995; 
Strittmatter et al., 1995).  In accordance with existing literature, current results 
demonstrate that a facial nerve crush, without any treatment, increased GAP-43 
expression.  Gonadal steroids have been shown to modulate expression of GAP-43 in the 
rat central nervous system (Shughrue and Dorsa, 1993a; Shughrue and Dorsa, 1993b; 
Lustig et al., 1991).  In a previous study using in situ hybridization, our lab found that 
administration of systemic TP prevented the transient decline in GAP-43 mRNA levels 
seen in untreated hamsters 7 d following facial nerve transection (Jones et al., 1997a).  
The present study in rats slightly differs in that it found no dip in GAP-43 expression at 
7d post-injury in the absence of treatment and thus no additional effects of TP. 
ES of the transected and sutured rat femoral nerve for 1 h has been shown to 
accelerate the increase in GAP-43 expression (Al-Majed et al., 2004).  Although our 
results demonstrate that 30 min of daily ES treatment also amplified GAP-43 expression, 
there are some differences.  In our facial nerve injury model, we did not find that ES 
upregulated GAP-43 expression earlier than injury alone.  Instead, the peak in GAP-43 
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expression occurs at the same time point following injury with or without ES 
treatment.  The slight discrepancy in results between our study and the study by Al-
Majed et al. (2004) may be due to differences in the molecular techniques used to 
quantify fold change (RT-PCR vs. in situ hybridization) and/or the nerve injury 
paradigms (facial nerve crush vs. femoral nerve transection and repair).  Nevertheless, the 
current finding that ES enhances GAP-43 expression lends insight into its potential 
mechanism of therapeutic action and how it may be different from that of TP.  The 
combinatorial treatment of ES plus TP upregulated GAP-43 expression similar to ES 
alone, further suggesting that ES enhances GAP-43 expression while TP has no 
supplementary effect.  
Motoneurons can respond to neurotrophins secreted by non-neuronal cells or by 
autocrine signaling.  Synthesis of BDNF and its receptor, trkB, increases in several 
motoneuron systems, including the facial nerve, following axonal injury (Meyer et al., 
1992; Funakoshi et al., 1993; Piehl et al., 1994; Kobayashi et al., 1997).  BDNF promotes 
motoneuron survival, reverses soma atrophy, and induces axonal outgrowth in vivo (Yan 
et al., 1992; Novikov et al., 1997; Novikova et al., 1997; Novikov et al., 1995; Kishino et 
al., 1997).  There are several lines of evidence supporting the effects of gonadal steroids 
on BDNF expression.  Gonadal steroids have been shown to regulate BDNF and trkB 
levels in the central and peripheral nervous systems (Ottem et al., 2007; Osborne et al., 
2007; Sohrabji et al., 1995; Solum and Handa, 2002; Jezierski and Sohrabji, 2001).  
Plasma BDNF levels have also been positively correlated with endogenous levels of 
gonadal steroids (Begliuomini et al., 2007).  The present study found that TP treatment 
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prolonged BDNF upregulation and maintained high mRNA levels during later phases 
of regeneration 
Since various studies demonstrate that membrane depolarization also induces an 
increase in BDNF levels, electrical activity may play an important role in regulating 
BDNF expression (Zafra et al., 1990; Patterson et al., 1992).  One hour ES of the rat 
femoral nerve has been shown to rapidly upregulate BDNF and trkB expression 
immediately following transection and surgical repair (Al-Majed et al., 2000b).  Our 
results also demonstrate that ES immediately augmented the fold change in BDNF 
upregulation, but that the effects were short-termed.  Combining ES with TP led to 
temporally additive effects: it produced the rapid increase in BDNF expression, as seen 
with ES alone, and it maintained the increase for a longer time course post-axotomy, as 
seen with TP alone.  
Neuritin was originally identified as a candidate plasticity-related gene whose 
expression is regulated by neuronal activity (Nedivi et al., 1998; Naeve et al., 1997).  It is 
a small, highly conserved, extracellular protein that is attached to the extracellular 
membrane via a glycosylphosphatidylinositol anchor.  Neuritin promotes neurite 
outgrowth, enhances dendritic and axonal arborization, and plays a role in synapse 
maturation (Nedivi et al., 1998; Cantallops et al., 2000; Javaherian and Cline, 2005).  
Following spinal cord injury in rats, neuritin levels are initially downregulated for 24 h 
and then strongly re-induced during the following 2 wk (Di Giovanni et al., 2005).  
Neuritin expression also increases 0-6 h following ischemia and reperfusion in rats 
(Rickhag et al., 2007).  The current study did not detect a significant increase in neuritin 
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mRNA levels over a course of 0 h to 21 d following a facial nerve crush, without 
treatment.  Our previous study in hamsters also reported no change in neuritin expression 
in axotomized, untreated animals but found an increase upon administration of TP.  
Silencing neuritin has also been shown to abolish androgenic effects on neurite outgrowth 
in vitro, suggesting that neuritin is a downstream effector of androgens (Marron et al., 
2005).  The current results support these previous finding by demonstrating that TP 
administration enhances and steadily maintains neuritin expression.   
Treatment with ES also enhanced neuritin expression, however, the effects were 
more immediate and transient as compared to TP treatment.  Since membrane 
depolarization is known to modulate neuritin (Naeve et al., 1997), ES of the proximal 
nerve stump may alter electrical activity in a way that leads to early transcriptional 
changes in neuritin.  Combining ES with TP led to both the early effects of ES and late 
effects of TP.  Therefore, a combinatorial treatment strategy may be beneficial in that ES 
may immediately increase synthesis of immediate early genes (i.e. neurotrophic factors 
and neuritin) until the effects of testosterone come in to play and preserve high levels of 
gene expression over an extended time course. 
Peripheral nerve axotomy has been shown to upregulate expression of PACAP in 
sensory neurons of the dorsal root ganglia and the mesencephalic trigeminal nucleus, the 
sympathetic neurons of the superior cervical ganglia, and the facial motor nucleus (Zhang 
et al., 1996; Zhang et al., 1995; Larsen et al., 1997; Moller et al., 1997; Zhou et al., 
1999).  PACAP promotes neurite outgrowth and cell survival, has anti-inflammatory 
effects, and is neuroprotective in conditions of injury such as ischemia, trauma, 
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neurodegeneration, and axotomy (Somogyvari-Vigh and Reglodi, 2004).  In the 
present study, PACAP expression increased substantially following axotomy alone, 
without any treatment. While TP administration has no additional effect on PACAP 
expression, treatment with ES tripled the fold change soon after axotomy.  Interestingly, 
combining ES with TP had additive effects on PACAP expression, suggesting that TP 
may potentiate the mechanisms used by ES to enhance PACAP expression.  
 A successful regenerative response following peripheral nerve injury requires 
coordinated expression of neurotrophic factors, growth-associated proteins, and structural 
components.  Characterizing the effects of potential treatments on gene expression is 
beneficial to understanding their underlying mechanisms of improving axonal 
regeneration and functional recovery.  The finding that ES and TP not only target 
different genes but also differ in their timing and duration of effects implies that they 
work through different mechanisms.  While ES may accelerate the onset of regeneration 
and immediately upregulate gene expression, the effects may be transient.  Testosterone-
mediated effects may require a longer lag time, but the changes in gene expression may 
be sustained, leading to an overall increase in rate of regeneration.  Since the two 
treatments appear to be working through different mechanisms, the use of a 
combinatorial treatment strategy would maximize therapeutic effects and thus warrants 
further investigation for clinical translation. 
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CHAPTER VI 
COMPARISON OF EXTRATEMPORAL AND INTRATEMPORAL 
FACIAL NERVE INJURY MODELS 
 
A.  ABSTRACT 
 The facial nerve is the most commonly injured cranial nerve, and injury results in 
significant functional and emotional disturbances.  Due to the nerve’s complex 
anatomical course, injuries can occur at different proximities from the FMN and lead to 
varying outcomes. The purpose of the third aim of this dissertation was to compare 
functional recovery and motor nerve conduction following a distal, extratemporal crush 
injury of the facial nerve at its exit from the SMF to a more proximal, intratemporal crush 
injury of the nerve during its course in the temporal bone.  Adult male rats were divided 
into four experimental groups: extratemporal crush, extratemporal sham-operated, 
intratemporal crush, and intratemporal sham-operated.  Animals were observed daily for 
return of facial nerve function, including the eyeblink reflex and vibrissae orientation and 
movement.  Motor nerve conduction studies were done weekly to quantify the changes in 
peak amplitude and latency of evoked response.  Assessment of facial motoneuron 
survival was done at 4 and 8 weeks post-operative (wpo).  Rats receiving the 
extratemporal facial nerve injury recovered full facial function by ~2 wpo and normal 
peak amplitude and latency recordings by 4 wpo and demonstrated no significant
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neuronal loss post-mortem.  In comparison, rats receiving the intratemporal facial 
nerve injury failed to reach complete functional recovery and peak amplitude of evoked 
response remained ~70% below normal at the end of 8 wpo, and they demonstrated a 
~15% cell loss. The findings indicate that the location of facial nerve injury strongly 
influences the recovery and regeneration outcome.  
 
B.  INTRODUCTION 
Facial nerve lesions are common clinical conditions that result in significant 
distortion of the face and severe emotional and psychological disturbances in patients.  
Additional complications of facial nerve injury often include synkinesis, eye infections, 
corneal ulceration, drooling, and speech difficulties (Mavrikakis, 2008).  Although facial 
function may return completely in some patients, others may demonstrate delayed 
recovery or residual deficits.  Unsatisfactory recovery may be due to significant neuronal 
loss, inadequate reinnervation, misdirection of regenerating axons, or denervation-
induced target atrophy.  
The susceptibility of the facial nerve to injury arises from its complex anatomical 
course from the brainstem to its muscles of innervation.  As the nerve travels 
intracranially, it may be injured through compression by tumors in the cerebellopontine 
angle (Danner, 2008).  When the facial nerve enters the temporal bone, it travels an 
intricate course confined within a prolonged canal, which in some cases is not much 
greater in diameter than the nerve itself.  In humans, this 30-mm course of the facial 
nerve within the temporal bone, the longest interosseous course of any cranial nerve, 
renders the nerve vulnerable to swelling and compression (Mavrikakis, 2008).  Bell’s 
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palsy, categorized as idiopathic, is the most common cause of facial paralysis, and 
believed to result from inflammation of the facial nerve during its course in the temporal 
bone, leading to compression and possibly ischemia and demyelination (Tiemstra and 
Khatkhate, 2007).  Other causes of intratemporal facial nerve injuries include temporal 
bone fractures, iatrogenic injuries, infections and compression by neoplasms (Mavrikakis, 
2008).  As the nerve exits the skull at the SMF, it courses through the parotid gland to 
branch into five main branches that innervate the facial muscles.  There it may become 
injured due to lacerations or complications arising from compression by or removal of 
parotid gland tumors (Danner, 2008).  The site of facial nerve injury influences the 
severity of facial paresis and the recovery outcome. 
Current treatments for facial nerve paralysis following transection injuries include 
direct anastomosis or cable grafting (Kumar et al., 2006).  Diagnosis of Bell’s palsy is 
usually followed up with a course of corticosteroids and anti-virals, but their efficacy is 
still controversial (Gilden, 2004).  For some patients, recovery from facial paralysis 
begins within a few weeks and is completed within a few months to a year.  However, 
this is not always the case; many patients have incomplete recovery and long-term 
sequelae from the paralysis (Mavrikakis, 2008).  Several factors influence the outcome of 
regeneration, including the type or severity of injury, time between injury and treatment, 
age of patient, and location of the injury.  Therefore, animal models that mimic the 
common facial nerve injuries seen in the clinic need to be developed so that potential 
therapies can be suitably investigated.  
Currently, existing animal models of facial nerve injury include intracranial 
transection and extratemporal transection and crush of the facial nerve (Mattsson, 1999; 
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Jones, 2001).  Thus far, an animal model of intratemporal facial nerve injury has not 
been characterized even though a majority of facial nerve lesions occur during its course 
through the temporal bone.  Therefore, the third aim of this dissertation aimed to develop 
a more clinically relevant intratemporal model of facial nerve injury and compare it to the 
well-established extratemporal facial nerve injury model.  Also, many insults to the facial 
nerve result form a stretching or compression of the nerve rather than its transection.  
Therefore, to more closely resemble such a clinical picture, this study used crush injury, 
in which the neural sheath is left intact while the axons are damaged.  Our findings 
demonstrated significant differences in recovery of facial function, motor nerve 
conductance, and motoneuron survival between the extratemporal and intratemporal 
models of facial nerve injury.    
 
B.  MATERIALS AND METHODS 
 
1.  ANIMALS  
Adult male Sprague-Dawley rats (~2 months old) were purchased from Harlan 
(Indianapolis, IN) and used for all experiments, as described in Chapter III.  For facial 
nerve crush injuries and weekly electromyographic (EMG) recordings, rats were 
anesthetized by intra-peritoneal injections of Ketamine (100mg/ml; 0.1ml/100g body 
weight) and Xylazine (20mg/ml; 0.025ml/100g body weight).  The experimental design 
for this study is illustrated in Figure 15.  Animals were divided into four experimental 
groups based on the type of facial nerve injury administered:  1) extratemporal crush, 2) 
Figure 15:  Experimental Design for Aim 3. This timeline will be followed to compare the two models 
of facial nerve injury, extratemporal and intratemporal. 
Facial N. Crush 
Facial N. Crush 
Sham 
Sham 
Intratemporal 
Extratemporal 
Daily Functional Recovery 
Assessment 
Weekly Motor Nerve Conduction 
Assessment 
8 wk 
Cell Survival  
Assessment 
4 wk 8 wk 
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extratemporal sham-operated, 3) intratemporal crush, and 4) intratemporal sham-
operated.    
 
2.  EXTRATEMPORAL FACIAL NERVE CRUSH INJURY 
A post-auricular incision was made, and the right facial nerve was exposed at its 
exit from the SMF (refer to Chapter III for details).  Approximately 1 mm distal to the 
SMF, before branching of the main trunk, the nerve was crushed with a hemostat for 1 
min.  The standard crush performed ensured that all nerve fibers were crushed while the 
axonal sheath remained intact.  For the extratemporal sham injury group, the right facial 
nerve was exposed but left uncrushed.  In all animals, the left facial nerve was left intact 
to serve as an internal control.  The post-operative survival time was 4 weeks, at which 
point the animals were sacrificed by CO2 asphyxiation 
 
3.  INTRATEMPORAL FACIAL NERVE CRUSH INJURY  
The surgical procedure is described in detail in Chapter III.  The facial nerve was 
exposed near its exit from the SMF and followed proximally to reach its intratemporal 
segment.  The dorsal and caudal aspects of the ear canal were incised to provide exposure 
of the tympanic bulla.  The tympanic bulla was saucerized using a dental drill and the 
lateral bony aspect of the epitympanic region was removed.   Ossicles were exposed and 
removed with jeweler’s forceps to provide access to the region of the temporal bone 
located medially, where the intratemporal segment of the facial nerve lies.  The bone 
covering the facial nerve was gradually thinned, beginning at the posterior aspect of the 
SMF and continuing antero-medially.  Once sufficiently thinned within its course in the
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facial canal, the facial nerve was crushed with a hemostat for 1 min.  Gelfoam was 
lightly packed into the middle ear cavity prior to wound closure.  In all animals, the left 
facial nerve was left intact to serve as an internal control. 
For the intratemporal sham injury group, the drilling procedure was done as 
described above to expose the right facial nerve within the facial canal; but the nerve was 
left uncrushed.  The post-operative survival time was 4 weeks for animals in the sham 
group.  As the animals that received the intratemporal facial nerve crush showed delayed 
recovery, the post-operative survival time was extended to 8 weeks.  Animals were 
sacrificed by CO2 asphyxiation. 
 
4.  FUNCTIONAL RECOVERY ASSESSMENT  
Recovery of facial function on the right side was compared daily to the intact 
function on the left side, as described in Chapter III.  Animals were observed for the 
return of eyeblink reflex and vibrissae orientation and vibrissae movement.  The recovery 
time to reach a functional level equal to that on the uninjured side was noted for analysis.  
For the eyeblink reflex, in addition to its complete recovery, the time till onset of the 
blink reflex was also analyzed.  Each group contained an n of 6-7.   
 
5.  ELECTROMYOGRAPHIC RECORDINGS  
Motor nerve conduction tests were done on anesthetized animals pre- and post-
operatively on the day of axotomy and weekly thereafter (refer to Chapter III for details).  
Two stimulating electrodes were placed below the infraorbital ridge, two recording 
electrodes were placed on the vibrissae pad to record the evoked muscle activity distal to 
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stimulation, and a reference electrode was placed inferior to the ear canal (Fig. 16).  
The facial nerve was stimulated at a frequency of 0.5 Hz with a 10 mA current, and an 
average of 25 responses was recorded for each trial.  Peak amplitude was defined as the 
maximum evoked potential and latency as the time from the stimulation to the onset of 
response.  Percent change in peak amplitude and latency, relative to the response on the 
unoperated side, was calculated and plotted as a function of weeks post-axotomy.  An n 
of 4-9/time point was used for each of the 4 experimental groups. 
 
7.  FACIAL MOTONEURON SURVIVAL ASSESSMENT 
 Animals in all 4 experimental groups were sacrificed by CO2 asphyxiation at 4 
wpo, but the animals in the intratemporal crush were also sacrificed at an additional time 
point of 8 wpo.  Brains were collected, and serial 40 µm cyrostat sections were taken 
fixed in 4% paraformaldehyde, and stained with thionin, as previously described n 
Chapter III.  Slides were coded by one investigator and subsequently counted under blind 
conditions by another investigator.  Cell profile counts were performed on every section, 
and the percentage change in surviving motoneurons between the left and right sides was 
calculated and compared between groups.  Only surviving FMNs containing a clearly 
visible nucleus were counted (Serpe et al., 1999; Serpe et al., 2000; Serpe et al., 2003; 
Byram et al., 2003).  
 
6.  STATISTICAL ANALYSIS  
For each functional parameter, statistical significance of the differences in 
recovery times for the intratemporal and the extratemporal facial nerve injury models was 
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determined using unpaired t-tests.  If any animals did not recover a functional 
parameter by the end of the study period (8 weeks), the recovery time was designated as 
>56 dpo.  For some functional parameters, when all animals in a group did not recover 
function by 56 dpo, and thus an unpaired t-test could not be used, a one-sample t-test was 
done with the hypothetical value defined as 56.  For motor nerve conduction studies, 
significant differences among the four experimental groups were determined using a two-
way ANOVA (factors = days post-axotomy and treatment), followed by a Newman-
Keuls’ multiple comparison post-hoc test at p<0.05.  Statistical differences among cell 
survival in sham and injury groups were determined using a one-way ANOVA, followed 
by a Newman-Keuls’ multiple comparison post-hoc test at p<0.05  
   
D.  RESULTS  
 
1.  DIFFERENCES IN FUNCTIONAL RECOVERY FOLLOWING 
EXTRATEMPORAL VS. INTRATEMPORAL FACIAL NERVE CRUSH 
An intratemporal model of facial nerve injury was successfully developed.  The 
distal, extratemporal site of facial nerve injury is compared to the proximal, intratemporal 
site in Figure 17.  The intratemporal crush site was ~6-7 mm more proximal to the FMN 
than the extratemporal crush site.  Figure 18 compares the return of facial nerve function 
in both models of facial nerve injury.  The onset of the eyeblink reflex 
 Figure 16.  Experimental setup for 
motor nerve conduction testing. 
Diagram illustrates the placement of 
electrodes for measuring facial nerve 
conduction. Sites for the two recording 
electrodes on the vibrissal pad (arrows) 
and the two stimulating electrodes below 
the infraorbital ridge (arrowheads) are 
marked. The reference electrode was 
placed below the ear.   
Figure 17.  Surgical design of 
extratemporal vs. 
intratemporal facial nerve 
injury.  Images illustrate 
extratemporal (A) and 
intratemporal (B) facial nerve 
segments.  The red arrowheads 
represent the site of crush. A 
ruler with 1 mm marks is also 
presented in (B) as a scale.  
SMF: stylomastoid foramen;  
ET: extratemporal;  
IT: intratemporal.       
SMF 
Ossicles 
ET Facial nerve  
A. Extratemporal crush 
Facial canal 
IT Facial nerve  
 1 mm  
B. Intratemporal crush 
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represents initiation of functional recovery and was significantly delayed in animals 
receiving the intratemporal facial nerve crush as compared to the extratemporal crush 
(Fig. 18A).   Following an extratemporal crush, the eyeblink first began to appear at 4.43 
± 0.37 dpo, whereas an intratemporal crush led to a delayed onset at 11.14 ± 3.04 dpo 
(p<0.05).  The complete eyeblink reflex returned in animals receiving the extratemporal 
crush at 11.14 ± 1.06 dpo (Fig. 18B).  However, in animals receiving the intratemporal 
crush, return of the complete eyeblink was also significantly delayed to ≥ 41.71 ± 7.04 
dpo (p<0.05).  Within this average recovery time for six animals, three animals recovered 
the full eyeblink reflex while the other three had an incomplete blink reflex even at the 
end of the study period of 56 dpo.  
Normal vibrissae orientation returned in animals before vibrissae movement (Fig. 
18C-D).  While animals receiving the extratemporal crush displayed normal orientation 
by 7.43 ± 0.90 dpo, animals with the intratemporal crush demonstrated significantly 
delayed return at 16.67 ± 0.76 dpo (Fig. 18C; p<0.05).  Unlike the eyeblink reflex, 
normal vibrissae orientation did return in all animals following an intratemporal crush.  In 
the extratemporal facial nerve injury model, full vibrissae movement appeared at 14.71 ± 
0.84 dpo. (Fig. 18D)  Comparatively, in all of the animals in the intratemporal injury 
group, vibrissae movement did not return to normal up till the end of the study period at 
56 dpo (p<0.05).   
As vibrissae movement is the last parameter to return, its return defines the 
recovery time for complete recovery of facial nerve function.  Therefore, Figure 18D also 
shows that in animals receiving the extratemporal crush, facial function was complete at 
14.71 ± 0.84 dpo.  An intratemporal injury of the facial nerve, however, resulted in 
Figure 18.  Comparison of recovery of facial nerve functional parameters 
between extratemporal and intratemporal models of facial nerve crush injury. 
Shown are recovery times for onset of the eyeblink reflex (A) and return of the full 
eyeblink reflex (B), vibrissae orientation (C), and vibrissae movement (D), 
following extratemporal and intratemporal facial nerve crush in rats.  A scatter plot 
overlies each bar graph to display the spread of individual animals values within 
groups.  Vertical lines represent standard error of the mean.  Asterisks represent 
significant differences between groups (p<0.05).   n = 6-7/group.  
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incomplete facial function at even 56 dpo (p<0.05).  Sham animals in the 
extratemporal and the intratemporal injury groups had an intact eyeblink reflex and 
vibrissae orientation and movement at 1 dpo, and thus they are not included in the graphs 
or analysis.  Importantly, however, sham animals confirmed that the surgical procedure 
did not injure the facial nerve.   
 
2.  DIFFERENCES IN MOTOR NERVE CONDUCTION FOLLOWING 
EXTRATEMPORAL VS. INTRATEMPORAL FACIAL NERVE CRUSH 
Motor nerve conduction studies were done weekly in the extratemporal and 
intratemporal sham and injury groups.  Figure 19 demonstrates the percent change in the 
peak amplitude of evoked response for the crushed nerve, relative to the unoperated side.  
In both the extratemporal and intratemporal sham-operated animals, the percent change in 
peak amplitude remained around baseline, with no statistically decreased response post-
injury as compared to the pre-injury time point at 0 wpo.  Following an extratemporal 
injury, the peak amplitude significantly decreased to -60.16 ± 6.00% at 1 wpo, as 
compared to the 37.73 ± 7.33% response prior to injury (p<0.05).  Relative to its sham 
group, the extratemporal injury group continued to have significantly lower peak 
amplitudes from 1-3 wpo (Fig. 19; p<0.05).  By 4 wpo following an extratemporal facial 
nerve injury, the peak amplitude increased to -15.95 ± 2.24%, a response not statistically 
different than that of the sham animals in this group (12.11 ± 5.53%; Fig. 19).  
 Following an intratemporal facial nerve injury, the peak amplitude significantly 
dropped to -83.28 ± 4.65% at 1 wpo, as compared to the 22.48 ± 6.42% response prior to 
injury (p<0.05).  With respect to its sham group, the intratemporal injury group had 
Figure 19. Comparison of peak amplitude of evoked response between 
extratemporal and intratemporal models of facial nerve crush injury.  Motor 
nerve conduction testing was done to record peak amplitude of the evoked response 
in the vibrissal pad upon facial nerve stimulation.  Shown are percent changes in 
peak amplitude on the injured side, relative to the unoperated side, over a time 
course.  Vertical lines represent standard error of the mean. (* = p<0.05 as compared 
to sham; # = p<0.05 as compared to extratemporal injury; n = 4-9/time point of each 
group).  Dotted red line at y-intercept represents baseline.  
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significantly lower peak amplitudes from 1-4 wpo (p<0.05; Fig. 19).  In addition, the 
peak amplitude failed to return to baseline levels even at 8 wpo, remaining at a value of -
72.24 ± 2.39% (p<0.05 as compared to baseline).  Also, in comparison to the 
extratemporal facial nerve injury, the intratemporal facial nerve injury led to significantly 
lower peak amplitudes from 1-4 wpo (p<0.05; Fig. 19).  Therefore, while the amplitude 
of facial nerve conduction returned to normal in the extratemporal injury group, the 
intratemporal injury group displayed no improvement.   
   Figure 20 demonstrates the percent change in latency of response for the crushed 
facial nerve, relative to the unoperated side, over a course of 8 weeks following injury.  
In both the extratemporal and intratemporal sham-operated groups, the latency fluctuated 
around baseline pre- and post-injury.  In animals receiving the extratemporal crush, the 
latency of response increased to 9.53 ± 4.56%, a response not statistically different than 
that prior to injury (-9.29 ± 3.46%).   Furthermore, the percent change in latency did not 
significantly change following an extratemporal crush relative to its sham.  At 1 wpo, 
latency increased to 9.53 ± 4.56% in the extratemporal crush group, while the sham 
group had a latency change of  -0.87 ± 1.95% (p>0.05; Fig. 20).   
Following an intratemporal injury, however, the latency was significantly 
increased at 1 wpo relative to the sham group (29.58 ± 5.35% and -4.35 ± 0.88%, 
respectively; Fig. 20).  By 2 wpo, the latency in the intratemporal injury group decreased 
to 20.74 ± 10.35%, not statistically different than the -5.37 ± 2.09% change in the sham 
group.  At 2 wpo, however, the latency of response in the intratemporal injury group was 
significantly increased compared to the extratemporal injury group (-5.50 ± 5.97%; 
Figure 20. Comparison of latency of evoked response between extratemporal and 
intratemporal models of facial nerve crush injury.  Motor nerve conduction testing 
was done to record latency of the evoked response in the vibrissal pad upon facial 
nerve stimulation.  Shown are percent changes in latency on the injured side, relative 
to the unoperated side, over a time course.  Vertical lines represent standard error of 
the mean. (* = p<0.05 as compared to sham; # = p<0.05 as compared to extratemporal 
injury; n = 4-9/time point of each group).  Dotted red line at y-intercept represents 
baseline. 
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p<0.05; Fig. 20).  Therefore, an intratemporal injury led to a longer latency in facial 
nerve conduction, comparative to not only sham but also extratemporal injury.   
As animals receiving the extratemporal facial nerve injury recovered full function 
by ~2 wpo and reached peak amplitudes close to baseline levels by 4 wpo, this group was 
only followed until the end of 4 wpo.  The intratemporal injury group was followed for a 
maximum of 8 wpo, in an attempt to capture return of functional recovery and normal 
motor nerve conduction.  However, results demonstrate that complete facial function as 
well as evoked amplitude and latency of response to stimulation did not return to normal 
in animals receiving the intratemporal facial nerve injury even at the end of 8 wpo.       
 
3.  DIFFERENCES IN FACIAL MOTONEURON SURIVAL FOLLOWING 
EXTRATEMPORAL VS. INTRATEMPORAL FACIAL NERVE CRUSH 
 Figure 21 demonstrates the percent of facial motoneurons survival in the two 
facial nerve injury models and their respective sham groups.  At 4 wpo, the amount of 
cell survival in the animals receiving the extratemporal facial nerve crush was 103.29 ± 
6.34%, similar to the 111.71 ± 3.24% survival in the extratemporal sham group (Fig. 21).  
Following an intratemporal facial nerve crush injury, cell survival in the FMN at 4 wpo 
was 89.43 ± 8.57, not significantly different than the 119.03 ± 13.35% survival in the 
intratemporal sham group.  As functional recovery in animals receiving the intratemporal 
facial nerve crush was incomplete at 4 wpo, cell counts were also assessed at 8 wpo.  At 8 
wpo, facial motoneurons survival in the intratemporal crush group dropped to 85.78 ± 
3.15%, significantly different than its respective sham group (p<0.05) but not different 
than the extratemporal crush group (Figure 21).  Therefore, while a distal extratemporal 
Figure 21. Comparison of facial motoneuron survival between extratemporal 
and intratemporal models of facial nerve crush injury.  Percent survival of 
neurons within the right FMN was calculated relative to the left FMN. Motoneuron 
survival was assessed at 4 wpo for all groups and at an additional time point of 8 
wpo in the intratemporal crush group. Vertical lines represent standard error of the 
mean.  Asterisk represents significant difference between the intratemporal crush 
animals at 8 wpo and their respective sham.  n = 3-5/group. 
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facial nerve crush did not induce any neuronal death, a proximal intratemporal crush 
lead to a ~15% loss of facial motoneurons.        
 
E.  DISCUSSION 
Facial nerve paralysis is a common peripheral nerve injury that has significant 
functional and emotional impact on patients.  Due to the nerve’s complex anatomical 
course, injuries can occur in different segments of the nerve (intracranial, intratemporal, 
and extratemporal), leading to different pathophysiological outcomes.  Development of 
animal models representing the different types and locations of facial nerve injury is 
imperative for investigation of potential treatments.  The current study compared the 
differences in functional recovery and motor nerve conduction in two models of facial 
nerve injury, the well-established extratemporal model and our newly developed 
intratemporal model.  Results show that crushing of the facial nerve within its 
intratemporal segment leads to significantly delayed recovery in comparison to crushing 
of the nerve after the its exit from the SMF.  It is important to note that no animal model 
has previously characterized the recovery outcome following an intratemporal facial 
nerve injury.  Therefore, the present findings have significant implications for patients 
with intratemporal facial nerve injuries as they may show hindered recovery and may 
require more assertive treatment strategies.   
In the current study, all facial functional parameters and motor nerve conductance 
returned to normal following an extratemporal but not an intratemporal crush.   Although 
the vibrissae orientation returned in animals receiving the intratemporal crush, the 
eyeblink reflex was incomplete in half of the animals at 56 dpo.  Also at the end of 56 
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dpo, full vibrissae movement and thus complete functional recovery were incomplete 
in all of the animals receiving the intratemporal crush.  In addition, motor nerve 
conduction study confirmed that the peak amplitude of the evoked response of the 
crushed facial nerve was still ~70% below that of the intact nerve at 56 dpo.  As the 
amplitude of the evoked response is determined by the number of functioning motor 
nerve fibers, the current findings suggest that a majority of motor nerve fibers have not 
regenerated to the vibrissal musculature by 8 weeks following an intratemporal facial 
nerve injury (Oh and Shin, 2003).  Latency, on the other hand, does return to normal by 2 
weeks following an intratemporal injury.  The latency of an evoked response is 
determined by how quickly the nerve impulse is conducted from the point of stimulation 
to the axonal terminal to result in muscle depolarization (Oh and Shin, 2003).  As axonal 
fibers within a nerve bundle regenerate at different speeds, it is possible that a few fast-
regenerating fibers may have reached the vibrissal musculature by 2 wpo to allow return 
of normal latency following an intratemporal crush.  As latency is also affected by the 
myelination status of a nerve, recovery of any demyelinating changes may have occurred 
by 2 wpo. 
Interestingly, although the severity of crush injury was similar in both 
extratemporal and intratemporal injury models, peak amplitude dropped to significantly 
lower levels following an intratemporal vs. an extratemporal injury at 1 wpo.  It was 
expected that the initial fall in amplitude would be similar following injury at both 
location sites.  A potential explanation for the higher amplitude in the extratemporal 
injury group is that since the first nerve conduction recording was taken at 1 wpo, the 
peak drop in amplitude may have occurred prior to that and thus may not have been 
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captured.  It is important to note that the extratemporal and intratemporal sham-
operated animals displayed no deficits in facial function and motor nerve conduction, 
verifying that the surgical procedure did not cause any additional damage to the facial 
nerve.   
While it is unclear why recovery is significantly delayed following an 
intratemporal crush, there are several possible explanations.  First, since the site of 
intratemporal injury is more proximal to the facial motor nucleus than the extratemporal 
injury, a greater neuronal cell loss was expected.  A previous study by Mattson et al. 
(1999) found that transection of the facial nerve 0.5 mm from the brainstem led to ~75% 
neuronal loss whereas transection at the nerve’s exit from the SMF led to ~25% loss.  
Although some studies have shown that peripheral nerve crush injuries do not lead to 
significant cell death, crush at sites more proximal to the cell body have not been reported 
(Swett et al., 1991; Swett et al., 1995).  Our findings indicate that while an extratemporal 
crush led to 100% facial motoneuron survival, intratemporal crush led to a significantly 
greater neuronal loss of ~15% compared to its respective sham.  A lack of statistical 
difference in cell survival between the extratemporal and intratemporal crush injuries 
may be due to large variability that needs to be reduced by increasing the n in each group.   
A ~15% cell loss may not be expected to compromise return of facial nerve 
function to as great an extent as was observed in our model.  However, cell loss may be 
more concentrated in some subpopulation of neurons within the FMN.  The musculotopic 
organization of the rodent FMN is divided into 6 distinct subnuclei, innervating specific 
facial muscles (Komiyama et al., 1984).  The anterior auricular musculature is 
represented in the dorsal medial (DM) subnucleus, while the posterior auricular 
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musculature is represented in the ventral medial (VM) subnucleus. The mentalis and 
platysma muscles are represented mainly in the ventral intermediate (VI) and dorsal 
intermediate (DI) subnuclei, respectively.  The orbicularis oculi and frontalis muscle are 
represented in the dorsal portions of the DI, DM, and dorsal lateral (DL) subnuclei.  
Finally, the nasolabial musculature is represented in both the DL and ventral lateral (VL) 
subnuclei.  Our lab’s previous studies in the mouse facial nerve axotomy model have 
found that following a transection of the nerve at its exit from the SMF, each subnucleus 
demonstrates a different pattern in the number of surviving neurons (Canh et al., 2006).  
While the VM and DM subnuclei are resistant to injury-induced cell loss, the VL 
subnucleus is more prone to degeneration.  As the VL subnucleus sends axon projections 
to the vibrissae musculature, facial motoneuron loss may be concentrated to this region 
and thus may be one reason for incomplete functional recovery in animals receiving the 
intratemporal facial nerve crush.  Interestingly, vibrissal movement is the functional 
recovery parameter that was always observed to be incomplete in animals receiving the 
intratemporal crush. 
Another possible reason for the impeded functional recovery in the intratemporal 
injury model is misdirection of regenerating axons.  Aberrant regeneration may occur 
when axons reach different muscle targets than their original targets during the recovery 
period.  Although misdirection is more common in transection injuries, it has been 
reported to occur following crush injuries of multiply branched motor nerves (Hadlock et 
al., 2008).  This phenomenon underlies the disabling condition of synkinesis often seen in 
patients with facial nerve injury.  Following nerve injury in adult animals, the 
somatotopical organization of the facial motor nucleus is lost with respect to the 
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ophthalmic and buccal branches, contributing to misguided regeneration (Park et al., 
1995).  Synkinesis results in involuntary movement of one segment of the face while 
attempting to voluntarily move another part of the face.  Currently, no therapy exists to 
prevent or treat synkinesis in patients who have suffered facial nerve injuries.  Recently 
Hadlock et al. (2008) described development of an apparatus in rodent models that would 
allow assessment of eyeblink and whisking on both sides of the face to quantify 
synkinesis.  Such a method could be used in the future to determine if synkinesis 
develops in our animal model of intratemporal facial nerve injury.  If aberrant 
regeneration does prove to be the cause of hindered functional recovery in animals 
receiving an intratemporal facial nerve crush, then this injury model could further be used 
to test different therapies that may improve recovery from or prevent development of 
synkinesis.        
Lastly, if the regeneration period is significantly prolonged, target muscles may 
undergo regressive alterations from the lack of reinnervation.  Muscle atrophy of 20-90% 
has been reported in cases of long-standing facial nerve paralysis (Kumar et al., 2006).  
Additional changes characterize the progression of denervation-induced muscle atrophy, 
including degenerated myofibrils, fibrosis, capillary reduction and fatty infiltration.  
Therefore, atrophy of the facial musculature may be preventing return of functional 
recovery in the intratemporal injury model described in this study.  Additional reasons for 
incomplete functional recovery may include a decreased ability of regenerating axons to 
traverse the crush zone or a lack of sustained neurotrophic support by neuronal and non-
neuronal cells.    
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 Facial nerve injuries have significant functional, emotional, and psychological 
impact patients.  Current findings demonstrate that a more proximal injury of the facial 
nerve within its intratemporal segment leads to notably delayed recovery of function and 
motor nerve conductance as compared to the same injury performed more distally at the 
nerve’s exit from the SMF.  As a significant number of facial nerve injuries occur during 
the nerve’s course within the temporal bone, the results have direct relevance for 
predicting the pathological and functional outcome in patients.  Future studies may 
determine whether the delayed recovery seen with the intratemporal crush is due to an 
inability of the axons to traverse the injury site, misguided regeneration, or significant 
neuronal loss within certain subnuclei of FMN that is sufficient to compromise function.  
Furthermore, the intratemporal model of nerve injury described can now be used to 
investigate treatment strategies that may enhance regeneration and recovery.   
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CHAPTER VII 
EFFECTS OF ELECTRICAL STIMULATION, TESTOSTERONE, AND 
PREDNISONE ON FUNCTIONAL RECOVERY FOLLOWING 
INTRATEMPORAL FACIAL NERVE INJURY 
 
A.  ABSTRACT 
 Although various surgical techniques exist for repairing the facial nerve following 
injury, recovery is often suboptimal and treatments targeting the molecular mechanisms 
of regeneration are lacking.  Results from Aim 1 and Aim 2 have demonstrated that 
administration of daily ES and systemic testosterone enhances regenerative properties 
and augments the growth program following an extratemporal crush of the facial nerve.  
The aim of the present study was to determine whether our combinatorial treatment 
strategy would be effective in the more clinically relevant intratemporal model of facial 
nerve injury, which demonstrates a substantially prolonged recovery time and induces 
significant facial motoneuron loss.  Furthermore, ES and TP treatments were compared to 
prednisone treatment, a regimen currently used in the clinic for promoting recovery 
following injuries to the facial nerve within the temporal bone.  A brief one-time ES, TP 
and prednisone treatment were administered in various combinations with each other 
following an intratemporal facial nerve crush injury in gonadectomized male rats.  
Results demonstrate that ES or TP treatment alone enhanced some functional parameters 
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more than the use of prednisone alone.  Brief ES of the proximal nerve stump also 
accelerated the onset of functional recovery.  None of the three treatments was effective 
in accelerating complete functional recovery or return of normal motor nerve conduction 
when administered alone.  Animals given the combinatorial treatment of ES plus TP, 
however, demonstrated enhanced complete functional recovery and normal amplitude 
and latency of evoked response during motor nerve conduction testing.  Therefore, our 
findings support that the combinatorial treatment strategy of using brief ES and TP 
together promises to be an effective therapeutic intervention even in the case of a more 
proximal injury of the facial nerve during its course in the temporal bone.   
             
B.  INTRODUCTION 
In 1821, Sir Charles Bell discovered that the facial nerve is responsible for facial 
muscle movement (Rosson and Redett, 2008).  Understanding the anatomy of facial 
nerve has given way to development of several therapeutic strategies.  Reconstructive 
treatments including direct anastomosis of the facial nerve stumps and nerve grafting 
procedures.  Decompression of the facial canal is also used in cases of Bell’s palsy with 
>90% degradation of facial nerve (Marais and Murray, 1995).  In patients with chronic 
facial nerve damage, long-term pulsatile stimulation of facial musculature is 
recommended to promote reinnervation (Targan et al., 2000).  Despite the advancements 
in technical repair of nerve injuries, recovery of function is frequently poor.  The 
detection of herpes simplex virus in the endoneurial fluid of patients with Bell’s palsy has 
led to the use of anti-viral agents in the past decade (May and Klein, 1991).  
Corticosteroid therapy is also widely used in cases of facial nerve inflammation and 
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edema.  For both antiviral and steroid therapy, however, randomized controlled 
studies demonstrate conflicting results (Turk-Boru et al., 2005; Sullivan et al., 2007; 
Allen and Dunn, 2004; Salinas et al., 2004).  As their efficacy remains controversial, 
further studies with larger patient populations and animal models need to be conducted.              
 As ES of injured nerves is associated with enhanced regeneration, it would be 
valuable to explore the translational potential of ES to facial nerve injury (Gordon et al., 
2008).  A summary of ES-mediated neuronal effects includes activating the excitability 
of neurons, upregulating expression of regeneration-associated genes, promoting 
regrowth of neurite after injury, improving selective targeting of regenerating axons, and 
enhancing the functional recovery of target organs (Al-Majed et al., 2000a; Brushart et 
al., 2005; Vivo et al., 2008; Gordon et al., 2003; Ahlborn et al., 2007; Zhang et al., 2007; 
Al-Majed et al., 2004; Al-Majed et al., 2000a).  Brushart et al. (2002) have reported that 
ES improves axonal regeneration not by increasing the regeneration rate but by 
accelerating the growth of axons across the site of injury and suture repair in the rat 
femoral nerve model.  Aim 1 of the present study also demonstrated that ES has no effect 
on accelerating the rate of regeneration of facial motor axons (Chapter IV).  However, ES 
reduces the initial delay before sprout formation begins following crush of the 
extratemporal segment of the rat facial nerve.  Results of Aim 2 further indicated that ES 
rapidly increases expression of regeneration-associated genes but the effects are transient 
(Chpater V).  Based on these findings, a combinatorial approach would most likely be a 
valuable clinical tool, with an initiation technique such as ES followed by a treatment that 
targets rate of regeneration and maintains responsiveness at the end organs.     
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 Use of gonadal steroids is one intervention that accelerates axonal 
regeneration rate.   Following an extratemporal injury of the facial nerve, testosterone 
effectively increased the rate of facial nerve regeneration but failed to reduce the delay 
before sprout formation (Chapter IV).  Aim 2 indicated that in comparison to the effects 
of ES, testosterone-mediated upregulation of regeneration-associated genes occurs later 
and is more sustained (Chapter V).  In cases of regeneration over long distances, such as 
following an intratemporal facial nerve injury, administration of testosterone may 
especially be beneficial to ensure that a regenerative response is maintained over an 
extended time course.            
 The aim of the present study was to administer prednisone, ES, and testosterone 
alone and in combination with each other and to evaluate the effects of these treatments 
on functional recovery.  Recovery of function following an intratemporal facial nerve 
injury was substantially delayed in comparison to extratemporal facial nerve injury 
(Chapter VI).  An intratemporal facial nerve injury was also associated with a ~15% 
motoneuron loss.  One reason for delayed recovery may be edema or an inflammatory 
response resulting from the injury within the facial canal that hinders regrowth of motor 
axons across the crush site.  Therefore, this study examined the effects of a prednisone 
regime similar to the one used in humans with facial nerve injury, where a short-term, 
high dose prednisone was given orally and tapered off over a course of 10 days.      
 Several studies have confirmed that a one-time ES treatment, administered 
immediately following injury, is as effective as long-term stimulation in improving 
functional recovery, enhancing regeneration, and attenuating axotomy-induced cell loss 
(Gordon et al., 2007; Ahlborn et al., 2007; Okazaki et al. 2008; Al-Majed et al., 2000a).  
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Studies from our lab using the extemporal model of facial nerve injury have 
compared that the effects of various short-term periods of ES to daily stimulation 
(Foecking et al., unpublished data).  Results demonstrate that just one, 30 min period of 
ES is no different than daily stimulation in improving recovery of facial nerve function.  
As short-term ES has more potential for clinical translation, the present study evaluates 
the effects of a one-time ES treatment.  Results demonstrate significant differences in 
functional recovery among the various treatment groups, with prednisone having minimal 
effect and the combination of ES and testosterone enhancing complete functional 
recovery the most.   
 
C.  MATERIALS AND METHODS 
 
 
1.  ANIMALS AND NERVE INJURY PARADIGM 
 
Adult male Sprague-Dawley rats (~2 months old) were purchased from Harlan 
(Indianapolis, IN) and used for all experiments, as previously described in Chapter III.  
Three to five days prior to nerve injury, rats were anesthetized with isofluorane and 
castrated (refer to Chapter III for details).  Figure 23 describes the experimental design 
for the present study.  Following facial nerve injury, animals were divided into 8 
experimental groups receiving various treatment combinations: [1] no treatment, [2] 
prednisone (P) only, [3] ES only, [4] TP only, [5] Stim + P, [6] TP + P, [7] Stim + TP, 
and [8] Stim + TP + P.      
The surgical procedure for the intratemporal facial nerve injury was performed as 
described in Chapter III.  The facial nerve was exposed near its exit from the SMF and 
Figure 22:  Experimental Design for Aim 4. This timeline will be followed for all 8 experimental groups. 
Gonadectomy 
No treatment 
ES only 
Prednisone only 
TP only 
Intratemporal Facial Nerve Crush Plus: 
ES + Prednisone 
 TP + Prednisone 
ES + TP 
ES + TP + Prednisone 
Daily Functional Recovery 
Assessment 
Weekly Motor Nerve 
Conduction Assessment 
8 wk 
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followed proximally to reach its intratemporal segment.  The tympanic bulla and the 
epitympanic region were exposed and drilled in a sacuerized fashion. Ossicles were 
exposed and removed with jeweler’s forceps to provide access to the region of the 
temporal bone located medially, where the intratemporal segment of the facial nerve lies.  
The bone covering the facial nerve was gradually thinned, beginning at the posterior 
aspect of the SMF and continuing antero-medially.  Once sufficiently thinned within its 
course in the facial canal, the facial nerve was crushed with fine jeweler’s forceps for 1 
min.  Gelfoam was lightly packed into the middle ear cavity prior to wound closure.  In 
all animals, the left facial nerve was left intact to serve as an internal control. 
 
2.  ELECTRICAL STIMULATION   
 Two Teflon-coated wires, bared of insulation for 2-3mm, were soldered to two 
“male” connector pins in a connector strip (refer to Chapter III for details).  Anesthetized 
animals received a one-time ES treatment during the axotomy surgery.  Prior to 
administration of an intratemporal facial nerve crush injury, electrodes were sutured in 
place as described previously, with one electrode adjacent to the nerve and another 3-5 
mm away.  The facial nerve was briefly stimulated for <5 sec before axotomy so that the 
voltage threshold for evoking a facial nerve response could be determined.  The voltage 
at which vibrissae twitching were elicited was used as the stimulating voltage.  
Immediately after axotomy, the facial nerve was stimulated proximal to the crush injury 
site at a frequency of 20 Hz for 30 min.  After the stimulation period, the electrodes were 
removed and wound sites were closed as described above.        
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3.  STEROID ADMINISTRATION 
 For administration of TP, a small incision was made on the mid-dorsal surface of 
animals.  A subcutaneous pocket was created for implantation of two Silastic capsules 
(0.062 in. id x 0.095 in. od; 10-mm length), equilibrated in physiological saline and 
containing 100% crystalline TP.  Capsules were implanted immediately following 
axotomy to establish supraphysiological levels of systemic TP (Kujawa et al., 1989; 
Hetzler et al., 2008; Tanzer and Jones, 2004). 
 A tapering dose of prednisone (dissolved in physiological saline) was 
administered orally using a 2”, 18-gauge gavage needle.  Starting on immediately 
following axotomy, a dose of 2.5 mg/kg was administered over a course of 11 days at the 
following intervals: twice daily for the first three days, once daily for the next 3 days, 
once every other day for the subsequent 3 days.  Animals not receiving the prednisone 
treatment received similar volumes of vehicle (saline) by oral gavage at the same dosing 
intervals.      
 
4.  FUNCTIONAL RECOVERY ASSESSMENT 
Recovery of facial function on the right side was compared daily to the intact 
function on the left side, as described previously in Chapter III.  Animals were observed 
for the return of eyeblink reflex and vibrissae orientation and vibrissae movement.  For 
each of these functional parameters, the recovery time to reach function symmetric to that 
on the uninjured side was noted for analysis.  For the eyeblink reflex, in addition to its 
complete recovery, the time till onset of the blink was also analyzed.  Each group 
contained an n of 5-6. 
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5.  ELECTROMYOGRAPHIC RECORDINGS   
Motor nerve conduction tests were done as described previously in Chapter III.  
Animals were anesthetized with intra-peritoneal injections Ketamine-Xylazine, and 
recordings were taken pre- and post-operatively on the day of axotomy and weekly 
thereafter.  Two stimulating electrodes were placed below the infraorbital ridge, and two 
recording electrodes were placed on the vibrissae pad to record the evoked muscle 
activity distal to stimulation.  A reference electrode was placed infererior to the external 
ear.  The facial nerve was stimulated at a frequency of 0.5 Hz and a 15 mA current, and 
an average of 25 responses was recorded.  Percent change in peak amplitude and latency, 
relative to the response on the unoperated side, was calculated and plotted as a function 
of weeks post-axotomy.  An n of 4-6/time point was used for each of the 8 experimental 
groups. 
 
6.  STATISTICAL ANALYSIS  
 Significant differences in functional recovery parameters among the various 
treatment groups were assessed using a one-way ANOVA, followed by a Newman-
Keul’s post-hoc test at p<0.05. To determine statistical significance among groups for 
percent change in amplitude and latency, a two-way ANOVA (factors = dpo and 
treatment), followed by a Newman-Keuls’s post-hoc test at p<0.05, was performed.  For 
ease of visual comparison, groups are often presented separately on graphs.         
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D.  RESULTS 
 
1.  DIFFERENCES IN FUNCTIONAL RECOVERY FOLLOWING TREATMENT 
WITH PREDNISONE, ES, AND/OR TP 
 Figure 23 demonstrates the effects of ES, TP, and/or prednisone on the timing of 
the onset and full recovery of the eyeblink reflex.  Administration of prednisone 
significantly accelerated the onset of the eyeblink reflex as compared to no treatment 
(18.8 ± 1.3 dpo and 24.5 ± 1.3 dpo, respectively; p<0.05; Figure 23A).  Administration of 
a brief ES treatment accelerated the onset of the eyeblink reflex to 7.6 ± 0.6 dpo, a 
significantly shorter recovery time than both the no treatment and the prednisone-only 
groups (p<0.05).  TP administration by itself significantly shortened the time for the 
onset of the eyeblink reflex (11.7 ± 1.4 dpo), as compared to no treatment and prednisone 
alone (p<0.05).  Adding prednisone treatment to ES or TP had no additional effect, as 
compared to ES or TP alone.  With ES plus prednisone, the onset of the eyeblink reflex 
occurred at 7.7 ± 1.4 dpo and with TP plus prednisone, the onset of the eyeblink reflex 
occurred at 16.2 ± 0.5 dpo (p<0.05 relative to no treatment).  Administration of ES plus 
TP or administration of ES, TP, plus prednisone had similar effects in accelerating the 
onset of the eyeblink reflex (7.2 ± 0.6 dpo and 5.9 ± 0.8 dpo, respectively), as compared 
to no treatment (p<0.05).  Importantly, administration of ES, alone or in combination 
with other treatments, shortened the time to onset of the eyeblink reflex even more than 
TP and/or prednisone treatments (p<0.05).                  
Recovery time of the full eyeblink reflex was significantly shortened in all 
treatment groups, relative to 54 ± 1.3 dpo in the no treatment group (Figure 23B).  Within 
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Figure 23.  Effects of prednisone, brief ES, and/or TP on onset and complete 
return of the eyeblink reflex following an intratemporal facial nerve crush 
injury.  Shown are recovery times for the onset of the eyeblink reflex (A) and return 
of the complete eyeblink reflex (B) following administration of various combinations 
of prednisone (P), ES, and TP treatments.  As animals were followed for a maximum 
of 56 dpo, incomplete return of any functional parameter was designated a recovery 
time of 56 dpo.  Vertical lines represent standard error of the mean.  (a = p<0.05, 
relative to no treatment; b = p<0.05, relative to prednisone only; c = p<0.05, relative 
to TP only; d = p<0.05, relative to TP + P).   n = 5-8/group.  
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the untreated group, only one-third of the animals recovered the full eyeblink reflex 
by the maximum post-operative survival time of 56 dpo.  The remaining two-thirds had 
an incomplete eyeblink even at 56 dpo.  Relative to no treatment, administration of 
prednisone significantly shortened the recovery time for the complete eyeblink reflex to 
33.3 ± 7.2 dpo.  ES and TP treatments alone also significantly accelerated the recovery of 
the full eyeblink to a similar extent (31.8 ± 2.3 dpo and 28 ± 5.3 dpo, respectively; 
p<0.05 relative to no treatment).  Addition of prednisone to ES or TP had no 
supplemental effect in enhancing recovery time for the full eyeblink, as recovery 
occurred at 25 ± 2.7 dpo with ES plus prednisone and at 24.6 ± 2.3 dpo with TP plus 
prednisone. Administration of ES plus TP or administration of ES, TP, plus prednisone 
had similar effects in accelerating the onset of the eyeblink reflex (25.8 ± 1.1 dpo and 20 
± 1.6 dpo, respectively), relative to no treatment (p<0.05).  In conclusion, recovery of the 
complete eyeblink reflex was enhanced in the presence of any treatment; however, the 
effects were more pronounced with the administration of ES and/or TP as compared to 
prednisone.   
 Vibrissae orientation returned in untreated animals at 27.7 ± 2.0 dpo (Figure 
24B).  Prednisone administration had no effect on the recovery time for return of 
vibrissae orientation (27.5 ± 2.1 dpo).  Relative to the no treatment and the prednisone-
only groups, treatment with ES significantly accelerated recovery of vibrissae orientation 
to 15.6 ± 1.6 dpo (p<0.05).  Administration of TP also significantly shortened the 
recovery time for vibrissae orientation to 14.7 ± 1.4 dpo, relative to no treatment and 
prednisone treatment (p<0.05). Addition of prednisone to ES or TP had no supplemental 
effect in enhancing recovery time for return of vibrissae orientation, as recovery occurred
Figure 24.  Effects of prednisone, brief ES, and/or TP on return of vibrissae 
orientation and movement following an intratemporal facial nerve crush injury. 
Shown are recovery times for return of normal vibrissae orientation (A) and full 
vibrissae movement (B) following administration of various combinations of 
prednisone (P), ES, and TP treatments.  As animals were followed for a maximum of 
56 dpo, incomplete return of any functional parameter was designated a recovery time 
of 56 dpo.  Vertical lines represent standard error of the mean.  (a = p<0.05, relative to 
no treatment; b = p<0.05, relative to prednisone only).   n = 5-8/group.  
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at 16.8 ± 1.8 dpo with ES plus prednisone and at 11.8 ±0.8 dpo with TP plus 
prednisone.  Administration of ES plus TP or administration of ES, TP, and prednisone 
had similar effects in accelerating the return of vibrissae orientation (11.3 ± 0.7 dpo and 
10 ± 0.7 dpo, respectively), as compared to no treatment (p<0.05).  Therefore, ES- or TP-
treated animals displayed accelerated recovery of vibrissae orientation relative to 
prednisone-treated and untreated animals.               
 As vibrissae movement is the last facial functional parameter to return, the 
recovery time for vibrissae movement also determines the time for complete recovery.  In 
all animals receiving no treatment, the recovery treatment for vibrissae movement was 
>56 dpo (Figure 24B).  Prednisone treatment did not significantly alter vibrissae 
movement recovery time (≥51.4 ± 4.6 dpo), relative to no treatment.  ES or TP treatments 
alone, or each in combination with prednisone, were also ineffective in shortening 
recovery of complete vibrissae movement  (ES only = >56 dpo; TP only = 50.8 ± 2.3; ES 
+ prednisone = ≥49.5 6.5 dpo; TP + prednisone = ≥48.2 ± 3.4 dpo).  Administration of 
the ES plus TP combinatorial treatment significantly reduced the recovery time for 
complete vibrissae movement to 37 ± 1.0 dpo, relative to no treatment (p<0.05).  Animals 
receiving ES, TP plus prednisone also displayed a similar enhancement in return of 
vibrissae movement, with a recovery time of 39.8 ± 1.8 dpo (p<0.05 relative to no 
treatment).  Therefore, only administration of ES and TP together was effective in 
accelerating recovery of vibrissae movement.       
 Table 3 breaks down the number of animals within each treatment group that did 
or did not attain complete facial functional recovery.  All of the animals in the untreated 
group displayed incomplete facial function at 56 dpo.  In the prednisone treatment group, 
Treatment Group
Animals with Complete Facial                          
Functional Recovery
Animals with Incomplete Facial                          
Functional Recovery
No treatment 0% 100%
P only 20% 80%
ES only 0% 100%
TP only 60% 40%
ES + P 20% 80%
TP + P 60% 40%
ES + TP 100% 0%
ES + TP + P 100% 0%
Table 3.  Percentage of animals achieving complete facial functional recovery following an intratemporal                      
facial nerve crush
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20% of the animals attained complete facial function while the remaining 80% still 
displayed incomplete recovery at 56 dpo.  While 100% of the animals receiving ES 
treatment did not achieve complete recovery, 60% of the animals receiving TP treatment 
did regain full facial function.  When prednisone was added to ES or TP, 20% of the 
animals in the ES plus prednisone group and 60% in the TP plus prednisone group 
achieved complete recovery of facial nerve function.  Lastly, in both the ES plus TP and 
the ES plus TP plus prednisone groups, 100% of the animals displayed complete regain 
of facial nerve function.   
 
2.  DIFFERENCES IN MOTOR NERVE CONDUCTION FOLLOWING TREATMENT 
WITH PREDNISONE, ES, AND/OR TP 
 Motor nerve conduction studies were performed weekly following axotomy and 
treatment with prednisone, ES, and/or TP.  Figure 25 demonstrates the percent change in 
peak amplitude of the evoked response for the crushed facial nerve in animals receiving 
no treatment, individual treatments (prednisone, ES, or TP), and the combination of ES 
plus TP.  Following axotomy at 1 wpo, peak amplitude dropped to -70-80% in all groups.  
By 8 wpo, peak amplitude in untreated animals or animals receiving individual 
treatments (prednisone, ES, or TP) remained ~60-70% below normal.  In comparison, in 
animals receiving the combined treatment of ES plus TP, the peak amplitude levels 
returned to normal baseline values (-15.4 ± 4.8%) at 8 wpo (p<0.05).  
 Figure 26 demonstrates the percent change in latency of the evoked response for 
the crushed facial nerve in animals receiving no treatment, individual treatments 
(prednisone, ES, or TP), or the combination of ES plus TP.  Following axotomy at 1 wpo, 
Figure 25. Effects of prednisone, brief ES, and/or TP on peak amplitude of 
evoked response following an intratemporal facial nerve crush injury.  Motor 
nerve conduction testing was done to record peak amplitude of the evoked response 
in the vibrissal pad upon facial nerve stimulation.  Shown are percent changes in 
peak amplitude on the injured side, relative to the unoperated side, over a time 
course.  Vertical lines represent standard error of the mean. (* = p<0.05 as 
compared to no treatment; n = 4-7/time point of each group).  Dotted red line at y-
intercept represents baseline. (P = prednisone).  
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Figure 26. Effects of prednisone, brief ES, and/or TP on latency of evoked 
response following an intratemporal facial nerve crush injury.  Motor nerve 
conduction testing was done to record latency of the evoked response in the 
vibrissal pad upon facial nerve stimulation.  Shown are percent changes in latency 
on the injured side, relative to the unoperated side, over a time course.  Vertical 
lines represent standard error of the mean. (a = p<0.05, relative to no treatment; b = 
p<0.05, relative to prednisone only; n = 4-7/time point of each group).  Dotted line 
at y-intercept represents baseline. (P = prednisone).  
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latency of response increased by ~20-30% in animals receiving no treatment, 
prednisone alone, or TP alone.  However, in animals receiving ES, no increase in latency 
was noted.  Rather the latency remained around normal baseline values in the ES only 
and the ES plus TP groups (-3.3 ± 3.4% and -4.0 ± 3.5%, respectively; p<0.05 relative to 
no treatment).   
 Figure 27 compares the percent change in peak amplitude and latency of the 
evoked response for the ES, TP and ES plus TP treatments with or without the addition of 
prednisone.  Administration of prednisone had no additional effects as compared to the 
ES, TP, or ES plus TP treatments alone.  The amplitude and latency remained below 
normal at 8 wpo unless both ES and TP were administered together.                   
 
E.  DISCUSSION 
 The present study found that administration of prednisone, ES, and testosterone 
had varying effects on functional recovery.  Although prednisone alone improved 
recovery of some functional parameters (eyeblink reflex), it did not significantly affect 
functional recovery.  ES and testosterone alone accelerated most functional recovery 
parameters to a greater extent than prednisone, but were still insufficient to improve 
complete functional recovery as compared to untreated animals.  The combination of ES 
and testosterone, however, significantly shortened the time till complete functional 
recovery, demonstrating the benefit of a combinatorial treatment approach.             
 Although corticosteroids are widely used in idiopathic facial nerve paralysis, their 
efficacy has not been clearly demonstrated.  In a randomized, prospective controlled 
study, patients were given steroids within the first 3 days after the onset of symptoms 
Figure 27. Effects of the addition of prednisone to ES only, TP only, and ES plus 
TP treatments on motor nerve conduction following an intratemporal facial 
nerve crush injury.  Motor nerve conduction testing was done to record peak 
amplitude and latency of the evoked response in the vibrissal pad upon facial nerve 
stimulation.  Shown are percent changes in amplitude (A) and latency (B) on the 
injured side, relative to the unoperated side, over a time course.  Vertical lines 
represent standard error of the mean. Dotted line at y-intercept represents baseline.  n 
= 3-7/time point of each group. (P = prednisone).  
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(Turk-Boru et al., 2005).  Although the initial response seemed to improve symptoms, 
by the end of 6 weeks, steroids had no significant effects as compared to no treatment.  In 
a retrospective study evaluating the effects of corticosteroid therapy, results demonstrated 
a non-significant difference, with a similar percentage of treated and untreated patients 
having incomplete recovery and cosmetically disabling sequelae six months after the 
onset of facial nerve paralysis (Salinas et al., 2004).  Prednisone has also been shown to 
be ineffective in promoting early recovery from post-parotidectomy facial nerve paralysis 
in a prospective, randomized trial (Roh and Park, 2008).  Although some studies do 
support the idea that corticosteroids shorten the time to complete recovery (Engstrom et 
al, 2008), evidence is inconclusive.  A similar short-term, high dose methylprednisolone 
treatment following optic nerve injury in rats was found to have no effect on cell survival, 
macrophage activity at the site of injury, axonal regeneration, or visual function (Ohlsson 
et al., 2004).  Following spinal cord injury in dogs, administration of methylprednisolone 
with DC electrical field improved function more than the use of either treatment alone 
(Shen et al., 2005).  In the current study, prednisone promoted earlier recovery of the 
eyeblink reflex but had no significant effect on complete recovery or return of normal 
nerve conduction.  When combined with ES or TP, prednisone had no additional effect.  
Therefore, either the dose of prednisone administered may have been insufficient to 
induce recovery, or prednisone as a treatment strategy may be ineffective in enhancing 
regeneration.       
           Following nerve transection and surgical repair, investigators have described 
axonal regeneration to be a “staggered” process, in which axons cross the injury site at 
asynchronous rates (Brushart et al., 2002; Al-Majed et al., 2000a).  Furthermore, axons 
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may branch repeatedly to enter several different endoneurial tubes, and some 
evidence also exists for axons proceeding backwards in search for distal nerve stumps 
(Witzel et al., 2005).  Although such events may be more commonly seen following 
transection and surgical repair of nerves rather than crush injuries, regeneration of axons 
across the injury site may nevertheless be a rate-limiting process.  As 1 h ES has been 
shown to substantially reduce the time for femoral motoneurons to regenerate axons 
across a suture site, the brief ES treatment in our intratemporal facial nerve injury model 
may also be accelerating growth across the crush site.   
Compared to no treatment and prednisone or testosterone treatments, ES 
shortened the time until the onset of the eyeblink reflex, suggesting that it helps initiate 
regeneration earlier.  Results from motor nerve conduction studies further demonstrated 
that administration of ES prevented the increase in latency of evoked response at 1 wpo.  
As the fastest arriving fibers of a nerve determine latency, ES may either have induced 
some of the fastest-growing axons to regenerate far enough to conduct the nerve impulse 
at a normal rate or it may have attenuated any demyelination associated with injury.  
However, ES administered by itself does not promote return of normal amplitude of the 
evoked facial nerve response.  Also, none of the animals receiving ES alone were able to 
reach complete functional recovery at the end of the study period.  Therefore, although 
ES may be effective in starting up the regeneration response, it may fail to promote 
recovery in the long run. 
In the extratemporal model of facial nerve injury, our studies have demonstrated 
that androgens increase the overall regeneration rate.  Testosterone administration alone 
in the present study did accelerate recovery of the eyeblink reflex and vibrissae 
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orientation, as well as complete recovery in 60% of the animals, a percentage greater 
than that achieved by prednisone or ES treatments.  In addition to its effects on axonal 
regenerative properties, testosterone may also be affecting the target musculature.  In 
untreated animals, prolonged denervation may be inducing muscle atrophy that would 
further prevent regain of complete facial function.  Testosterone has been demonstrated 
to decrease expression of the ubiquitin ligase muscle atrophy factor, termed MAFbx, 
which is associated with denervation-induced muscle loss (Zhao et al., 2008).  
Testosterone represses the MAFbx promoter via an AR-dependent mechanism.  AR 
receptor is found in muscles that are highly responsive to androgens and AR expression is 
enriched at the neuromuscular junctions.  Therefore, the facial muscles may also be sites 
of androgen action that aid in prevention of muscle atrophy and/or promotion of 
reinnervation.  In the adult rat sciatic nerve, AR mRNA levels are also localized in the 
endoneurial compartment, specifically in the endoneurial fibroblasts and endothelial 
cells, and within Schwann cells (Jordan et al., 2002).  These additional sites of androgen 
action may also maintain a regenerative-permissive environment over a prolonged period.   
The effectiveness of the combinatorial treatment of ES and testosterone in 
substantially accelerating functional recovery and return of normal motor nerve 
conduction may be explained by faster regrowth across the crush site, stimulated by ES, 
in addition to an enhanced regenerative response sustained by TP.  These findings have 
direct clinical relevance for cases of intratemporal facial nerve injury in which functional 
recovery is significantly prolonged.  Furthermore, results imply that ES and testosterone 
may serve as better treatment strategies than the use of corticosteroids in facial nerve 
injury.  Corticosteroid treatment is contraindicated in children and patients with 
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conditions such as diabetes, liver disease, immunodeficiency, and glaucoma.  As 
Bell’s palsy is 4 times more likely to occur in diabetics and in people over the age of 65, 
such patient populations may benefit from other treatment strategies (Finsterer, 2008).  
Therefore, the combinatorial approach using ES and testosterone may be a valuable 
clinical tool.     
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CHAPTER VIII 
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
 
A.  SUMMARY 
 The overall findings of the present study are depicted in Figure 28.  Aims 1 & 2 
investigated the effects of ES and TP in the extratemporal crush model of facial nerve 
injury, and the results are summarized as follows: 
1) Daily ES and systemic TP differentially enhanced facial nerve regenerative 
properties.  While ES shortened the initial delay before sprout formation 
begins, TP accelerated the rate of axonal regeneration.  Administration of the 
combination treatment of both had additive effects on regeneration, as the 
delay in sprouting was shortened and the rate was enhanced.   
2) Daily ES and systemic TP differentially enhance expression of regeneration-
associated genes.  ES and TP targeted different genes, with ES upregulating 
expression of α1-tubulin and GAP-43 and TP upregulating expression of β-II 
tubulin.  While both treatments upregulated expression of BDNF and neuritin, 
the effects of ES were rapid but transient and the effects of TP were delayed 
yet sustained.  The combination of ES and TP induced both early and late 
upregulation as well as additive effects on expression of some genes such as 
PACAP. 
1) Crush, ES 2)  - ↑ Ca
2+ influx 
      - ↑ Neuronal activity 
3) ∆ in transcription: ↑ Neuritin (6hr) 
↑ BDNF (1d) 
↑ PACAP (1d-7d) 
↑ GAP-43 (7d) 
4) - ↓ Sprouting delay 
    -  Early initiation of    
       regeneration ↑ α1-tubulin (2d) 
1) Crush, TP 
2) Binding to AR 
↑ Neuritin (2d) 
↑ BDNF (7d) 
↑ βII-tubulin (7d) 
4) - ↑ Regeneration rate 
     - ↑ Axonal elongation      
      over time 
3) ∆ in transcription: 
FMN 
T T 
T 
FMN 
COMBINATION: 
Enhanced effects 
on regeneration 
events and 
functional 
recovery 
Figure 28.  Working model of the effects of ES and TP treatments on axonal regeneration.  Effects of ES (A) and TP (B) 
are summarized in chronological steps from 1-4.  Step #2 for both treatments has been demonstrated in previously published 
studies.  FMN: facial motoneuron;       electrode; TP; AR crush; 
A.  Electrical Stimulation 
B.  Testosterone 
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Aims 3 & 4 focused on development of a more clinically relevant, 
intratemporal crush model of facial nerve injury and investigation of the effects of 
prednisone, ES, and TP herein, as summarized below: 
1) Compared to an extratemporal facial nerve crush, an intratemporal facial 
nerve crush in rats led to significantly delayed return of normal facial nerve 
function.  Functional recovery and motor nerve conduction failed to return to 
normal at the end of the study period of 8 wpo.  In addition, an intratemporal 
crush injury was associated with a ~85% cell survival, whereas an 
extratemporal crush injury produced a ~100% cell survival.      
2) Administration of prednisone, ES, and TP had varying effects on functional 
recovery following an intratemporal crush.  ES and TP improved recovery of 
facial functional parameters more than prednisone.  Neither treatment by itself 
was able to shorten the time till complete functional recovery, as compared to 
no treatment.  Only the combined administration of ES and TP was effective 
in accelerating complete recovery and returning motor nerve conduction to 
normal.      
 
B.  CONCLUSIONS 
 The overall results of the present study, as described above, have been presented 
and discussed in the corresponding chapters.  The following topics now incorporate the 
results together in context of current peripheral nerve regeneration research. 
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1.  INSIGHT INTO MECHANISM OF ES-MEDIATED THERAPEUTIC EFFECTS 
 Previous studies have assessed whether ES enhances regeneration through a 
conditioning mechanism.  A conditioning lesion, which precedes test injury, has been 
shown to accelerate rate of regeneration in concert with enhanced slow transport of 
cytoskeletal proteins (Bisby and Tetzlaff, 1992; McQuarrie 1986).  Administration of ES 
1 week prior to crush injury has no effect on promoting regeneration, suggesting that ES 
in the absence of injury does not alter the future behavior of motoneurons (Brushart et al., 
2002).  Also, unlike a conditioning lesion, ES promotes the onset of regeneration without 
increasing its speed.  ES does, however, recruit more motoneurons to regenerate across 
the site of injury and enter the distal nerve stump (Brushart et al., 2002).  Similarly, our 
results demonstrate that ES fails to accelerate the axonal elongation rate, but it 
significantly reduces the estimated delay before sprouting.  Therefore, ES may serve as 
an effective treatment to initiate regeneration, followed by other treatments that speed 
and prolong axonal regeneration.     
 ES has previously been demonstrated to mediate its positive effects by directly 
affecting the cell body (Al-Majed et al., 2000a).  Our results indicate that ES rapidly 
enhances expression of various regeneration-associated genes and thus may in turn 
enhance the motoneurons response to injury.  The genes that were found to be 
upregulated play an important role in growth cone dynamics, axonal elongation, neuronal 
survival, neurite outgrowth, and target reinnervation. Activation of neurotrophin 
signaling is most likely an important result of ES treatment and precedes upregulation of 
cytoskeletal proteins (Al-Majed et al., 2000b; Al-Majed et al., 2004).  Another important 
source of neurotrophic factors are denervated Schwann cells and the distal nerve stumps; 
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however, the upregulation of BDNF and GDNF at these sites has been reported to be 
delayed relative to the time of axotomy (Hoke et al., 2006; Boyd and Gordon, 2003a; 
Boyd and Gordon, 2003b).  As this source of neurotrophic factors does not become 
available till later, the neuronal source is of critical importance during earlier times of 
axonal outgrowth. Hence, the immediate upregulation of neurotrophic molecules induced 
by ES is a likely mechanism of enhancing regeneration.   
 The ability of ES to initiate the onset of regeneration probably leads to earlier 
target muscle reinnervation.  Gordon et al. (2007) have demonstrated that brief ES of the 
median nerve increases the number of motor units in the median nerve-innervated thenar 
muscles.  Ahlborn et al. (2007) report that although ES considerably accelerates the rate 
of functional recovery following femoral nerve injury in mice, the overall functional 
outcome at the end of the study period is not considerable different between stimulated 
and unstimulated animals.  Similarly, we also find that ES initiates return of facial 
function noticeably early but does not shorten the overall recovery period following 
intratemporal facial nerve injury.   
 
2.  INSIGHT INTO MECHANISM OF TP-MEDIATED THERAPEUTIC EFFECTS 
 A postulated mechanism by which gonadal steroids accelerate regeneration rate is 
by “priming” the cell body metabolically.  Administering gonadal steroids to axotomized 
motoneurons at the time of injury may accelerate the genomic switch from a normal to a 
reparative mode, thereby enhancing the neuronal response to injury.  A conditioning 
lesion similarly “primes” the neuron to enter a growth state prior to a testing lesion and 
results in an accelerated rate of peripheral nerve regeneration.  The positive effects of a 
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conditioning lesion require an interval of days to weeks prior to the testing lesion.  
For gonadal steroids, on the other hand, immediate exposure is required to accelerate 
regeneration, with delayed exposure having no effect (Kujawa and Jones, 1990).  
Therefore, gonadal steroids are likely to alter the synthetic capabilities of neurons more 
rapidly than a conditioning lesion.   
 Previous studies have demonstrated that the androgen-induced augmentation of 
facial nerve regeneration is AR-dependent.  Administration of flutamide, a potent AR 
blocker that prevents binding of TP, prevents the increase in regeneration rate (Kujawa et 
al., 1995).  Interestingly, axonal injury results in significant downregulation of AR in the 
FMN and SNB models (Drengler et al., 1997; Lubischer and Arnold, 1995).  A potential 
explanation for this result is that injury induces transcription of cytoskeletal and growth-
associated genes, while shutting down production of other genes such as AR that may be 
less necessary at the time.  Therefore, the upregulation of regeneration-associated genes 
by TP may be mediated by preexisting steroid receptors.  While alterations in genomic 
regulation are the classic mechanism of steroid action, recent studies have recently 
demonstrated that rapid, non-genomic mechanisms involving ion movements and/or 
initiation of signal transduction cascades may also underlie the observed effects on 
regeneration. 
 As testosterone can be aromatized to estrogen via the enzyme aromatase, the 
neurotherapeutic effects of TP observed in the present study may in part be mediated by 
its conversion to estradiol.   Within the mammalian brain under normal conditions, 
aromatase is expressed mainly in neurons and at low levels in astrocytes (Balthazart and 
Ball, 1998; Negri-Cesi et al., 1992).  Conditions of injury have been demonstrated to 
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increase the levels of aromatase in both neurons and glia (Zwain and Yen, 1999; 
Peterson et al., 2001).  The denditc morphology of rodent SNB has been shown to be 
disrupted by blocking aromatase (Burke et al., 1999).  Recent studies from our lab 
demonstrate that following an extratemporal facial nerve injury in rats, administering 
DHT or estradiol (metabolites of testosterone) does not enhance functional recovery and 
regeneration rates to the same extent as TP (Foecking et al., 2009).  As DHT is a non-
aromatizable form of androgen, results suggest that a synergistic action of androgens and 
estrogens may be required to obtain maximal effects on regeneration events.            
 
3.  BENEFITS OF A COMBINATORIAL TREATMENT APPROACH 
 The present investigated a novel combinatorial treatment strategy based on the 
hypothesis that if the two treatments, ES and TP, work through different mechanisms, 
then together they might be used to obtain additive effects on regeneration.  Our findings 
demonstrate that while ES enhances regeneration by reducing the delay in sprouting and 
rapidly upregulating gene expression, TP enhances regeneration by accelerating the 
axonal regeneration rate and prolonging expression of regeneration-associated genes.  
Therapeutically, a combination treatment may be effective because ES could be used to 
start up regeneration events, followed by TP to maintain the reparative process.   
The need for a combinatorial treatment is especially evident as neither ES nor TP 
alone are effective in improving complete functional recovery in rats following a more 
proximal, intratemporal injury of the facial nerve.  The finding that the combinatorial 
treatment of ES plus TP substantially shortens the recovery period may be due to ES 
recruiting more motoneurons to cross the crush zone early and TP maintaining expression 
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of neurotrophic factors and growth-associated genes long-term to promote target 
reinnervation.  In addition, TP may also prevent muscle atrophy associated with 
prolonged target denervation.  As ES has previously been reported to improve specificity 
of reinnervation, brief ES treatment may also enhance the outcome of an intratemporal 
facial nerve injury by reducing aberrant regeneration along the multiply branched motor 
nerve.  Therefore, a combinatorial treatment strategy would be especially beneficial in 
cases of prolonged recovery periods following nerve injury.               
 
4.  CLINICAL IMPLICATIONS OF THE INTRATEMPORAL FACIAL NERVE 
INJURY MODEL 
 Prior to this study, an animal model representing intratemporal facial nerve injury 
had not been developed.  As intratemporal injuries of the facial nerve are more prevalent 
than injuries occurring after the nerve’s exit from the skull, the model developed in the 
present study is of clinical importance.  Furthermore, an intratemporal facial nerve crush, 
~6-7 mm proximal to the extratemporal crush, leads to dramatically delayed facial 
functional recovery and return of normal motor nerve conduction.  In a series of studies, 
Fu and Gordon (1995) provided evidence that the regenerative capacity of injured 
motoneurons regressively deteriorates with increased distance and time (Fu and Gordon 
1995a; Fu and Gordon 1995b).  Therefore, comparison of the extratemporal and 
intratemporal facial nerve injury models in the present study also supports the idea that 
there may a limited window of opportunity for optimal nerve regeneration, which may be 
narrowed by an injury more proximal to the cell body. 
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 Based on current findings, patients presenting with intratemporal vs. an 
extratemporal facial nerve injury can also be predicted to have delayed recovery from 
facial paralysis or increased chances of complications such as synkinesis.  Although most 
studies have found that significant neuronal loss does not occur following crush injuries 
of the peripheral nerves, more proximal injuries and/or prolonged periods of target 
denervation may lead to some degree of cell loss as reported in our intratemporal facial 
nerve injury model.  The ~15% cell loss observed may not account for the substantially 
delayed functional recovery.  However, as full vibrissae movement is the main functional 
parameter whose recovery remains incomplete, the majority of the cell loss may be 
localized to FMN subnuclei projecting to the vibrissae muscles and thus may explain the 
lack of recovery.  Investigating the amount of cell loss in different FMN subnuclei would 
shed additional insight into predicting the pathological result of proximal facial nerve 
injuries seen clinically.  Also, the present studies assessed facial motoneuron survival at a 
maximum of 8 wpo; however, cell loss may further increase at later time points.  If 
neuronal loss does play a critical role in preventing successful facial nerve regeneration, 
then therapies promoting long-term cell survival should be used in the clinical setting.   
 Lastly, the finding that prednisone appears to improve recovery of some but not 
all facial functional parameters undervalues its therapeutic use in crush or transection 
injuries of facial nerve.  However, because of its anti-inflammatory actions, prednisone 
may nevertheless be important in cases of considerable facial nerve edema or 
inflammation.  To promote successful regeneration after such injuries, prednisone would 
have to be combined with other treatments.           
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5.  THERAPEUTIC NEED AND POTENTIAL FOR TRANSLATION OF THE ES 
PLUS TP TREATMENT STRATEGY 
 In comparison to animal models of peripheral nerve regeneration, regeneration in 
humans is known to be 3 times slower (Gordon et al., 2008).  Given the ~3 mm/d 
regeneration rate for the fastest growing axons in rats, the expected regeneration rate in 
humans would be ~1 mm/d.  Furthermore, the latency period for the axons to cross the 
site of injury and enter distal nerve stumps is also longer in humans.  Not only is the 
inherent regeneration rate slower, but peripheral nerves in humans also have to grow over 
longer distances.  Therefore, suboptimal functional recovery is often seen following 
peripheral nerve injuries, such as that of the facial nerve.  The past quarter of a century 
has focused on optimization of surgical repair of injured nerves.  However, therapies 
targeting molecular mechanisms of regeneration are lacking.   
 As ES and TP differentially enhance the intrinsic ability of neurons to regenerate, 
together they have the potential to be an effective treatment strategy.  Several studies 
demonstrate translation of ES and TP treatments into clinic.  Brief ES of the median 
nerve in patients with carpal tunnel syndrome has been shown to improve functional 
recovery (Gordon et al., 2007).  Direct ES of the sacral and hypoglossal have also been 
conducted in patient trials for treatment of bladder dysfunction and obstructive sleep 
apnea, respectively (Sutherland et al., 2007; Schwartz et al., 2001).  Therefore, ES for a 
brief duration represents a feasible approach for treatment of peripheral nerve injuries.  
Similarly, testosterone treatment has been tested in multiple patient trials.  For example, 
an intramuscular testosterone treatment in men diagnosed with Parkinson’s disease 
increased total testosterone levels by ~270% and improved non-motor symptoms of the 
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disease (Okun et al., 2006; Okun et al., 2002).  Clinical trials in male multiple 
sclerosis patients have demonstrated that application of testosterone gel to the upper arms 
increased circulating hormone levels by an average of 50% and improved cognitive 
function, slowed brain atrophy rate, and induced production of neurotrophic factors 
(Sicotte et al., 2002; Gold et al., 2008).  Sublingual administration of testosterone in 
healthy females also attenuates the integrated central stress response (Hermans et al., 
2007).   
Testosterone treatment in patients with peripheral nerve injuries has not yet been 
investigated.  As different doses and routes of delivery for testosterone treatment are 
currently being used in patient trials, the most effective dosage and administration 
method would have to be determined.  Our studies have demonstrated that endogenous 
testosterone levels in male hamsters are not sufficient to promote regeneration and that 
supraphysiological levels (>3 times normal levels) are effective.  Further studies in our 
animal models can determine the minimal TP dosage required to obtain enhanced effects 
on regenerative properties and functional recovery.  Previous studies from our lab have 
demonstrated that following an extratemporal facial nerve crush in male hamsters, TP 
needs to be administered soon after injury in order to have beneficial effects (Tanzer and 
Jones, 2004).  A 6 h delay in treatment prevents TP from augmenting regeneration.  
Furthermore, a 6 h immediate TP exposure enhanced regeneration and functional 
recovery to the same extent as a 7 d treatment.  These findings have important clinical 
implications and suggest that an immediate but short-term treatment with gonadal 
steroids may have significant therapeutic advantages for peripheral nerve injuries.        
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C.  FUTURE DIRECTIONS 
 The present study offers insight into the effects of ES and TP on functional 
recovery and molecular mechanisms of regeneration in two facial nerve injury models.  
However, there are several questions that need to be answered and thus are presented as 
future directions below.  These additional studies will further advance the translation of 
the proposed combinatorial treatment strategy (ES plus TP) into the clinic.   
 
1. What is the minimal dose and duration of TP treatment required to achieve 
therapeutic effects? 
2. Why is return of functional recovery and motor nerve conduction substantially 
delayed following an intratemporal vs. an extratemporal facial nerve crush 
injury? 
a. Using retrograde dye labeling, determine the number of motoneurons 
that cross into the nerve segment distal to the crush site following an 
intratemporal vs. extratemporal injury. 
b. Using retrograde dye labeling, determine the number of motoneurons 
that reinnervate vibrissal muscles following an intratemporal vs. 
extratemporal injury. 
c.  Determine facial motoneurons survival in different subnuclei of the 
FMN to assess if cell loss is greater in certain subpopulations. 
 
3. Can the combinatorial treatment of ES plus TP attenuate the 15% cell loss 
induced by the intratemporal crush? 
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4. Do ES and TP enhance regeneration by altering subcellular trafficking 
between the cell body and the distal processes? 
a. Determine whether ES and TP increase levels of axoplasmic proteins, 
such as importins, that are retrogradely transported after injury to 
modulate the regenerative response. 
b.  Determine the timing and degree of increase in levels of neurotrophic 
factors and growth-associated proteins in the nerve relative to the cell 
body following treatment with ES and TP. 
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